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ABSTRACT
When modern high voltage radiotherapy is used in
combination with simple mastectomy for the treatment of
breast cancer, the lung apex on the treated side receives
up to 4250 rads. Minor changes in overall lung function following
such therapy have previously been reported (Emirgil and
Heinemann, 1961). These changes are more pronounced when
radiation pneumonitis develops, which occurs in about 11%
of such patients (Gross, 1977).
Two groups of patients were studied, both having had
simple mastectomy followed by megavoltage radiotherapy
(4250 rads to the axilla and supraclavicular region and
4500 rads to the chest wall by tangential fields, in 10
fractions over four weeks), as part of their treatment for
carcinoma of the breast.
Overall and regional lung function measurements, chest
x-ray and electrocardiograph were carried out in each patient.
Overall lung function was assessed by static lung volumes
(TLC, VC, RV, RV/TLC%), dynamic lung volumes (FEVi, FVC,
FEVi/FVC%), transfer factor of carbon monoxide (T^q), flow
volume curves and airways resistance. Regional distribution
133
of ventilation was measured with radioactive Xe , and regional
133
distribution of perfusion with radioactive Xe in the first
9 9m
study and with Tc macro-aggregated albumin in the second
study, using a gamma camera linked on-line to a computer.
The first study involved a longitudinal sequential
measurement in the same group of ten patients prior to
radiotherapy, but after simple mastectomy "control" and at
1, 3, 6, 9 and 12 months after radiotherapy. There were no
signficant changes in VC, FVC, Tqq> Vmax 50, Vmax 30 and
sGaw after radiotherapy, as compared to control values.
However, there was a significant reduction at 5% level in
TLC, RV and FEV^ at 6, 9 and 12 months after radiotherapy,
as compared to the control values. Chest x-rays were unchanged
in most of these patients. Comparison of regional ventilation
between the irradiated and the non-irradiated "control"
lung at the same vertical height showed no changes either before
radiotherapy or sequentially at 1, 3, 6, 9 and 12 months
thereafter. However, there was a significant reduction in
perfusion of the upper zones of the irradiated lung corresponding
to the region receiving the radiotherapy in most of these
patients. This perfusion reduction was significant at the
5% level at 1 month and at 6 months after radiotherapy, but
was not significant thereafter.
The second study was a cross-sectional one in a group
of 48 patients at an interval of one to fourteen years after
radiotherapy, given by the same technique. The chest x-rays
showed some changes in 52% of these patients. Their values
of TLC, VC and FEVi were distributed around 100% of the
predicted normal values, thus showing normal values, but their
Tco was below 100% of the predicted normal value in most.
There was no significant change in regional ventilation between
the irradiated and the non-irradiated lungs, when compared
at the same vertical height, but there was a highly
significant reduction in perfusion of the upper zones of the
irradiated lung, as compared to the non-irradiated "control"
lung in the same patient.
It is concluded that:
1) This do$C and technique of radiotherapy had little
effect on overall lung function in these women with normal
lungs..
2) However, perfusion to the alveolus was reduced
in the irradiated region, without clinical or radiological
changes, from as little as one month, to as long as 14 years
after radiotherapy in some patients.
3) The earliest effect of radiotherapy appears to be
upon the pulmonary vascular bed in the irradiated region.
ABBREVIATIONS
Post RT Post radiotherapy
Hb Haemoglobin
WBC White blood cell
ECG Electrocardiograph
CXR Chest x-ray
TLC Total lung capacity (litres)
VC Vital capacity (litres)
RV Residual volume (litres)
FEVi Forced expiratory volume at 1.0
second (litres)
FVC Forced vital capacity (litres)
vmax Maximum flow at 50% VC (litres/sec)
Vmax 30 Maximum flow at 30% VC (litres/sec)
Tco Transfer factor for carbon
monoxide (mmol/min/kPa)





V Volume per unit of time in the gas
phase
Q Volume per unit of time in the blood
phase
(Ellis, 1971)
V% Lung volume% of total lung volume
V/E% Ventilation/alveolus of that if it
was uniformly distributed
Q/E% Perfusion/alveolus of that if it
was uniformly distributed
E Regional equilibration count rates
at TLC
I. INTRODUCTION
The lung has been defined by Ali B.R. Al-Tabari
in 850 A.D. in his book "Paradise of Wisdom" - as "An elastic
organ with wide tubes and it happened like that in order
to make it easy for the air to enter during inspiration, to
take out the burden from the heart during contraction and
relaxation".
He also mentions that "any injury in the lungs will
heal quickly, but if it is infected, it will dry the chest
dampness and push these fluids and secretions through the
throat out to the mouth".
On the other hand, cancer has been known even before
that time and Hippocrates, who said that "cancer is an
untreatable disease and any attempt to treat the cancerous
patient will cause death of that patient earlier than if it
is left alone". Furthermore, Al-Tabari explained that
"cauterizing or burning the cancer will cause its spread
to the vital organs and will kill the patient. Unless the
cancer is situated peripherally then it could be amputated
without causing a great harm to the patient" (Siddiqi, 1928).
Thus, it would appear that there is good historical precedence
for the idea that the treatment of cancerous patients should
be based on the principle of destruction of cancer tissue,
either by• amputation or by cauterization and burning.
Nowadays, possibly following similar principles, cancer
is treated by surgery and/or radiotherapy.
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i) History of radiotherapy
Following the discovery of x-rays by Roentgen in
1895, Emil H. Grubble used these rays to treat an ulcerated
carcinoma of the breast. Moreover, several workers used
the rays on many diseases. Also, the Curies discovery of
radium added a further source of radiation and this was used
at the beginning of the twentieth century for the treatment
of tumours lying deep in the body where the electrically
generated x-ray penetrated poorly.
Thereafter with developments in technology, more
powerful x-rays were produced, operating above 200,000 volts
(i.e. Ortho voltage x-ray machines). These machines produced
x-rays capable of giving high radiation doses to tissues
lying deep in the body using multiple fields all directed
at the tumour (Deeley, 1976). To obtain the maximum
destructive effect, the maximum dose of radiation to the
treatment area was given. Consequently, the effect of
overdose, necrosis of tissue, infection and sometimes death
occurred. These effects were recognised early and attempts
were made to reduce them; for example, the effect of
radiation on the lung as a result of radiation therapy to
the breast cancer was recognised as early as 1923 by
Groover, Christie and Merritt, for the x-ray fields in the
treatment of breast cancer then, were applied directly to
the breast, therefore inevitably irradiating the underlying
lung. Thus the technique of tangential therapy to the chest
wall following mastectomy was developed to minimize the
effect of radiotherapy on the lung.
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Thereafter attempts were made to measure the dose of
radiation given to the tumour, so as to provide an adequate
dose of radiation to the tumour and yet minimizing that
given to normal tissue. A unit of dose was defined as the
"roentgen" (R) which is the radiation absorption dose in
air (Deeley, 1976). A few years later, with the advancement
in medical engineering, new machines were constructed
capable of producing high voltage x-rays in the million
volt ranges (Mega voltage), e.g. linear accelerator, which
produce x-rays at very high energies with enormous penetration.
The first linear accelerator used clinically in 1953 worked
at 8,000,000 volts (Deeley, 1976).
Mega voltage therapy provided greater penetration of
rays in tissue, with a lower skin dose and thus less
radiation damage to skin and bones, reduced morbidity and
allowed for greater accuracy in definition of treatment
fields (Morrison, 1967).
At the same time advances in radiobiology revealed
that tumours which are well oxygenated were more sensitive
to irradiation that anoxic tumours, leading to the use of
hyperbaric oxygen as an adjunct to treatment. Also a better
understanding of the effect of radiation on growing tissue
was achieved by growing human tumours in culture media.
Later, the development of computers made possible
easier and more accurate calculation of the isodose
distribution. Progress was made in the locat/oA/ of
tumours, ensuring correct alignment of fields using shells
and check radiographs. Moreover, a new unit, the rad>
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(radiation absorption dose) was used clinically for measuring
the dose of radiation in' tissue (1 rad = 100 ergs/gm).
Careful attention was taken to reduce the radiation effect
on normal tissue and attempts were made to increase the
effect on the tumour by using mega voltage therapy and
the application of radiobiology in addition to the use of
computer to calculate isodose distribution and to record
clinical details. Clinical trials investigating the value
of combined methods of treatment, with surgery, radiotherapy
and chemotherapy were undertaken.
ii) Radiation physics
Ionization radiations are those radiations which are
capable of interacting with atoms and molecules in the body
to produce biological effects. The atom consists of two
parts:
1. Nucleus : containing protons with positive
charge and neutron with mass only
2. Shells : consisting of an equal number of
electrons to the protons, with
a negative charge, circulating
around the nucleus and maintained
in their orbit by the attractive
forces of the protons
Some atoms are unstable (e.g. radium) and break down
naturally into more stable substances. These unstable atoms
all have high atomic weight and during the process of decay,
alpha, beta and gamma rays are given off from the atom. Alpha
rays are particles which have the total mass of helium
nucleus. They can penetrate only a little into the tissue
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before they collide with the nucleus of an atom and release
their energy. Beta rays are electrons with a smaller mass
and penetrate more deeply before losing their energy.
Gamma rays are ionizing electro-magnetic radiations with
energy, but no mass and thus they are able to penetrate
deeply into the tissues. The depth of penetration depends
on the energy of such rays, which in turn depends on the
atoms whose breakdown or decay leads to the formation of the
ray. X-rays, on the other hand, are ionizing electro¬
magnetic rays with energy, but they are produced electrically.
Thus, x-rays and gamma rays are both electro-magnetic
rays, having a wave formation with a wave length and
frequency. As an ionizing radiation the x-rays and gamma
rays have the smaller wave length than ultra violet in the
spectrum of electro-magnetic waves. The energy of x-rays
varies according to the energy applied to the machine used
to produce them. Essentially they are produced when a
stream of electrons, accelerated by a high voltage applied
between the cathode and anode, strikes the target (anode)
and the electrons give up their energy to produce x-rays
with a high energy. A method has been devised for
accelerating the passage of electrons down an evacuated
tube and thus they hit the target with a very high velocity
and produce x-rays at very high energy (e.g. linear
accelerator) (Deeley, 1976).
These rays penetrate the tissue and the depth of
penetration varies inversely with their wave length; the
shorter the wave length, "hard rays", the deeper the
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penetration and visa versa. The quality of a radiation
beam may be expressed as the "thickness of the absorber
which reduces the intensity of radiation by one half"
("half value layer of the beam [HVL]") (Deeley, 1976). In
tissues the energy of the radiation beam is absorbed and
released locally, the remaining energy at a particular
point depending on the distance that it has penetrated
and the density of the tissues. Thus, it was possible to
measure the energy of a beam at different points in the
tissues and a chart joining together points with the same
percentage of the dose;- these lines being called isodose
curves. The dose of any particular point and the shape of
the isodose curve varies according to the energy of the
radiation beam, e.g. the isodose curve of the linear
accelerator is shown in Figure 1.
Measurements of radiation are made in Roentgen,
which is the ionization produced in 1 ml of air at normal
temperature and pressure (NTP). The measurement of radiation
absorbed dose in tissue was introduced (rad), 1 rad being
equivalent to 100 ergs/gm of tissue. The units, roentgen
and rad, are equals in cases of gamma rays or x-rays.
iii) The uses of radiotherapy
Radiotherapy is used mainly in the treatment of
malignant diseases, either alone or in combination with
surgery and/or chemotherapy. The selection of the method
for treatment may vary with the characteristics of the




The isodose curve of the linear accelerator. These numbers
are the percentage of the dose of the applied radiation
beam as distributed below the skin surface. (After Deeley, 1976)
cancer the primary may be removed by surgery and the lymph
node area may be treated by radiation.
The radiation treatment given may be radical, aiming
at a cure, or palliative, aiming at the control of the dise
e.g. tumours of the breast may be kept in control by the
doses of radiation, supplemented by hormones and chemo¬
therapy. On the other hand, radiotherapy may be palliative
to relieve distressing symptoms.
In general, the following principles are usually
followed in radiation treatment planning (Johns, 1961):
1. A homogenous dose is given to the tumour
and the maximum and minimum tumour dose
usually evaluated and recorded.
2. The field size selected to just cover the
tumour and a safe margin around it and enough
number of fields used to make the tumour
dose at least 50% larger than any other
tissue dose.
3. For ortho and mega voltage radiotherapy the
dose at the maximum in skin is usually
stated.
4. Correction of the tumour dose for air
cavities and surface irregularity is
made using bolus (material which has the
same radiation absorption characteristics
as normal soft tissues). Wedge filters may
be used also to correct for irregularities
of contour, e.g. in tangential fields in
breast.
5. The relative biological effect is determined
by the way the dose is administered. Thus
the overall treatment time, the number of
treatments and the number of fields treated
per day are recorded. It is generally accepted
that the biological effect of a given amount
of radiation depends on the fractionation of
the total dose over a period of from 3 to 5
weeks. Accordingly, the overall period between
the first and last treatment and the number of
exposures is usually stated.
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6. The source to skin distance and the half
value layer (HVL) or energy of radiation
is recorded, as these factors are involved
in determining the tumour dose.
iv) The effect of radiation on biological tissues
Radiation leads to ion production along the track of
ionizing particles, due to interaction of electro-magnetic
radiation with matter._ These ions either affect the DNA
of the cell directly or indirectly by the interaction of the
ions with water, thus generating free radicles (such as
H, OH, 0, H02 and H202) which are short-lived and very
reactive with effects on subsequent cell division and
produce chemical changes. After this damage the
cell recovers for about 4 hours, then shows the original
effect, as revealed by sensitivity to the second dose
of radiation. Thereafter further recovery occurs and
recovery is maximal at 24 hours after radiation, but
still not complete (Ellis, 1967).
Some of the chemical changes produced by the free
radicle are reversible, but if oxygen molecules are
present, a chemical reaction will take place between the
oxygen and the free radicle, producing organic peroxides
which cause the chemical lesion in a non-reversible form.
The radiation causes damage both to the genetic
material, DNA and non-genetic macromolecules such as
proteins and polysaccharides. It causes breakage of
polymer strands which can be repaired to some extent
in vivo in the first few hours after irradiation. The
lethality of damage to genetic material is a function of
the mitotic rate of the irradiated tissue.
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The damage to the non-genetic material is more
immediate and widespread, but probably less lethal.
The increased membrane permeability and fragmentation of
connective tissue produces immediate effects on function
and late effects may also occur by destruction of
basement membrane cells, as in the lungs, where this
may prevent reconstruction of tissue architecture and
result in scar formation and later functional
derangement (Gross, 1977).
Bloomer and Hellman (1975) categorised the
responses of the normal tissue to radiation therapy as
acute, intermediate and late. These responses depend upon
such factors as the nature of the irradiated normal
tissue, the volume of normal tissue irradiated and the
various time-dose features in the treatment programme.
I. Acute effects are more a function of dose rate
and time-dose fractionation characteristics than of the
total applied dose; they result primarily from the
depletion of actively proliferating cells in otherwise
homeostatic cell renewal systems. Normal tissues typically
involved in these acute radiation reactions are bone
marrow, gut, skin and other epithelial tissues.
II. Intermediate effects are related to time-dose
fractionation characteristics, as well as total effective
dose, and probably result from injury to cells with slowly
proliferating renewal systems, as in endothelium or
connective tissue. Radiation pneumonitis and pericarditis
are important intermediate effects.
III. Late effects are directly related to the
total dose received by the limiting normal tissue within
a treatment portal. This is assumed to be endothelium
or connective tissue (Rubin and Casarett, 1968). It
involves a slowly proliferating endothelial cell renewal
system, or causes alteration of the structural integrity
of certain macromolecules in the connective tissue stroma
(Bloomer et al, 1975).
) Effect of radiation on the lungs
The term radiation pneumonitis was given to early changes
in the lung following radiation, whereas the term radiation
fibrosis was given to the late changes.
The clinical recognition of the intra-thoracic changes
following radiotherapy of malignant disease (breast
carcinoma) was first reported by Groover, Christie and
Merritt in 1923. These authors described the first case
of lung reaction and compared this reaction to skin changes.
Subsequently there have been many reports concerning the
occurrence, clinical features, pathology, radiological and
physiological effects of radiation in the lungs.
1. Occurrence
The incidence of radiation pneumonitis was first reported
by Evans and Leucutia in 1925. Out of 42 patients treated by deep
Roentgen therapy for the mammary carcinoma, 5 patients showed
radiographic evidence of pulmonary fibrosis and of these, only
one was symptomatic. This paper gave about 12% incidence of
radiation pneumonitis. On the other hand, Mcintosh and Spitz
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in 1939 reported that 60% of their series (i.e. 36/60
patients with breast cancer treated with fractionated
radiation treatments of 800-2000 rads to each 5 portals)
developed radiographic evidence.of pneumonitis at 3 and
6 months after irradiation and 17% became symptomatic
(i.e. 10/60 patients).
However, Engelstad in 1940 observed that out of 386
cases of breast carcinoma treated with roentgen (given as
a tangential irradiation) and/or radium (given as a tele¬
radium treatment), only 21 patients developed the radiation
reaction in the lung (as detected by radiological changes),
i.e. the incidence was 5.4%; whereas Leach, Farrow, Foote
and WaWro in 1942 reported 77 instances of roentgenographic
evidence of pulmonary fibrosis in 347 patients with breast
cancer (i.e. 22.1%). On the other hand, Ross in 1956 used
serial radiographs to follow 49 patients with breast cancer
who were treated with the "glancing" or tangential technique.
The "fibrotic" reaction was slight in 23 patients and more
pronounced in 21 patients; only 5 patients showed no evidence
of pulmonary changes (i.e. the incidence was about 90%).
Thus the incidence, as shown by radiological changes,
varied from 5.4% to 90% in these reports. Differences in
technique, awareness, method of reporting and the evolution
of radiotherapy itself may account for some of these
variations (Gross, 1977).
Considering only breast cancer patients who were treated
with mega voltage therapy, the occurrence of radiological
changes corresponding to radiation pneumonitis was reported
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by Chu, Phillips, Nickson and McPhee (1955) as 24.5% out
of 49 patients treated with a tangential technique at
1000 kv roentgen rays. Symptomatic radiation pneumonitis
occurred in 8% of these patients. On the other hand, in
a series of 50 patients with breast carcinoma, treated on
2 million volt unit, the tumour dose was 3000-5000 given in
5 weeks. Bate and Guttman (1957) found that 35 patients (i.e.
70%) developed radiation pneumonitis, detected radiologically
within 6 months after radiotherapy. Only 7 patients (i.e.
14%) had subjective respiratory complaints attributed to
radiation. Late radiological changes corresponding to
radiation fibrosis occurred in 30 patients of this series
(i.e. 60%). They also observed that these changes increased
with increasing tumour dose.
In 1959 Gish, Coates, Dusault and Doub reported that
20% of their series developed radiological changes following
Cobalt-60 therapy for patients with breast carcinoma.
However, Fleming, Filbee and Wiernick in 1961 recorded the
incidence of radiation pneumonitis in 135 patients with
breast cancer treated with mastectomy (usually radical),
followed by a course of radical x-irradiation given in
15 treatments over 35 days, delivered at 250 kv (kilo volt).
Radiological changes developed in 56% and symptoms were
present in 13% of all patients. Late radiological changes
(i.e. fibrosis) was reported in 57%. Thus the mean
occurrence of radiation pneumonitis following mega voltage
radiotherapy is about 41% (adjusting for the number in
each series) and adjusted mean occurrence for symptomatic
14.
radiation pneumonitis is approximately 11% (Gross, 1977).
Radiation pneumonitis is also described in association
with treatment of carcinoma of the lung (Hellman, Kligerman,
Essen and Scibetta, 1964) and Hodgkin's disease (Libshitz
and Banner, 1974).
2. Clinical features
The clinical syndrome can be divided into two consecutive
phases (Smith, 1963; Rubin and Casarett, 1968; Gross, 1977):
I. An acute phase called "radiation pneumonitis"
(consisting of early x-ray changes and/or
symptoms) occurring one to six months after
the completion of four to six week course of
x-irradiation.
II. A late phase "radiation fibrosis" which may
follow the acute phase-
Acute phase
The symptoms in this phase are dependent upon the degree
of pulmonary involvement and may vary from none, through
vague symptoms of malaise, to severe respiratory distress
at rest. If less than half of one lung is involved, there
may be mild fever, vague respiratory symptoms and a feeling
of "fullness" in the chest. If more lung tissue is involved
in the reaction, shortness of breath and cough, particularly
on exertion, may appear (Rubin and Casarett, 1968). The
cough is an early troublesome symptom which is irritative
or harsh and initially non-productive, but, later, small
amounts of sputum may be produced. Dyspnoea may be at
first present only on exertion, but in a severe case it may
progress rapidly to dyspnoea at rest. Fever may appear in
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severe cases. Chest pain is rarely a prominent feature,
but may be due to associated complications with the
radiation pneumonitis, such as rib fracture, pleural or
pericardial changes (Gross, 1977). Physical signs in the
chest are usually absent, but some times consolidation is
present in the region corresponding to pneumonitis. A
pleural friction rub or pleural fluid may be detected and
skin changes caused by irradiation may provide a clue to
the presence or severity of the pulmonary reaction. In
severe forms, the pneumonitis can be considered part of the
spectrum of the adult respiratory distress syndrome, with
cyanosis refractory to oxygen, breathlessness, stiff lungs
and widespread alveolar infiltrates on chest x-ray.
Occasionally evidence of acute cor pulmonale appears.
The acute stage of clinical radiation pneumonitis may
persist for as little as a week and then subside gradually.
In severe cases, the progression from mild dyspnoea to death
in respiratory failure may occur in a matter of days
(Gross, 1977).
Late phase
Symptoms are again directly related to the degree and
extent of lung damage. Scarring of up to half of one lung
is well tolerated and rarely causes symptoms. Although the
majority of patients with clinical radiation pneumonitis may
become asymptomatic during later months, nearly all will
eventually develop radiological evidence of pulmonary
fibrosis in the region of the pneumonitis (Bates and Gutman,
16.
1957; Fleming et al, 1961; Hellman et al, 1964). In few
patients (e.g. those who had severe pneumonitis) the
distortion of pulmonary architecture by superimposed fibrosis
may result in severe physiologic abnormalities and chronic
respiratory failure with symptoms of dyspnoea on effort,
reduced exercise tolerance, orthopnoea, cyanosis and some
times chronic cor pulmonale (Rubin and Casarett, 1968).
The time course of these late changes is variable.
Symptoms of pneumonitis (mentioned before) may proceed
directly to those of fibrosis (i.e. dyspnoea on effort,
orthopnoea and cyanosis) and may be separated from them
by an interval of several months, during which scarring
becomes more severe. Some patients may present with symptoms
only in the state of fibrosis, following a silent pneumonitis.
Once a scar develops, it persists for life (Gross, 1977).
Occasionally symptoms due to tumour are confused, especially
when the radiotherapy has been used to treat lung cancer.
3. Associated complications
a. Pleural changes: Pleural reactions, such as a friction
rub or pleural fluid, have been reported by Chu et al (1955)
in two out of 18 patients with breast cancer treated with
a tangential technique at 250 kv. On the other hand, Bate
and Gutman (1957) noted pleural effusions in 3/30 patients
treated for breast cancer with a dose of <5000 rads and in
4/20 patients who received >5000 rads. Moreover, Bachman and
Macken in 1959 reported a pleural reaction in 11/200 patients
who received radiation therapy for breast cancer. In this
series the pleural effusion appeared 2-6 months after
completion of radiotherapy, always accompanied radiation
pneumonitis and some times persisting for very long periods.
b. Spontaneous pneumothorax: Libshitz and Banner (1974)
reported the occurrence of spontaneous pneumothorax in two
patients who received extended field radiation therapy to
the thorax for Hodgkin's disease; radiation changes in the
lung (i.e. radiation pneumonitis) was present in both
patients.
c. Radiation effect on the heart and pericardium: Electro¬
cardiographic (ECG) changes caused by irradiation were
reported by Eggers in 1941 who described T-wave changes
following x-ray therapy for lung tumours. Thereafter
several reports have described the ECG changes following
radiation therapy in breast cancer. Catteral and Ogilvie
(1959) found that 5/6 patients who had their 250 kv x-ray
therapy to the left chest showed ECG changes four months after
irradiation; whereas none of the 6 patients who received
the same radiation to the right chest developed any ECG
changes. The ECG changes consisted mostly of T-wave changes
(i.e. flattened, biphasic or inverted T). These findings were
confirmed by Catteral in 1960 who noticed abnormal T-waves
in the ECG in 9/12 patients with left breast cancer, subjected
to post-mastectomy treatment from 250 kv machines. There
were no ECG changes in 8 patients with right sided breast
cancer. These ECG changes were found also following
radiotherapy of malignant intra-thoracic tumours (Jones
and Wedgewood, 1960; Takaoka, Kaneda, Urano and Kikkawa,
1968; Rubin and Casarett, 1968). However, the origin or
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exact causes of these changes have not been definitely
proved. Structual changes in the human myocardium and
damage to the normal pericardium have been observed and
associated with very large doses of radiation (Rubin and
Casarett, 1968). Later on, Westerhof and Vander Putte (1976)
reported a case of constrictive pericarditis due to radiation
for Hodgkin's disease. At necropsy an extensive fibrosis of
the myocardium was located in the anterior part of the
heart. On the other hand, Green and Ricks (1977) reported
the development of pericardial effusion in 3 patients treated
with radiation for carcinoma of the left breast. The
effusions were loculated on the right side of the pericardium.
4. Pathological changes in radiation pneumonitis and fibrosis
The lung damage induced by radiation results in a loss
of reproductive capacity of dividing cells. Thus the
radiation-induced chromosomal changes will be most marked
in the bronchial epithelial cells, capillary endothelial
cells and type 2 pneumocytes as these cell types have the
highest mitotic rates (Spencer and Shorter, 1962; Tannock
and Hayashi, 1972; Gross, 1977). The pathological changes
of radiation damage have been derived mainly from animal
studies, as the pathologic material is irregularly available
from humans who have received radiation to the lung and
usually these patients show a late stage of radiation damage.
Animal studies
Radiation-induced lung damage was studied by Engelstad
(1940) in rabbits. Thereafter several ultrastructural.studies
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were made in rats (Jenning and Arden, 1961; Phillips, 1966;
Adamson, Bowden and Wyatt, 1970; Phillips and Margolis,
1972); and in hamsters (Madrazo, Suzuki and Churg, 1973)
and were reviewed by Rubin and Casarett (1968) and Gross (1977).
In general the pathological changes are divided into
three chronological phases; the early phase, occurring up
to about two months after irradiation, is followed by the
intermediate phase from 2-9 months and the late phase after
9 months (text Table 1). Radiation thus has acute damaging
effects on all tissues in the lungs. Rubin and Casarett
(1968) suggested that the damage and response of the fine
vasculature (capillaries, arterioles and venules) and the
connective tissue elements played a prime role in the reaction
of lung to irradiation. Many authors concluded that damage
of capillaries may be the major factor in the genesis of
subsequent pathology.
Histopathological changes in humans
Studying the sequence of pathological changes in human
radiation pneumonitis is difficult because of the lack of
material obtained systematically and also due to the
presence of secondary changes resulting from superimposed
infection, heart failure and post mortem artefacts.
Histological studies on the lungs of patients dying 4-12
weeks after completion of radiation therapy showed lesions
in all the structures of the lung.
1. Vascular lesions were evidence by engorgement and
thrombosis of capillaries and arterioles, oedema, intimal
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proliferation and medial changes, together with subintimal
accumulation of lipid-laden macrophages (Bennett, Million
and Ackeaman, 1969; Rubin and Casarett, 1968; Gross, 1977).
2- The alveolar epithelial cells (type 2 pneumocytes)
showed atypia, hyperplasia and desquamation (Warren and
Spencer, 1940; Jenning and Arden, 1962; Bennett et al, 1969).
3. The alveolar space The presence of fibrin-rich -
deposition and hyaline membranes in the alveolar space were
reported by many authors.
4. The alveolar septum showed early thickening due
to oedema, mononuclear cellular infiltration and laying
down of connective tissue (Warren and Spencer, 1940;
Jenning and Arden, 1962; Bennett et al, 1969).
5. Changes in the bronchial wall, including focal
necrosis, of the mucosa have been reported (Mcintosh and
Spitz, 1939). Pleural changes are occasionally observed
(Chu et al, 1955) and changes in the right ventricle have
been considered secondary to the pulmonary changes (Smith, 1963).
5. Radiological changes
The earliest radiological evidence of damage occurs
at 2-3 months and consists of a ground glass opacification,
or diffuse haze (Bate and Gutman, 1957), or indistinctness
of the normal pulmonary markings. Depending on the time
and severity of the changes, the appearances may be
alveolar, nodular or dense, resembling consolidation
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(Gross, 1977). Pleural interlobar or pericardial
effusions are occasionally noted (Rubin and Casarett,
1968). Hagen and Kolbenstvedt (1971) studied the chest
x-ray in 70 patients with breast cancer treated by radical
mastectomy followed by irradiation; 13% of these patients
had no changes on the x-ray, 23% had slight changes, 43%
had moderate changes and 21% had marked changes. The
initial changes, influenced by the technique of radiotherapy,
appeared at about 2 months as an indefinite, fan-shaped
infiltration with its apex pointing towards the hilum;
this subsequently changed to radiating strands suggesting
fibrosis. Shrinkage gradually followed which caused
elevation of the hilum and upper diaphragm. Compensatory
emphysema of the lower part of the lung has been observed
as well. Pleural thickening was a common change also
(Hagen and Kolbenstvedt, 1971).
In general, radiologic pneumonitis will invariably
proceed gradually to the stage of radiologic fibrosis
unless treated (Libshitz and Banner, 1973), When fibrosis
occurs, the lesion shows linear streaks radiating from the
area of previous pneumonitis. Contraction of the region,
pleural thickening and tenting of the diaphragm are also
seen. In severe unilateral cases, contraction of volume
may result in retraction of the hilum or mediastinum toward
the region,, with tracheal deviation, elevation of the
diaphragm and the appearance of a densely fibrotic
contracted lung segment with compensatory emphysema of the
adjacent or contralateral lung tissues (Gross, 1977).
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These changes may take 12 months or more to produce
and may appear up to 2 years after irradiation (Fleming
et al, 1961).
6. Causes of lung damage
The incidence and severity of radiation damage to the
lungs are related to several technical factors, including
the volume of lung tissue irradiated, the quality of
radiation, the total dose and mainly the rate at which the
total dose is delivered [as repair of sublethal damage
occurs between each fractional dose (Gross, 1977)] . The
relationship between the biological effect of radiation
[Nominal Standard Dose (NSD) in ret (radequivalent therapy)]
and the total dose absorbed (rad), number of fractions (N)
and the time over which the total dose is delivered (T)
can be described by:
NSD (ret) = total dose (rad). N-0'24 .T~0,11 (Ellis, 1969
Phillips and Margolis (1972) and Wara, Phillips, Margolis
i
and Smith (1973) have modified this formula to calculate the
effect of radiation given to the entire lung volume, in both
mice and humans. They found that there is a 50% probability
of developing clinical pneumonitis with a dose of 713 ret,
or 3050 rad given in 20 fractions over 4 weeks when this
dose is given to the entire lungs.
Factors such as concommitant chemotherapy (e.g.
bleomycin and radiotherapy), previous radiation therapy or
steroid withdrawal have been considered to potentiate the
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damaging effects of radiation (Wara et al, 1973;
Whitfield, Bond and Arnott, 1956; Castellino, Glatstein,
Turbow, Rosenberg and Kaplan, 1974). Age, on the other
hand, was not considered as an important contributing
factor for the development of radiation damage in the
lung (Rubin and Casarett, 1968), but is possibly related
to the severity of radiation reaction once it occurs
(Hagen and Kolbestvedt, 1972).
7. The physiological changes
Many studies of changes in pulmonary function have
been carried out on animals, as well as in human patients
with breast or lung cancers. The majority of these studies
had radiological changes of radiation pneumonitis and/or
radiation fibrosis, and the results differ slightly between
these studies. Previous human retrospective studies
(Leach et al, 1942, 1943; Whitfield et al, 1956; Stones,
Schwartz and Green, 1956) suggested that radiation damage
of the lung (radiation fibrosis) causes reduction in
lung volumes and maximum breathing capacity as compared
to their expected values, based on the usual prediction
formulae. Later, several studies of pulmonary function before
and after radiation were reported, and comparisons between
the results of each measurement were made. Measurements
of pulmonary function in animals before and after radiation
were made by Sweany, Moss and Haddy (1959) who studied the
effect of two different irradiation schedules, applied to
the mid-chest of eight dogs (in a single exposure) and of
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another seven dogs (in fractionated doses). They found
that the functional residual capacity (FRC) (as determined
by the open circuit method during spontaneous breathing),
total thorax, lung and chest wall compliance (obtained
by the static method), the diffusing capacity (estimated
by the steady state CO method during spontaneous breathing)
and pulmonary vascular resistance (as measured at cardiac
catheterisation) were unchanged within the first few
weeks following irradiation, although pathologic changes
were evident. However, the FRC, lung compliance and
pulmonary diffusion capacity then fell progressively at
81, 137 and 172 days following irradiation, but the
pulmonary vascular resistance remained normal for a period
of five months following irradiation.
Moreover, Teates in 1965 studied the effect of
unilateral thoracic irradiation (in fractionated doses)
on the lung function in 5 dogs. He compared the function
of each lung (i.e. the irradiated and the shielded) prior
to irradiation and at frequent intervals up to 207 days
after irradiation. The function of the irradiated lung
was reduced as compared to the non-irradiated lung in all
indices measured (minute ventilation, diffusing capacity,
02 consumption and C02 production and compliance) as shown
in Figure 2. This reduction was significant at 200 days
after irradiation. The chest x-rays and pathology of the
irradiated lung confirmed radiation pneumonitis, although
there were considerable variations in the degree of damage
from one animal to another and within the same lung.
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Figure 2
The percentage changes of the ratio (irradiated lung to
non-irradiated lung) of ventilation (Ve), transfer
factor for Co (DLCo), compliance (C), oxygen consumption
(V02) and CO2 production (VC02), plotted against time (days)
after radiotherapy, in 5 dogs. (After Teates, 1965).
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Furthermore, clinical experience has been related to
serial physiological studies carried out before and after
thoracic irradiation for lung or breast cancer. Catteral
and Ogilvie (1959) studied the pulmonary function of 12
patients with breast cancer treated with mastectomy and
deep x-ray therapy. They measured the vital capacity,
maximum voluntary ventilation and flow rate, the diffusing
capacity and an exercise tolerance test before radiotherapy
and at two weeks, one month, three months and four months
after radiotherapy. They found that there was a reduction
in the vital capacity and diffusing capacity four months
after radiotherapy. These findings were confirmed by
Cooper, Guerrant, Harden and Teates (1961) who found that
the ventilatory function (as measured by vital capacity and
maximum breathing capacity) was impaired in patients having
radiotherapy at 3000-4500 rads tissue dose at 3-5 cms, over
3-5 weeks for their breast cancer. This impairment persisted
or progressed as the acute reaction in the lung subsided
into the chronic stage (shown by serial x-rays and
clinical examination); for example, the vital capacity
was reduced by an average of 500 ml at 3 months after
irradiation and this reduction persisted at six, nine and
12 month measurements, whereas the arterial oxygen saturation
was reduced only in the acute period.
These studies illustrated the importance of studying
patients with normal lungs prior to irradiation. Thus,
Emirgil and Heinemann (1961) followed 15 patients who were
free of cardiac and pulmonary diseases before receiving
irradiation so as to determine the effect of radiation on
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pulmonary function. Control measurements had been made
before irradiation in only four patients with mammary
carcinoma (treated with 4000-5000 rads using a 2 MeV machine),
in whom serial studies were made during the follow-up period
which lasted as long as 297 days after the start of
radiotherapy. Their results were as follows:
1. Lung volumes
A measurable reduction in total lung capacity (TLC)
was detected from one to three weeks after irradiation in
all subjects with unilateral pneumonitis, and this reduction
was accompanied by a decrease in vital capacity (VC) and
residual volume (RV) (Figure 3).
2. Oxygen and carbon dioxide content and tension in
arterial blood
All subjects with unilateral pneumonitis had mild to
moderate hypoxia at rest which improved as time elapsed.
3. Diffusing capacity for carbon monoxide and oxygen
Evidence of a transient reduction in diffusion capacity
of carbon monoxide (DLC0) appeared later at 60-162 days
in patients with unilateral pneumonitis. In time the DLC0
returned to normal in most patients..
4. Ventilation
The tidal volume decreased and the respiratory frequency
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Figure 3
Lung volumes in ml BTPS before irradiation and at different
intervals after irradiation in 4 subjects with unilateral
radiation pneumonitis. (After Emirgil and Heinemann, 1961).
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5. Mechanics of breathing
The maximal breathing capacity (MBC) was decreased in
proportion to the degree of involvement. Pulmonary compliance
was reported to be reduced progressively in some patients.
The mean pulmonary resistance to air flow (flow-resistance)
was slightly elevated in several subjects.
These authors indicated that irradiation of the
chest, using a 2 MeV unit, with a tumour dose of 4400-5000
roentgen over 36-39 days, is complicated by a fall in lung
volumes, an impairment of the diffusing capacity and an
increase in the work of breathing at 80-200 days after
irradiation. They also suggested that tests such as lung
volumes and diffusion capacity are more sensitive than
radiologic changes in anticipating clinical radiation
pneumonitis. Thereafter several authors have studied the
effects of radiation therapy on pulmonary function in carcinoma
of the lung.
Tt IT
Voutilainen, Mahonen and Heinonen (1962) measured
the vital capacity (VC), total lung capacity (TLC), residual
volume (RV), function residual volume (FRV), maximum
breathing capacity (MBC) and the diffusing capacity for
carbon monoxide (DLCO) of 15 patients with bronchogenic
carcinoma treated by radiotherapy. Their measurements
were made before radiotherapy and were repeated immediately
and at 3, 6 or 9 months after radiotherapy. They found that
there was reduction in the functional residual volume (FRV)
and DLCO in those cases who had abundant fibrotic changes due
to irradiation, as shown on the chest x-ray. These results
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were confirmed by Brady, Germon and Cander (1965) who
found that reduction in the single breath diffusing
capacity for carbon monoxide (DLCO) was the single and most
significant change at 4 weeks after radiation therapy
(median dose of 5200 rads over median elapsed time of 34 days)
in 14 patients with carcinoma of the lung. In 1968, Germon
and Brady studied the physiological changes before and
after radiation treatment for carcinoma of the lung in 30
patients. Chest x-ray and pulmonary function measurements
were made prior to therapy and at 1, 3, 6, 9 and 12 months
after irradiation. They found that the vital capacity (VC)
generally increased at one month interval and progressively
decreased thereafter. The residual volume (RV) was found
to decrease in the majority of their patients after
radiotherapy. The diffusing capacity measurements were
reduced in all except 5, at the one month study, but at 3, 6,
9 and 12 months further reduction of a lesser magnitude was
noticed. On the other hand, the lung scan results [using
131 131
I serum albumin aggregated (MAA I human)] before
radiotherapy showed areas of abnormally reduced pulmonary
capillary blood flow. These areas showed further reduction
after radiotherapy. These authors suggested that the lung
function changes were non-specific changes and that alterations
in the capillary blood flow and the resultant tissue
changes were initiated by the co-existing tumour and
aggravated by the radiation therapy.
However, in 1969, Cudkowicz, Cunningham and Haldane,
studied a group of 36 patients with breast cancer treated
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either with simple or radical mastectomy followed by
Cobalt-60 radiotherapy. Pulmonary function tests were
performed after 9 treatments, at completion of irradiation
and at 3, 6, 12 and 18 months after radiotherapy. They
compared their results with a group of normal women of
similar age. These authors reported progressive reduction
in physiological dead space, reaching a maximum decline at
12 months following irradiation with a partial recovery
thereafter, but the reduction in the diffusing capacity
was rapid and recovery began at 18 months and improvement
recorded later. Residual volume was found to be raised
immediately at the end of radiotherapy, but rapidly returned
to normal. These results showed the combined effect of
mastectomy and radiotherapy, but without having control
values for these measurements before therapy.
In 1970 Boushy, Helgason and North studied 42 patients
with bronchogenic carcinoma treated with radiotherapy.
All had pulmonary function studies and chest x-rays before
radiotherapy and 33 had repeated studies after completion of
therapy (i.e. at about 7 weeks). Their results showed
that there was a significant reduction in the diffusing
capacity for carbon monoxide (DLCO) after irradiation and
a reduction in the pulmonary resistance at expiration;
whereas a significant increase in the minute ventilatory
ventilation was reported after radiotherapy in these patients.
These results were thus confirmed by other reports.
Moreover, studies of lung function after upper
mantle-field irradiation for Hodgkin's disease were
reported in 1973 by H0st and Vale who studied 17 patients
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before radiotherapy and at 2 and 15 months after
radiotherapy. They found a reduction in vital capacity
following radiotherapy which was confirmed by Evans,
Sagerman, Ringrose, Howland, Auchincloss and Bowman (1974)
who studied 11 patients with Hodgkin's disease treated
in the same manner. A reduction of total lung capacity (TLC)
and residual volume (RV) caused by radiotherapy was also
found by H0st and Vale (1973), as shown in Figure 4.
Changes in pulmonary compliance caused by ionizing
radiation have been studied in rats by Nairmark, Newman
and Bowden (1970). They studied the deflation pressure
volume curves in the irradiated lungs and compared them
with those of the control lungs. They found that the compliance
of the lungs was normal one month after radiation, but
thereafter a progressive reduction in compliance was
recorded, associated with the severity of the radiation
reaction in the lung. This reduction in compliance of
the irradiated rat lungs was confirmed by Shrivastava,
Hans and Concannon (1976) at six weeks after irradiation,
when the dose of irradiation delivered to the rat lung
exceeded 1500 rads.
On the other hand, Teates in 1968 studied the pulmonary
blood flow changes following a unilateral right thoracic
irradiation of 3 dogs. A mid-lung dose of 3000 rads was
directed to the entire right lung, but sparing the left lung
in 3 doses over a 5 day period. A lung scan and thoracic
x-ray were carried out prior to irradiation and at frequent
intervals up to about 400 days after irradiation. Scans
131





















The lung volume changes [vital capacity (VC) and residual
volume (RV)] before and after upper mantle-field irradiation
for Hodgkin's disease in 17 patients. (After H0st and Vale,
1973).
macroaggregated human albumin. Pulmonary arteriograms were
also performed at about 400 days after irradiation in each
l
dog. The total scan density of the right lung was compared
to the total scan density of both lungs and the values
for estimated percentage artery perfusion of the right
lung were calculated. The estimated blood flow to the
right lung prior to irradiation averaged 49.5% of the
total lung perfusion in the 3 animals, and by 52-109 days
after irradiation the flow was markedly reduced, as shown
in Figure 5. Loss of volume of irradiated lung was noticed
on the arteriogram. The pathology of the irradiated lung
and the chest roentgengrams confirmed the presence of
radiation pneumonitis. The results showed no significant
improvement in the blood flow as the pneumonitis cleared,
leaving the late fibrotic stage. Johnson, Sagerman and
Dombrowski (1970) also confirmed the reduction in pulmonary
blood flow following irradiation of the entire right lung
131
in Swiss mice, using an injection of a suspension of I
labelled macroaggregated human serum albumin (radioactivity
content was measured by a scintillation counter). The
results were expressed as Pulmonary Perfusion Ratio (PPR)
of the irradiated lung to the control lung. They concluded
that the pulmonary ischaemia caused by radiation is an
irreversible process and that the intensity of this ischaemia
is affected by both the size of the radiation dose and
also by the length of survival following treatment. Korsower,
Skovron, Ghossein and Goldman (1971) studied pulmonary artery
perfusion in 44 rabbits, following a single exposure of
3000 rads to either hemithorax, through an anterior field
36.
Days Post - Irradiation
Figure 5
Estimated percentage of pulmonary blood flow to the
irradiated right lung. The average values for the
3 animals and their ranges are indicated. (After
Teates, 1968).
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over a period of 15-18 minutes. Lung scans (using I.V.
131
injection of I MAA) and chest x-rays were performed
on each animal prior to irradiation and 2 hours, 24 hours
and 48 hours after irradiation, some animals also being
studied 3 weeks and 2 months following irradiation. They
found the chest x-ray to be normal before therapy and at
2, 24 and 48 hours after irradiation; whereas the lung
scan showed moderate to marked reduction in pulmonary
arterial perfusion of the irradiated lung in 52% of the
rabbits (as compared to the control lung and to the lung
scans prior to irradiation) as soon as two hours after
irradiation. Pulmonary angiograms performed (on 5 animals)
at that time demonstrated delayed opacification in pulmonary
artery and vein on the irradiated side, indicating reduced
blood flow on that side. However, perfusion was reported
to return to normal at 24 hours, 48 hours and 3 weeks, as
assessed by lung scans. Yet, the 5 rabbits studied two
months after irradiation showed marked reduction in
pulmonary artery perfusion on the irradiated side. Later
on, Freedman, Lofgren and Kligerman (1974) confirmed the
reduction in perfusion 2-4 hours after a lethal dose of
irradiation (4500-6000 rads), but also reported early
hyperemia with increased perfusion during the first few
days after a single dose of irradiation (1500 and 3500 rads)
to the right lung of their experimental rabbits. These
results were confirmed by Fernholz, Elfes, Frik and
Breining (1977). A reduction in perfusion in the lung scans
of these animals was reported at 3 weeks and onward, this
reduction reaching a level of 50% of the base-line at about
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the hundredth day after irradiation (Figure 6).
Fernholz et al (1977) found that perfusion returned
to normal between the third and tenth day after a single
dose of irradiation, but by the twenty-first day the
perfusion was found to be diminished in the affected
lung with a corresponding increase in perfusion in the
non-affected lung. On the other hand, changes in pulmonary
artery perfusion in humans following thoracic irradiation
have also been reported (Johnson, Sagerman and Jacox, 1968;
Goldman, Freeman and Ghossein, 1969; Bake, Bjure,
Johansson, Rosengren and Stiksa, 1969; Shinohara and
Arkiawa, 1972; Abe, 1974), seven out of the 16 patients
(with intra-thoracic tumours treated by radiotherapy)
studied before and after radiotherapy being found to have
ischaemic changes or an increase in the pre-existing
131
ischaemia as shown by the lung scan with I macroaggregated
albumin, but the x-ray signs of radiation damage to the
lung or pleura were less marked in these patients
(Johnson et al, 1968). These results were confirmed by
Goldman et al (1969) who studied 36 patients undergoing
thoracic irradiation before treatment, at the completion
of the treatment and at several intervals thereafter
(1£, 3, 6 and 12 months after radiotherapy). One third
of their cases had evidence of radiation pneumonitis and/or
fibrosis with changes on either chest x-ray or in a
perfusion scan with a defect suggesting radiation
pneumonitis. These ischaemic changes shown in lung
scans were greater than the fibrotic infiltrate seen on




The reduction in the blood flow to the right irradiated
lung as a percentage of the control lung in the
rabbits following different doses of irradiation.
Early hyperemia, with increased perfusion during the
first few days, was reported. (After Freedman et al, 1974).
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On the other hand, Bake et al (1969) studied the
pulmonary perfusion as part of their regional lung function
studies in patients with a local pulmonary radiation
reaction. They studied nine patients with carcinoma of
breast treated with mastectomy and conventional radio¬
therapy. The first study was carried out when the patients
showed radiological changes (i.e. about 2-4 months after
treatment); the second study was performed at 1-4
months later (i.e. when radiographic changes and clinical
symptoms diminished). Their studies included
quantitative evaluation of tissue density using gamma
137 131
radiation from Cs , lung scan with I labelled MAA
133
(200 mCi) and a xenon scan (regional ventilation and
perfusion scan). They found that there was a reduction
133
in both perfusion (lung scan and xenon scan) and
ventilation in the irradiated region of the affected lung, as
compared to the other lung in their patients showing
x-ray changes after radiotherapy. However, in the second
study (1-4 months later, when x-ray changes were resolving)
there was no difference between the perfusion or ventilation
of the affected lung, as compared to the other side, but
the ventilated lung volume of the affected side was less
than the unaffected. Thus, these authors concluded that
the total ventilation and perfusion to the affected side
was reduced. Moreover, Shinohara and Arikawa (1972)
reported that the relative pulmonary arterial blood flow
reduces in the irradiated side of the lung before the
occurrence of radiation pneumonitis in patients receiving
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incidental pulmonary irradiation for post-operative
radiotherapy for breast cancer. They concluded that
131
lung scanning using I labelled MAA could be used for
earlier detection of radiation pneumonitis. These
findings were confirmed by Abe (1974) who carried out
131
quantitative radioisotope scanning (using I.V. I MAA)
before and after radiation therapy in 25 patients receiving
post-operative irradiation for breast cancer. He reported
that the pulmonary blood flow reduced after irradiation
and that the degree of reduction was proportional to the
post-irradiation changes in the chest x-rays. He found
also that the reduction of the blood flow occurred before
the alteration of the chest x-rays.
In addition, recently Prato, Kurdyak and Saibil (1977)
0 0
studied 18 patients who had received post-operative Co
radiotherapy for their breast cancer. They studied each
patient once from 3 months to 6.7 years after the start
of their radiation therapy. These patients were chosen
to be free of pulmonary or metastatic disease and had simple
or modified radical mastectomy followed by 5 field radiation
treatment (anterior and posterior supraclavicular and axilla,
two parallel opposed tangential fields to the chest wall
and an anterior field to the internal mammary glands) using
Cobalt 60. Another group of 20 patients who had the same
operation about one month previously, but who had not
started their radiation therapy, were also clinically free
from pulmonary or metastatic disease, and were used as
a control group.
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These authors measured both static and dynamic
lung volumes (TLC, FRC, VC, ERV, FEV^, FVC), maximum
breathing capacity (MBC), maximum end-expiratory flow
from 75% to 25% of vital capacity (MMEF) and blood gases
and pH using arteriolized capillary blood. Clinical
examination and chest x-ray were also carried out at
this time. Regional lung function measurements were also
133
made, using radioactive Xe in the supine position, measuring
ventilation/unit lung volume ([V]r), blood flow/unit
ventilated lung volume ([Q]r), regional total lung capacity
(TLC)r, blood flow to the ventilated alveoli (Qr) and
the ratio of residual volume to total lung capacity (RVr/TLCr).
These authors found that values for FEV]_, FVC and ERV to be
significantly reduced in the irradiated group as compared
to their control group, but that the arterialized capillary
blood gas tensions were within the normal range. They
calculated their indices of regional lung function as
a ratio of that variable in the irradiated apex to an
equivalent area of the opposite (untreated) lung apex and
compared these ratios (i.e. irradiated/non-irradiated) with
those of the control group. They found that the ratio of
([Q]r), ([V]r), (Q)r and (TLC)r was significantly lower in
the irradiated group as compared to those of the control
group; whereas the RVr/TLCr ratio was significantly higher.
They also found that their radiographs under-estimated
functional radiation damage and that in each patient
blood flow changes were either more severe or equally
severe as the changes in TLCr. On the other hand, some of
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their cases had better function in the irradiated apex, thus
suggesting that these variations could be due to pre-existing
physiological differences and/or the response to radiation
treatment. They therefore suggested that it is necessary
to study patients before and at various times after
treatment.
In a further study, the same authors (Prato,
Kurdyak, Saibil, Rider and Aspin, 1977) studied 25 patients
irradiated for breast cancer (using the same technique as
in their previous work). They repeated the same total
measurements and regional measurements of pulmonary blood
flow and ventilation before and at various times (from
16-407 days) after radiotherapy and also estimated the
dose in the irradiated apex from the 5 radiation fields and
found that it varied from between 846 to 1536 rets (rad
equivalent therapy). Thus, they suggested that since the
pulmonary tolerance was thought to be between 800-1000 ret
(Wara, Phillips and Mangolis, 1973), then most of their
patients received more than this dose. They found that only
FVC and ERV were significantly reduced on the average
values measured 100 or more days after the start of treatment,
by comparison to their pre-treatment values. The pre-
treatment regional lung function was compared to the
average of the values measured 60 days or more after
radiotherapy. They found that radiation caused marked
reduction in the regional blood flow to the ventilated
alveoli (Qr) at all times after treatment and a similar
reduction was also found in TLCr. Furthermore, the
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reduction in ventilation ([V]r)and perfusion ([(^]r) was not
very marked and shortly after irradiation the reduction in
([Q]r)was smaller than ([V] r) with a subsequent recovery, and
beyond 300 days the average values of ([Q]r) and ([V] r) were
virtually the same. However, values at 232 days showed
a picture of under-perfusion rather than under-ventilation.
The results of their regional studies are shown in Figure 7.
The authors also estimated the perfusion by two
13-3
techniques; by Xe injection and from the injection of
9 9m
Tc macroaggregated albumin in 5 patients at 42 days or
more after radiotherapy. They found that these two
techniques gave very similar estimates of the amount of
blood flow damage. Moreover, these authors suggested that
changes in blood flow ([Q] r) preceed and are more severe than
changes in the volume of ventilated tissue (TLCr) and that
the alveolar damage results from the direct effect of
irradiation.
On the other hand, these authors reported no
relationship between clinical symptoms and either radiological
changes or lung function measurements. They suggested
also that prediction of those individuals who are going
to develop severe pulmonary complications could be made by
measuring the regional lung function at the end of 3 weeks
or more following radiotherapy.
In general therefore, pulmonary function changes
following irradiation of the lungs (animals or humans)
could be summarised (Gross, 1977):
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Figure 7
The regional lung function [Q]r, [V]r, TLCr and Qr)
in 25 patients after post-operative Co°0 radiotherapy
for breast cancer. Each point represents the average
value of that parameter for a group of 6 patients, plotted
at the mean time after the start of radiotherapy. All
measurements are normalized to pre-irradiation values.
(After Prato et al, 1977).
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I Lung volumes: a symmetrical reduction in all
compartments (TLC, VC, RV, FVC) observed at 11 weeks after
radiation and which, in some cases, may develop earlier
and may persist for 5 years or for as long as 14 years.
II Transfer factor for carbon monoxide (TCP): probably
indicating impaired gas exchange reduced at 4-11 weeks after
radiotherapy and may remain reduced for 6-18 months, then
may gradually return to normal. These changes have been
associated with mild arterial hypoxia and an increased
alveolar to arterial oxygen gradient.
III Lung mechanics: a reduction in compliance related
to both dose and time has been seen in both animal and
human studies, coinciding with radiological pneumonitis and
progressing to fibrosis. Maximum breathing capacity (MBC)
has been reported previously to be reduced, but Prato et
al (1977) reported a non-significant increase in MBC.
Airway resistance has been reported to be either normal or
slightly increased. The elastic work of breathing is
increased as a result of the reduced compliance.
IV Reduction in pulmonary perfusion: has been shown
on both clinical and experimental studies to occur in the
irradiated lung. Moreover, hypoperfusion was found to be
confined to the irradiated lung by both lung scansjand by
133
regional pulmonary perfusion studies with Xe , with
reduction in perfusion involving the irradiated region.
These perfusion changes were reported to appear one to
two months after irradiation and presumed to result from
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the structural effects of radiation on the pulmonary
capillary bed.
Breast cancer is a common malignant disease and,
as mentioned above, since radiation pneumonitis occurs mainly
following radiotherapy for breast carcinoma, it therefore
follows that the effect of radiation on lung function
(regional and total), in otherwise normal lung, can be
studied in these patients; whereas such a study in women
involving radiation for experimental purposes only would
clearly be unethical.
vi) Carcinoma of the breast
Carcinoma of the breast principally affects women
aged between 40-50 years. The tumours characteristically
spread:
a) locally to the neighbouring tissues
such as pleural involvement through
the chest wall
b) lymphatic, either by emboli or by
permeation to involve the axillary,
supra-clavicular, internal mammary
lymph nodes and also the opposite
breast and the mediastinal lymph
nodes
c) haematogenous with skeletal, liver
and brain metastases
Histopathological varieties of breast carcinomas include
(Bruce and Hayward, 1975): scirrhous carcinoma (63%),
anaplastic carcinoma (17%), intraduct carcinoma (8%),
atrophic scirrhous carcinoma (5%) and others.
In the present studies the carcinoma was staged
clinically at the time when the patient was first seen.
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The Manchester staging system was in use until 1958, this
then being replaced by the International TNM (Tumours, Nodes,
Metastases) system until 1973, when the Union International
Contra Cancer and the American Joint Committee on Cancer
Staging (UICC/AJC) issued an agreed system of staging
(TNM, 1973). The International Staging is summarised as
follows (Langlands, 1976):
Stage I A tumour of 5 cm or less + partial
fixation to overlying skin
Stage II As in Stage I, but associated with
palpable mobile homolateral
axillary lymph nodes
Stage III The remainder
Stage IV Associated with blood borne
metastases
vii) Treatment of breast cancer
The methods of treatment depend on the stage of the
disease. Stage I and stage II are generally treated by
simple or radical mastectomy and/or radical radiotherapy.
However, it was found that when radical post-operative
radiotherapy is used in the treatment of stage II carcinoma
of the breast, a modified simple mastectomy was preferable
to a radical mastectomy (Brinkley and Haybittle, 1971).
On the other hand, the more advanced stages may be
treated by simple mastectomy, radiotherapy or endocrine
therapy in those tumours which are hormone dependent
(Bruce and Hayward, 1975) or chemotherapy (Fisher, Carbone,
Reonomou, Frelich, Glass, Lerner, Redmond, Zelen, Band,
Katryck, Wolmark and Fisher, 1975).
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The curability of treated breast cancer by simple
and/or radical mastectomy and radiotherapy was studied
in 704 women in the Cambridge area from 1947 - 1950
(Brinkley and Haybittle, 1975). It was found that
after 21 years the survival curve of breast cancer patients
runs parallel to the expected survival curve of a similar
normal population, as shown in Figure 8. However, in
the South-East region of Scotland, in which some 500 cases
of breast cancer are seen each year, from a population at
risk (both sexes) of 1.25 million, the survival rate is
shown to vary according to the size of the tumour (Langlands,
1976) (Figure 9). This region includes cases from Edinburgh,
parts of Fife and parts of the Borders. Figure 10 shows
the number of cases referred from 1973 - 1976 (Annual Report,
Department of Radiotherapy - Edinburgh). The mortality
rate of breast cancer in Edinburgh, Fife and the Borders,
over the years 1972 - 1976, is shown in Figure 11 (Annual
Report of Registrar General, Scotland).
The routine method of treatment of breast cancer is by
simple mastectomy followed by radiotherapy (which is carried out
whenever it is technically possible to do so). Simple mastectomy
is performed in nearly all operable cases and also in many
patients with locally advanced lesion, aiming for the
removal of the involved tissue. Thereafter radiotherapy is
given (at about two weeks after simple mastectomy) as the
sole method of treatment of the regional lymph nodes. Thus,
to treat the axillary node in continuity with the supra¬
clavicular nodes, two opposed fields are used. Moreover,
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Figure 8
Survival rates after treatment of 704 women with breast
cancer, compared with expected survival of normal
populations of the same age distribution. (After




Age-corrected survival rates according to the size of
the primary tumour on clinical examination. All cases
treated by simple mastectomy and x-ray therapy.
(After Langlands, 1977).
Figure 10
Number of patients with breast cancer referred to the
radiotherapy department in Edinburgh from the South-East
region of Scotland (Edinburgh, parts of Fife and the
Borders), from a population at risk of 1.25 million.
Figure 11
Number of deaths due to breast cancer from 1972 - 1976
in Edinburgh, Fife and the Borders region.
tangential fields are used to irradiate the whole
thickness of the chest wall, including the pleura and
the internal mammary nodes (McWhirter, 1955). The
fields of radiotherapy are shown in Figure 12.
Field I is an anterior supra-clavicular one
which extends downwards from the supra-sternal notch
to the second costal cartilage (about 10 cm) and
laterally to include the axilla (about 20-22 cm, as
measured in each individual case).
Field II is a posterior supra-clavicular one
which is about the same size as field I, but is
angled to include the axillary nodes as well as the
posterior clavicular nodes and is also positioned about
1 cm laterally away from the spinal cord. The dose
given in these fields (I and II) is 4250 rads "to max".
Therefore fields I and II, which are parallel,
semi-opposed fields, will include the apex of the lung.
Thus, that volume of lung irradiated (which varies as
the fields extend to about 4-6 cm from the apex of the
lung) will receive a dose of 4250 rads "to max".
Fields III and IV are tangential parallel opposed
fields (wedge corrected to allow for the shape of the
chest wall). The size of each field is 10 x 15 cm.
Furthermore, field III, given at 1 cm away from the midline,
(i.e. into the opposite side) is angled at 60° from the
vertical plane towards the body to include the internal
mammary nodes as well as the chest wall thickness, pleura
55.
Fields of radiotherapy for breast cancer
Figure 12
The four fields of radiotherapy:
I & II Anterior and posterior supra-clavicular
III & IV Tangential fields to the chest wall
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and a thin layer of the anterior slice of the lung on
the treated side (Figure 13). The dose given in this pair of
fields is 4500 rads "to max".
Each pair of fields (I and II, III and IV) is
treated on alternate days, thus 10 treatment fractions
are given over a 4 week period.
Routinely, each patient is examined clinically
before the start of radiotherapy and marking the area to
be treated is usually made then. Furthermore, the marks
are checked with an adjustable light beam which coincides
with the x-ray beam on the linear accelerator (6 MeV)
(Figure 14). The x-ray beam is given at a focus skin
distance (FSD) of 100 cm.
A bolus (tissue equivalent material) is used with
fields I and II and a bolus and wedge are used with fields
III and IV in order to correct for the irregularities and
any gap in the treated areas (Langlands, 1977).
As mentioned above, the upper part of the lung
receives 4250 rads "to max" from fields I and II. Thus
to calculate the exact dose of radiation given in these two
fields, phantom experiments were made. From these
experiments the percentage of dose of each field was
calculated at different distances from the skin surface
and with different field sizes. For examples, for field
size 20 x 10 cm, using the 6 MeV linear accelerator,
100% of dose of one field is situated at 1.5 cm depth
below the skin facing that field and the percentage of
dose at different depths from the skin surface is shown in





Showing the irradiated area by tangential fields III
and IV in a cross-sectional diagram of a patient after
mastectomy of the right breast.
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Figure 14
• The (6 MeV) linear accelerator routinely used for the
radiotherapeutic treatment of breast cancer patients in




The thick line in this figure shows the percentage
of the dose of field I as calculated at different
distances from the skin surface for a field size of
20 x 10 cm. If the separation distance between the
anterior and posterior borders of skin in a patient
is 20 cm for example, as shown in the dotted line, the
thin dark line then shows the percentage of dose of
field II.
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a certain percentage of the dose applied via the opposed
field, depending on the separation distance between the
anterior and posterior borders of the skin (which differ
in each individual case). Thus, knowing that the
maximal dose required at 1.5 cm below the skin surface
is 4250 rads, this is made up of 100% dose from the first
field + x% dose from the opposed field (where x% depends
on the separation distance). The 100% dose in rads can
then be calculated for each case, this being the actual
treatment dose for each field. For example:
If the anterio-posterior separation distance
in a patient is 20 cm, then, as shown in
Figure 15, the % dose at 1.5 cm depth =
100% + 42.5% = 142.5%; this is = to 4250
rads. Hence = 100% = 2982.5 rads, which
is the dose used in each field
These measurements are always done before starting the
treatment. Using the same idea, the minimal and central
dose could be calculated, which is equal in this
example to 68% + 68% = 136%, which is = to 4056.2 rads.
Therefore in this case the lung apex receives a minimal
radiation dose of 4056.2 rads as the lung is situated in
almost the central part of fields I and II.
viii) The Aim of this study
As discussed above, this dose of radiation is more
than the tolerance of the lung tissue to radiation, thus
there is inevitably a radiation reaction in the lung.
For example, for the last two years the Department of
Medicine in the Royal Infirmary, Edinburgh has had
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6 patients referred with symptomatic radiation
pneumonitis following radiotherapy of their breast
cancer. Figure 16 shows an x-ray of one of these
patients. With such problems in mind, this study was
carried out in order to answer the following questions:
I What are the effects of routine radiotherapy,
given for breast cancer, on total and
regional lung function in women with
normal lungs?
II Does this routine radiotherapy have more
effect on lung function in some of
these women than in others?
In addition, the techniques evolved for this
study, and the results obtained, would then allow the
planning of a later study on the consequences of
therapeutic irradiation of lung tissue as involved in the
treatment of oat cell carcinoma of the lung and also
provide guidance on the methods to be used in this
later study to ascertain the role of previous disorders
of lung function in determining the response of the
lungs to radiotherapy.
Figure 16
An x-ray of a referred patient with symptomatic radiatioi
cance°nitiS ^ 6 1110111:1:18 after radiotherapy of her breast
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II METHODS
i) Patients and Protocol
The aim of this study, as discussed in the previous
chapter, required that both total and regional lung
function should be measured. Two groups of patients
were studied. The first study involved a longitudinal
sequential measurement in the same group of patients
prior to radiotherapy, but after simple mastectomy and
then subsequently at 1, 3, 6, 9 and 12 months after
radiotherapy.
The second study was a cross sectional study in a
group of patients at intervals from 1-14 years after
radiotherapy as the technique and dose of mega-voltage
radiotherapy for breast cancer in Edinburgh had not changed
since 1963.
Ethical permission was given by three committees; the
Surgical, the Radiotherapy and the Physicians Ethical
Advisory Committees of the Royal Infirmary, Edinburgh.
In the first group the measurements were made before
radiotherapy, but after recovery from simple mastectomy,
when the tumour had been staged and the therapeutic decision
taken by the surgeon and radiotherapist. These measurements
were done to determine the pre-radiotherapy control values
and to exclude any possible effect of the operation (i.e. the
simple mastectomy) on lung function in this group. All
the measurements were repeated at 1, 3, 6, 9 and 12 months
following radiotherapy. Only 10 patients were included in
this group as patients dealt with were treated by surgeons
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and radiotherapists. Thus, first, permission of both had to
be obtained for the submission of their patients to our
study. Second, i,nformed consent had to be obtained from
these patients for this study, after full explanation of the
purpose, the non-invasive nature of these studies and that
these measurements were not related to their treatment,
but were primarily for research purposes. These patients
had only very recently been told that they had cancer of
the breast, that they would have their breast removed and
that they would have a course of radiotherapy to treat any
possible cancerous tissue left after surgery. In these
circumstances it might not have been surprising if they
had refused to take part in the study as a 'guinea-pig'.
Many of these patients thought that participation in the
study was another problem they had to consider at this
time of great stress and so rejected it. Third, some of
the patients who gave their initial consent to participate
in the study appeared to have a benign lesion at surgery and
thus radiotherapy was not indicated. Another group comprised
of patients who withdrew during the course of the study.
One of the ten patients withdrew because the study was
interfering with her working hours.
The age range of this group was 35-61 years, two being
smokers and the rest non-smokers. The side of the cancer,
and thus the simple mastectomy and radiotherapy, was on the
right in three of these ten patients.
In the second study, a group of 48 patients who had
previously had simple mastectomy and radiotherapy for their
breast cancer between 1 and 14 years, were studied on one
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occasion only. The age range of these patients was 36-73
years, 20 patients were non-smokers, 5 were ex-smokers and
23 were smokers. The side of cancer and thus the simple
mastectomy and radiotherapy, was on the right in 29 of the
48 patients.
No difficulty was found in obtaining the patient's
informed consent for this second study, perhaps because these
patients had already had successful treatment.
In each study the MRC questionnaire (Medical Research
Council Report, 1960) of respiratory symptoms was recorded
for each patient, with their height and weight. Haemoglobin
and white cell count were measured in venous blood. Overall
and regional lung function were measured, as described later.
In addition to these measurements, routine 6ft chest x-rays,
postero-anterior (PA) and lateral (according to the side of
radiotherapy) were taken and a standard 12 lead electrocardio¬
graph (ECG) was carried out. The overall lung function
included measurements of forced vital capacity (FVC), forced
expiratory volume at one second (FEVi), measurements of
lung volume, flow volume curves, measurement of airway
resistance and specific airway conductance (sGaw) and
measurements of transfer factor for carbon monoxide (Tco).
ii) Overall lung function measurements
1. Forced expiratory volume at one second (FEVi) and
forced vital capacity (FVC) measurements
A "vitalograph" dry spirometer was used to measure
FEVi and FVC. The characteristics of performance of the
vitalograph have been reported by Drew and Hughes (1969).
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The patients were seated and instructed to take
a full inspiration, then close their lips around the
mouthpiece and blow out as hard and as fast as possible and
to continue blowing until no more gas could be squeezed
from their chest. The volume at one second was recorded
(FEVi) and the total volume at the end of expiration was
recorded also (FVC). Three measurements were made of the
FEVi and FVC, the highest being taken. The results were
reported as litres at ATPS and also expressed as percentage
of FVC. The predicted values for our studies were calculated
using the following formulae for females:
FEVi (litres ATPS) = [(height x 2.27)-(0.02 x age)-0.56]
+ 0.36 (S.D.)
FVC (litres ATPS) = [(height x 3.78)-(0.019 x age)-2.60]
+ 0.34 (S.D.)
FEVi/FVC (%) = [(-0.261 x age)+92.1] + 5.4 (S.D.)
(Cotes, 1968)
2. Lung volume measurements
Lung volume measurements were made with a "Fenyves
and Gut" body plethysmograph, which is a pressure compensated
flow plethysmograph (Figure 17). Pneumotachograph signals
were integrated electronically, the resulting volume signals
being recorded on an X-Y recorder. The pressure compensation
in this body plethysmograph was made by adding an electrical
signal (proportional to the pressure developed inside the
plethysmograph) to the integrated flow signals to improve its
67.
Figure 17
A schematic diagram of the patient sitting in the body
plethysmograph:
/Vb = integrated flow signals of the body
plethysmograph
/Vm = integrated flow signals at the mouth
pm = pressure at the mouth
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frequency response (Van de Woestijne and Bouhuys,' 1969).
To measure the vital capacity and its components
(tidal volume, inspiratory reserve volume and expiratory
reserve volume) the patient was seated in the body
plethysmograph, breathing through the mouth pneumotachograph
with a mouthpiece and a clip on her nose. The volume
changes at the mouth were plotted against time on the
X-Y recorder. The recorder was calibrated using a one
litre syringe.
For measuring the functional residual capacity (FRC)
the patient was seated in the closed body plethysmograph
and again using a mouthpiece and nose clip, she was
instructed to breath quietly. A shutter, which could be
operated by remote control to block off the mouthpiece,
was activated at the end of a normal expiration. The
patient then inspired against the closed shutter and the
pressure changes at the mouth (Pm) were measured by a
pressure transducer. This pressure is equal to the
alveolar pressure when the airway is closed by the shutter
and there is effectively no flow.
The changes before and during closure of the shutter
were plotted on an X-Y recorder, the volume changes of
the body plethysmograph (Vb) being plotted on the X-axis
and the pressure changes in the mouth (Pm) on the Y-axis.
As a result of the measurement (i.e. application of
the shutter while breathing quietly), a slope is generated
on the X-Y recorder, as shown in Figure 18. From this slope
the angle 9 was drawn, where:
Tan 9 = b
a
THORACIC GAS VOLUME (TGV)
Pmouth





The slope generated on the X-Y recorder as a result of
application of the shutter while breathing quietly,
where b corresponds to changes in mouth pressure (Pm)
and a corresponds to changes in plethysmographic
volume (Vb).
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The use of the body plethysmograph to measure the thoracic
gas volume was described by Dubois, Botelho, Bedell,
Marshal and Comroe (1956). Boyles Law states that at a
constant temperature, the product of pressure and volume for
a given mass of any gas is constant, i.e. PV = constant (1).
If the P and V changes by AP and - AV respectively, then:
(P + AP).(V - AV) = PV (2)
This relationship is simplified to:
V = P. AV (3)
AP
where P = alveolar dry gas pressure which is equal to
barometric pressure - water pressure in the lung = PB - 47 mmHg.
V = Thoracic gas volume
AV = Changes in the volume due to compression of
the chest by respiratory muscle when the
airways are obstructed by the shutter.
AP = Changes in alveolar pressure when breathing
against the shutter.
Thus V = (PB - 47). AV (4)
AP
at this point V in mis
PB - 47 in mm Hg
AV in mis
AP in mm Hg
According to the range used, which was recommended by the
manufacturers, the calibration of 20 mis air = 10 mm
20
displacement of the X-Y recorder. Thus, AV = a mm x =
a x 2 ml. Also the calibration of 25 cms HgO = 50 mm
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25
displacement and to change that to mmHg, ^ mm Hg = 50 mm.




Therefore v = (Pb - 47) x 2 x a - b (5)
2.72
= (Pb - 47) x 2 x 2.72 x a
b
- 5.44 x a x (Pb - 47) (6)
b
The dead space between the mouthpiece and the pneumotacho¬
graph is subtracted, this being measured by water displacement
and found to be 140 mis. Thus, to get the VTG (Thoracic
gas volume) or FRC (Functional residual capacity), the
following formula was applied:
VTG (in mis) = 5.44 x a (Pb - 47) - 140 (7)
b
3. Airway resistance (AWR) and specific airway
conductance (sGaw)
For these measurements the patient was seated in
the closed body plethysmograph and was instructed to pant
at the frequency of a metronome of about 1.0 breath/second
for five seconds. During the first part of the measurement
the patient rebreathed through a heated pneumotachograph,
connected to a plastic bag inside the body plethysmograph,
the bag being filled with humidified air at a temperature
of 37°C. The patient then panted against a closed shutter
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at the same frequency (according to the method of
Dubois, Botelho and Comroe, 1956).
During each measurement the results were plotted
on the X-Y recorder. In the first manoeuvre (with the
shutter open), the flow signals at the mouth (Vm) were
plotted on the Y-axis against the volume signals of the
body plethysmograph (Vg) on the X-axis, giving a loop,
as shown in Figure 19. A line was drawn between the points
on the loop corresponding to the flows of zero and 0.5
litre/second during inspiration (Cotes, 1975) and the slope
d of this line was measured,
c
Using equation (3)
AV = V . AP (8)
P
Dividing both sides of the equation by V (flow)
— = I O)
V * V
Hence:
AP AV PB - 47
vm Vm V
— (10)
Where AP = The pressure difference between the
alveoli and Pg (mm Hg)
AV = Changes in the chest volume caused
by AP (ml)
Pg - 47 = Dry gas pressure (mm Hg)
V = Thoracic gas volume (ml)
Vm = Flow at the mouth (litre/second)
l. e Resistance = AV Pg - 47 , TT /T . . ..




The loop generated on the X-Y recorder as a result
of panting with the shutter open, where d corresponds
to changes in flow at the mouth (Vm) and c corresponds








— was obtained from the slope in the first measurement
Vm
(i.e. panting with the shutter open); whereas
PB was calculated from the slope in the second measurement
V AP
(i.e. panting against the closed shutter) which =
(PB - 47) mm Hg = (PB - 47) x 1.36 cm H20
Therefore,
Resistance (R) = x (PB - 47) x 1.36 (12)
Vm
For the settings used in this measurement, the calibrations
were 0.5 L/sec = 10 mm displacement (i.e. Vm = d (mm) . )
and 20 ml of air = 10 mm displacement (i.e.AV = c (mm) . 20j
10
Therefore,
o cx2 1.36 (Pb - 47) u A / t / ^-i o a=
d/20 X VTCT cmH20/L/sec (13)
According to the manufacturers, the mechanical
resistance of the system is 0.25 cmH20/L/sec and this should
be deducted from the airway resistance which was
calculated from equation (13). Thus, the correct
formulae which was used to calculate the airway resistance
(AWR) is:
AWR = 54.4 x c x (PB^47) _ Q>25 cmH2o/L/sec (14)
The results were expressed as conductance (i.e. reciprocal
of resistance) per litre of thoracic gas volume, and the
index obtained was the specific conductance (sGaw):
sGaw = 1/AWR c cmH q-1 sec"1
VTG (L) VTG (L)
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The relationship between airway resistance (AWR)
and thoracic gas volume (VTG) for a normal subject is
a rectangular hyperbola (i.e. the resistance varies
inversely with the volume of the gas in the thorax at the
time of the measurement); whereas the airway conductance
(Gaw) is assumed to be directly proportional to the thoracic
gas volume (VTG) (Brisco and Dubois, 1958). Thus, on that
assumption, airway conductance (Gaw) had been standardized
for the thoracic gas volume (VTG) changes by using the
index specific conductance (sGaw), which is equal to
Gaw/VTG (Guyatt, Alpers, Hill and Bramley, 1967).
4. Flow volume curves
The flow volume curve describes the relationship
of the maximal flow rate to the intrathoracic gas volume
during forced expiration (Figure 20).
The flow volume curves were obtained using the body
plethysmograph to measure the changes in the lung volume
(Vb) during maximal expiration from total lung capacity;
whereas the flow rate (Vm) was obtained by differentiating
the volume signals through a fast response spirometer
(Ohio) which was connected to the mouthpiece. Both these
signals were fed into an on-line PDP 11/40 computer for
direct calculation of the maximal flow at 50% vital
capacity (Vmax 50) and at 30% vital capacity (Vmax 30).
These measurements were repeated at least three times and
the greatest values for Vmax 50 and Vmax 30 were taken.
The variations in the forced vital capacities (FVC) over









The flow volume curve, as drawn following maximal
forced expiration. The X-axis shows the changes in
plethysmographic volume and the Y-axis shows the flow
changes (Vm).
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The maximum expiratory flow rate in these
measurements (when made in a body plethysmograph),
breathing air, depends primarily on three factors:
Firstly, the elastic recoil pressure of the lung (Pst)
which is important throughout the whole vital capacity
(VC) range, as the effective driving pressure producing
the maximum expiratory flow rate (MEFR). Secondly,
the cross-sectional area of large airways which is important
at high lung volumes. Thirdly, the frictional resistance
of small airways (R) which is important at low lung
volumes (Macklem and Mead, 1967). Furthermore, Hyatt,
Schilder and Fry (1950) demonstrated that the relationship
between the maximal expiratory flow and the degree of
lung inflation was effort-dependent over the upper half
of the vital capacity. However, over the lower half of
the vital capacity, that relationship was independent of
effort, uninfluenced by the addition of external resistances
and highly reproducible.
Thus, measurements of the maximal flow at 50% vital
capacity (Vmax 50) and at 30% vital capacity (Vmax 30) are
dependent on the elastic recoil of the lung (Pst) as the
total effective driving pressure (which is equal to
Palv-Ppl) and on the resistance of the airways between
the alveoli and the points when the total pressure drop
equal to Pst. These points were termed equal pressure
points (EPP), since the pressure at the inner wall of the
airways at these points equal to Palv-Pst which is equal to
Ppl. The resistance of airways between the alveoli and EPP
is referred to as the upstream resistance (Rus), so that
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"Do -j-
the MEFR = (Macklem and Mead, 1967).
Therefore measurements of the maximal flow at lower lung
volumes were used as an index of the airway resistance at
the upstream segments (Rus), i.e. the resistance of the
small airways.
5. Measurement of transfer factor for carbon
monoxide (Tco)
The transfer factor (diffusing capacity) for the lung
for carbon monoxide is the rate at which carbon monoxide
is absorbed from the alveolar gas in mmol/minute/unit of
effective alveolar transfer gradient. This index is a
function of both the diffusing capacity of the alveolar
capillary membrane and the rate at which carbon monoxide
combines with haemoglobin in the alveolar capillaries
(Roughton and Forster, 1957).
If Ti is the transfer factor (diffusing capacity)
for the lung for carbon monoxide (CO), Dm is the diffusing
capacity of alveolar capillary membrane, Vc is the volume
of the blood in the alveolar capillaries and 9 is the reaction
rate of CO with oxy-haemoglobin, then:
A. =—is the relationship between them
J-l um 9 v c
The Resparameter (Mk IV), (PK Morgan Ltd) was used
for the measurement of transfer factor for CO, using the
single breath technique. This method was first described
by Marie Krogh at the beginning of this Century, a single
deep breath of mixture of CO in air being taken into the
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lung. Then, this method was modified by Fowler, who
suggested that the inspired gas mixture should contain
Helium in addition to CO (Bates and Christie, 1965), to
measure the alveolar volume simultaneously, so allowing
for varying dilution of the inspired CO and this in
alveolar CO pressure.
The patient was seated (with a mouthpiece and a
clip on her nose) breathing quietly into the Resparameter.
She was then instructed to breath out to residual volume
and then inhale a vital capacity breath of the test gas
(approximately 0.3% CO, 12% Helium and the remainder air),
hold her breath for 10 seconds, then exhale slowly. After
exhalation of 700 ml a sample of the alveolar gas was
collected for analysis. The procedure is illustrated in
Figure 21. The period of effective breath holding started
after the first 700 ml of inspiration, until the end of the
first 700 ml of expiration, to allow for dead space washout,
as given automatically by the resparameter.
Following these measurements the amount of CO in the
alveolar gas at the beginning and at the end of breath
holding was calculated and the alveolar volume during this
time was calculated from the dilution of the Helium in the
test breath. .
The following formula was used to calculate Tco (single
breath):




This illustrates the procedure used in the measurements
of Tco.
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Where Va = alveolar volume in ml BTPS
t = the time of effective breath holding
in seconds
FIC0 = concentration of CO in inspired gas
FAC0 = concentration of CO in alveolar gas
at the end of the breath hold
FIHe = concentration of Helium in inspired gas
FAHe = concentration of Helium in alveolar gas
b = 53.6 = constant
Where the alveolar concentration of carbon monoxide at
time zero is:
(FoA CO) = Fjqq x Fa He (as derived by Cotes, 1975)
FI He
Alveolar effective volume Va = (Vt x he) litres BTPS
Fa He
Where Vj = volume of gas inspired in litres BTPS
Fi jje anc* fA He = Helium concentration in the
inspired and expired alveolar
gas
For calculation of the predicted values, the following
formula is applied for females:
Tcq (mmol/min/kPa) = [(height x 6.87) - (age x 0.017)
1.83]+ 1.44 (S.D. )
(Cotes and Hall, 1970)
Accuracy of measurements
1. Calibration
Each instrument used for these measurements was
calibrated as below. The vitalograph which is a dry
spirometer was calibrated by water displacement, as shown
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WEIGHT OF WATER (g)
Figure 22
The calibration of the vitalograph by water displacement.
The X-axis shows the weight of the water in gms and the
Y-axis indicates the recorder volume in litres.
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in Figure 22. Also, the spirometer of the P.K. Morgan
Resparameter (for measuring Tco) was calibrated by water
displacement; whereas the carbon monoxide and Helium
analyser was calibrated using different dilutions of
Helium and carbon monoxide, as shown in Figure 23 and
Figure 24. On the other hand, the mouth pressure (Pm)
transducer of the body plethysmograph was calibrated and
checked periodically against a water manometer. Moreover,
the volume signals at the mouth were calibrated daily
using a one litre syringe. The fast response spirometer
volume signals were calibrated using a one litre syringe.
The body plethysmograph/computer system was calibrated
daily by introducing volume signals, using an accurate
one litre syringe (previously calibrated by water
displacement); the flow was calibrated by an electrical
signal which had previously been calibrated against a
rotameter. Thereafter a more accurate absolute flow
calibration was obtained through a slow expiration manoeuvre
made by a subject (with normal airway resistance) in the
body plethysmograph.. Thus, the integrated flow signals
at the mouth (fVm) and the volume signals of the body
plethysmograph (Vbox) are recorded, compared and equalized
by the computer (i.e. /Vmouth = Vbox). The slow expiration
manoeuvre is made to minimize gas compression.
2. Reproducibility
Lung volumes, airway resistance and flow volume
curves were measured in five normal women aged 20-28 years,
Figure 23
The calibration of Helium analyser, with different
dilutions of Helium. The X-axis indicates the
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Figure 24
The calibration of carbon monoxide analyser, with
different dilutions of carbon monoxide. The X-axis
shows the predicted CO percentage and the Y-axis
shows the observed Co percentage.
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staff in the department.
The lung volumes and airway resistance measurements
were repeated for each subject on five different occasions,
over a period of 10 weeks. The mean and standard deviation
for each subject of the total lung capacity (TLC), residual
volume (RV), thoracic gas volume (VTG) and specific
airway conductance (sGaw) are shown in text Table 2a. The
coefficient of variation for these measurements are shown
in text Table 3', which show values from 11.4% for RV,
2.44% for TLC, 2.05% for VC, 1.88% for VTG and 3.13% for
sGaw.
The flow volume curve measurements were also
repeated for each subject on 5 different occasions over a
period ,of two weeks. The mean and standard deviations
of forced expiratory volume at 1.0 second (FEVi), Vmax 50
and Vftiax 30 for each subject are shown in text Table 2b.
The coefficient of variation for these measurements are
also shown in text Table 3, which shows values of 2.37%
for FEVi, 3.55% for Vmax 50 and 4.88% for Vmax 30.
The transfer factor for carbon monoxide (Tco) was
measured in 5 normal women (staff of the department) and
the measurement was repeated on 5 different occasions over
a period of 2-8 weeks. The means and standard deviations
for each subject are shown in text Table 4, together
with their coefficient of variation.
As shown, the reproducibility of these measurements
was adequate.
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TEXT TABLE 2 a
Reproducibility of Lung Volume Measurements (TLC, RV, VC, VTG) § Specific
Conductance (sGaw) in 5 Normal Women (Mean + S.D.)
Subject
TLC RV VC VTG sGaw
(litres) (litres) (litres) (litres) (sec.-lkPa-1)
4.83 + 0.16 1.41 + 0.10 3.42 + 0.10 3.49 + 0.14 1.831 + 0.156
3.65 + 0.07 0.54 + 0.05 3.11 + 0.04 2.72 + 0.03 1.904 + 0.051
4.17 + 0.09 0.68. + 0.12 3.50 + 0.07 3.18 + 0.07 1.940 + 0.022
4.02 + 0.08 0.64 + 0.07 3.38 + 0.06 2.81 + 0.03 2.189 + 0.035
5.64 + 0.16 0.81 + 0.10 4.83 + 0.11 3.89 + 0.04 1.609 + 0.028
TEXT TABLE 2b
Reproducibility of Flow Volume Curves (FEV^, Vmax 50 and
Vmax 50 in 5 Normal Women (Mean + S.D.)
Subiect FEVl W 50 V®ax 30suDject (litres) (L/sec) (L/sec)
L Mc 3.60 + 0.10 4.86 + 0.17 3.04 + 0.32
P K 2.83 + 0.05 3.04 + 0.10 2.32 + 0.07
C 0 3.02 + 0.09 3.63 + 0.20 2.10 + 0.08
r
M L 3.64 + 0.07 4.29 + 0.13 2.37 + 0.07









































































Reproducibility of Transfer Factor Measurements (TCo) § Coefficient
of Variation in 5 Normal Subjects (Mean + S.D.)
„ , . TCo Coefficient of variation
iuDject (mmol/min/kPa) (%)
I 7.04 + 0.185 2.63
II 6.88 + 0.073 1.06
III 8.16 + 0.052 0.64
IV 7.95 + 0.177 2.23
V 7.08 + 0.266 3.76
Mean 7.42 + 0.151 2.06
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3. Linearity of the measurements
The linearity of the body plethysraograph flow
meters (i.e. the mouth pneumotachograph and the "box"
pneumotachograph) were tested using a one litre syringe
which slowly pumped air into the closed body plethysmograph
via the external orifice of the mouth flow meter and out
through the "box" flow meter. The integrated volume
changes and integrated "box" volume changes were plotted
on an X-Y recorder. These volume displacements were linear
up to 10 litres, as shown in Figure 25.
The linearity of the Ohio spirometer was tested using
also a one litre syringe connected to a three-way tap.
Air was slowly pumped into the spirometer and the output
signal recorded against time on an ink jet recorder
(Minograph). The volume displacements were linear up to
10 litres, as shown in Figure 25.
For transfer factor (Tco) measurements, the spirometer
volume was calibrated by water displacement and found to
be accurate up to 7 litres. The analyser readings for
Helium and carbon monoxide were found to be linear in
the range of (0.00 - 14%) for Helium and in the range of
(0.00 - 0.30%) for carbon monoxide, on using serial dilutions
of Helium and carbon monoxide mixtures made by a precision
mixing pump (Wosthoff).
4. Dynamic response study
To test the frequency response of the body plethysmograph
flow meters and the Ohio spirometer, a modified 500 cc




Linearity of the plethysmograph flow meters and the
Ohio spirometer. The integrated flow change (volume)
displacements in mm (X-axis), plotted against volume
changes in litres for each parameter.
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500 ml was available. This engine, used as a constant
amplitude oscillating pump, was driven at frequencies from
0.5 Hz up to 12 Hz by an electric motor.
The output of the pump was introduced into the closed
body plethysmograph via the external orifice of the mouth
flow meter, the plethysmograph venting to air via the
"box" flow meter, as illustrated in Figure 26.
The amplitudes of the sinusoidal waves from the
mouth flow meter and the "box" flow meter were plotted
against frequency as a percentage of the amplitude at
0.5 Hz. As shown in Figure 27 the amplitude responses of the
mouth flow meter and the "box" flow meter were adequate from
0.5 Hz up to 8.0 Hz, which is adequate as the patients
were panting at a rate of approximately 1.0 Hz for the airway
resistance measurements and at about 0.3 Hz for the lung
volume measurements.
The output of the pump was also introduced into
the Ohio spirometer via the mouth flow meter. The
amplitudes of the sinusoidal waves from the Ohio spirometer
was plotted against frequency as a percentage of the
amplitude at 0.5 Hz, as shown in Figure 27. The amplitude
response of the Ohio spirometer was flat from 0.5 Hz to
6.0 Hz, which was considered adequate for the measurements
• •
of Vmax 50 and Vmax 30. These responses were considered
adequate for these measurements (McCall, Hyatt, Noble
and Fry, 1957).
The phase differences in degrees (1 cycle = 360 degrees)









Testing the frequency response of the body plethysmograph
flow meters. The motor cycle engine pumps into the
plethysmograph via the mouth flow meter and the body




The frequency response (X-axis) of the amplitude of the
sinusoidal waves (drawn as percentage of that at 0.5 Hz),
of the plethysmograph flow meters and the Ohio spirometer.
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between the mouth flow meter and the Ohio spirometer
were plotted against frequency (Figure 28). There was
negligible phase lag from a frequency of 0.5 Hz up to
8.0 Hz in the former, and up to 11 Hz in the latter.
iii) Regional lung function measurements
The regional distribution of ventilation and perfusion
in the lung was studied using the technique of Ball,
Stewart, Newsham and Bates (1962), which allowed for
quantitative measurements based upon relating both
ventilation and perfusion to regional lung volume, as
described in detail by Milic-Emili, Henderson, Dolovich,
Trop and Kaneko (1966), and Anthonisen and Milic-Emili
(1966) giving the regional pulmonary ventilation/unit
alveolus (V/E) and the regional pulmonary perfusion/unit
alveolus (Q/E).
1. Technique
In this study the patient was seated upright on a
chair with her back to the gamma camera (Nuclear Enterprises
Scinticamera V), breathing around functional residual capacity
(FRC) through a mouthpiece (with noseclip), connected to a
closed circuit spirometer containing room air. The patient
was positioned so that the total lung at maximal inspiration
was within the gamma camera field of view. To maintain the
patient's position, two centre spots from electric light
beams focused on the anterior chest wall were used and an
anatomical marker was also used to mark the supra-sternal
















The frequency response (X-axis), plotted against the
phase difference (0) in degrees between the sinusoidal
waves of the mouth flow meter and those of the "box"
flow meter and between the sinusoidal waves of the
mouth flow meter and those of the Ohio spirometer.
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Thereafter the patient was instructed to breath-hold
133
at FRC while a bolus of 1 mCi of radioactive xenon (Xe )
was administered at the mouth. The patient was then
instructed to inspire at a constant flow rate (measured
by a flow meter consisting of a mesh screen pneumotachygraph
connected to a micro manometer) to total lung capacity
(TLC) and then to hold the breath for 10 seconds
(Figure 29) whilst the regional count rates
(disintegration/sec) were recorded, either directly
into a computer (PDP 11/34) or onto videotape (Nivico JVC)
for subsequent replay into an off-line (PDP 12) digital
computer. The patient was then instructed to expire to
FRC and then to rebreath quietly through the closed circuit
spirometer until equilibration was achieved, as indicated
by a constant unchanging count rate from each region.
Once again the patient's position was checked by the
anatomical marker and the patient instructed to inspire
(at whatever flow rate she wished) to TLC, and then to hold
her breath for 10 seconds whilst the count rates from each
region were recorded. The spirometer circuit was then
opened to air, to allow studies of the rate of washout
133
of the Xe and the count rates were also recorded.
In the sequential study, before and at intervals
after radiotherapy, the distribution of ventilation was
measured at two different inspiratory flow rates, 0.2 L/sec
[where the distribution of ventilation is determined mainly
by the regional lung compliance (Milic-Emili et al, 1966;
Dollfuss, Milic-Emili and Bates, 1967)] and 1.5 L/sec
[where ventilation distribution is mainly determined by
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Figure 29
This illustrates the procedure used in the measurements
of regional ventilation/perfusion. The Xel33 (bolus)
given at FRC and breath holds at TLC for 10 seconds,
whilst the regional count rates were recorded.
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regional resistance (Robertson, Anthonisen and Ross, 1969)].
In the cross-sectional study, at one time after
radiotherapy, the ventilation distribution was measured
only at an inspiratory flow rate of 0.5 L/sec.
The regional distribution of perfusion (Q/E) was
133
measured using radioactive xenon (Xe ) in the sequential
study, this being injected intravenously (I.V.) (as a 1 mCi
bolus in saline solution) into the arm on that side
opposite to the breast which received radiotherapy. The
patient was then instructed to inspire to TLC and hold
her breath for 10 seconds, whilst the regional count rates
were recorded. Thereafter the regional count rates during
133
washout of Xe delivered to the alveoli by perfusion were
also recorded. However, the regional distribution of
pulmonary perfusion (Q/E) for the cross-sectional study
99m
was measured using 2 mCi Tc labelled macroaggregated
albumin, which was injected slowly I.V. into the arm,
whilst the patient was lying supine [so as to get a
relatively uniform distribution of perfusion throughout
the lung, relatively unaffected by the gravitational
field (Kaneko, Milic-Emili, Dolovich, Dawson and Bates,
1966)] when breathing quietly for a few minutes. The
patient was then positioned sitting upright with
her back to the gamma camera as before and instructed to
inspire to TLC and to hold her breath for 10 seconds,
whilst the regional count rates were recorded.
2. The radionuclide
In this study the radionuclides used were radioactive
100.




Xe injections were obtained in sterile isotonic
saline solution in a multidose syringe cartridge (as 10
mCi in 10 ml saline - Code XAS.110P) from the Radiochemical
133
Centre, Amersham (RCC). Xe is chemically and
physiologically inert and was us-ed as a radioactive
indicator with a half-life of 5.25 days. The energy of
gamma-emission is 81 KeV and a dose of 1 mCi injection
133
delivers only 14 mrads to the lungs. Xe has been used
as an indicator for the assessment of rates of perfusion and
ventilation/unit lung volume in various regions of the
lung (Ball et al, 1962; Milic-Emili et al, 1966;
Anthonisen and Milic-Emili, 1966; Dollfuss, Milic-Emili
and Bates, 1967; Bake, Wood, Murphy, Macklem and
Milic-Emili, 1974; Warren, Warren, Hare and Muir, 1976;
Muir, Warren, Warren and Hare, 1975). In this study a
133
dose of 1 mCi of Xe was withdrawn into a 20 ml syringe
containing air and shaken well; then administered as the
133
gaseous form of Xe , to be inhaled by the patient for
133
the regional ventilation measurements. However, Xe
was administered I.V. to give a 1 mCi dose as a saline
solution, for measurement of the regional perfusion. The
133
total dose of Xe given to the patient was 3 mCi, in
the sequential study and 1 mCi in the cross-sectional study.
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B. Technetium-99m labelled macroaggregated
albumin (MAA) (Tc^m)
99m
Tc was also obtained from the Radiochemical
99m
Centre. The Tc sterile generator, which contains
molybdenum-99 was absorbed on alumina in a sterilized
plastic column, surrounded by lead shielding. The
column was eluted aseptically using pressurized vials
of sterile saline and emptied into a sterile collection
vial. The elute obtained was labelled onto macroaggregated
9 9m
albumin, thus yielding a technetium-99m (Tc ) labelled
suspension suitable for I.V. injection for lung scintigraphy.
99m
Tc is a transitional metal which decays by isometric
99
transition (half-life 6 hours) to Tc , with the emission
of a gamma ray with an energy of 140 kilo electric
volts (KeV) (Castronovo, 1975).
99m
In this study a dose of 2 mCi of Tc MAA, containing
a minimum of 200,000 particles, was injected I.V. into
the arm, whilst the patient was lying supine and breathing
quietly for a few minutes. These particles ranged
between 10 to 100 pm in diameter. On I.V. injection
the majority of these particles are removed from the
circulation when first filtered through the pulmonary
capillary bed and as these particles, which are thus
embolised in the lungs, are labelled with a gamma-emitting
radionuclide, this enables the perfusion pattern of the
lungs at the time of injection to be observed using the
gamma camera (Williams, Lyall, Vernon and Croft, 1974;
Bateman and Croft, 1976).
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3. The gamma camera
The gamma camera was first described by Anger
in 1958. The basic imaging action of the Anger camera
consisted of reconstructing the position of light-emitting
points in a scintillation crystal from the information
contained in sets of current pulses, obtained from
photomultiplier tubes, coupled to the crystal (Eichling
and Siegel, 1974). Figure 30 shows a schematic diagram
of an Anger camera. The action of the camera could be
divided into three steps:
1. A light-scintillation image is formed in
the scintillation crystal, from the radionuclide
distribution in the object, where the gamma photons
emitted from the patient pass through the holes of the
collimator to reach the scintillation crystal.
2. Conversion of the light scintillations into
photomultiplier pulses (the light being transmitted
to the hexagonal array of 37 photomultiplier tubes,
where the pulses are multiplied in the phototubes).
3. Conversion of these pulses into voltages
proportional to positional co-ordinates, by using these
multiplied pulses as input to a ratio circuit which
determines the location of the scintillation within the
crystal and subsequently causes a flash to occur on a
cathod-ray oscilloscope display in the appropriate
position.
(Eichling and Siegel, 1974).
Figure 30
A schematic diagram of a scintillation gamma camera
with the multi-channel collimator. (After Eichling
and Siegel, 1974).
104.
In this study a Nuclear Enterprises Mk 5 HR
gamma camera was used, with a standard field of view of
25 cm diameter so that to view both lungs simultaneously,
a high sensitivity diverging collimator (NE 8926)
(which has about 15,000 holes in 25 cm diameter face)
was necessary. The energy window was preset at 25%
and the analyser of the gamma camera was set at 80 KeV
for Xe"^^ and 140 KeY for Tc^m MAA studies.
Estimate of errors involved
1. The uniformity of the gamma camera was checked
at weekly intervals and was always maintained within + 15%,
being measured within a field size of 250 mm diameter,
using a test cell size of 10 mm or smaller and
expressing the results by the following formula:
(maximum cell - minimum cell) nn rTS , „ mnn
7 t 7^— :—: 5-7-7 x 100 (Hannan and Hare, 1976(maximum cell + minimum cell) v '
Although the uniformity of the camera was used + 15%,
this affects all the derived variables that were measured
• •
[i.e. ventilation (V), equilibration (E) and perfusion (Q)]
equally. Thus, on taking ratios of (V/E) and (Q/E) this
uniformity difference will tend to be cancelled out,
if the uniformity variation remains constant over the
time for which these measurements were made.
2. The system resolution at 10 cm depth in
tissue was 28 mm (full width at half height). The
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Figure 31
Illustrates the system resolution measurements for high
sensitivity diverging collimator in air and in tissue
equivalent material (hardboard), as measured using the
full width half the height of an 0.5 mm line source of
TC99m positioned along with X or Y axis at different
distances from the collimator surface. (After Hannan and
Hare, 1976).
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in air and in tissue equivalent material is shown in
Figure 31, as measured using an 0.5 mm line source of
99m
Tc being positioned along the X or Y axis at different
distances from the collimator surface (Hannan and Hare,
1976).
3. The linearity of the gamma camera was measured
99m
using several Tc line sources which were positioned
3 cm apart along the X or Y axis and their profiles
measured on a multi-channel analyser (Laben 4096).
Figure 32 shows the graph of line position versus channel
number and indicates a linearity within + 3 mm (Hannan and
Hare, 1976).
4. The count rate. The observed count rate at
different true count rates is shown in Figure 33. The true
count rates were measured by two different methods.
Firstly, by extrapolating the straight line part of a
count rate versus activity graph. Secondly, by plotting
99m
the count rate from a Tc source on a log scale against
time on a linear scale, and extrapolating the straight
line portion (T£ = 6 hours) of the graph. Good agreement
was found between the two methods (Hannan and Hare, 1976).
5. The system sensitivity was measured using a
99m
10 cm x 10 cm source of Tc . The sensitivity was found
to be 16380 counts.sec-1.mCi-^, when using the high
sensitivity diverging collimator (NE 8926), which indicates













10 20 30 40 50
CHANNEL NO. FOR PEAK COUNT RATE
60
Figure 32
Illustrates measurements of the linearity of the gamma
camera using several Tc^m line sources, positioned 3 cm
apart along the X or Y axis and their profile measured
with the multi-channel analyser. The line position versus
the channel number is illustrated and shows linearity







Illustrates the observed count rate at different true
count rates. (After Hannan and Hare, 1976).
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Analysis of the regional V/E and Q/E measurements
The count rates after any particular manoeuvre
are always related to the count rates at TLC after
rebreathing to equilibrium (E). The count rates at
equilibration represent the distribution of the Xe
133 .
in
alveolar spaces, which are all equally distended at TLC
(West, 1977), so correcting for difference regional lung
volumes.
The actual count rates were either accumulated on
a videotape for subsequent replay into a PDP 12 digital
computer through the interface onto a 64 x 64 matrix, or
the counts were taken directly from the gamma camera to
an on-line PDP 11/34 computer. The data is then analysed
on a regional basis, the sizes of the region being
operator-chosen and usually are an 8 x 4 matrix; thus
dividing the lung fields into 32 segments with 8 horizontal
slices. The anatomical marker was used to set the midline
which separated the two lungs, and a hard copy of the
display on the VDU obtained from Tectronics 4010 Hard
Copy Unit, as shown in Figure 34. The data was analysed
on the assumption that counts at equilibration (E)
at TLC represent the regional lung volumes, so that the
percentage distribution of ventilation to region i (i = 1/32),








REGIONAL LUNG FUNCTION OF A BREAST CANCER
PATIENT AFTER RADIOTHERAPY
Figure 34
The two lungs, divided into 32 segments with 8 horizontal
slices.
a. shows the regional perfusion distribution
b. shows the regional ventilation distribution
c. shows the regional lung volumes (equilibration)
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Where the total matrix amounted to 32 cells (4x8), so
that 1 = -k
Vi = the ventilation count rate in region i
32
ZVi = the total ventilation count rate (i.e. V-po^) in■* all 32 cells of the matrix
Ei = the equilibration count rate to region i
32
/ Ei = the total equilibration count rate (i.e. Erpot) in
Y-\ all 32 cells of the matrix
V/E% = ventilation/unit alveolus % (i.e. % of that if it
was not uniformly distributed by basis of lung
volume)
Furthermore, using the same equation, the percentage
distribution of perfusion to region i was:
Qi / Ei
i=l
32 X X 100 = Q/E%
y Qi Ei
i=l
Where Qi = the perfusion count rate in region i
7 Qi = the total perfusion count rate (i.e. Q-p0t) in
p-p cells of the matrix
Q/E% = perfusion/unit alveolus % (i.e. % of that if it
was uniformly distrubted by basis of lung
volume)
On the other hand, the percentage of the total lung volume




~22— x 100 = Vi% assuming that at equilibration,
~ when measured at TLC, all
Ei alveoli are uniformly
distended7i=l
Where Vi% is the lung volume in region i, as a percentage
of the total lung volume. Thereafter, the average of the
two segments (inner and outer) in each vertical slice of
the treated lung was compared to that of the same two
segments in the same vertical slice of the untreated
lung. This average value was calculated using the
following formula:
V
_ (Vl/El). VI + (V2/E2). V2
E VI + V2
Where VI = V/E% (Q/E%) of segment 1, slice I
VI = Lung volume% of segment 1, slice I
V2 = V/E% (Q/E%) of segment 2, slice I
V2 = Lung volume% of segment 2, slice I
V = the weighted average (weighted to the
E lung volume) of the two segments in
slice I for one lung
On the same principle, the weighted average of
each of V/E%, Q/E% and V% of the upper 3 slices in the
treated lung were compared with those in the untreated
lung. It was assumed that the upper 3 slices were the
region of the treated lung which received the total
ratiation dose of up to 4250 rads "to max", from the supra¬




The "control" measurements prior to radiotherapy, but
after simple mastectomy, are summarised in Table 1 for all
10 patients. The age range of these patients was 35-61
years, with an average of 49.4 years. One patient (2)
was a smoker, one patient (7) was an ex-smoker and the
• rest were non-smokers. The average height was 1.67 metres
and the average weight was 66.6 kilograms. The pathological
type of tumour and the stage was also recorded, as was
the side of the tumour; on the right in 4 patients and
on the left in the rest (Table 1). Haemoglobin concentration
(Hb) and white blood cell (WBC) count in the venous blood
were normal in all but one (9), who was mildly anaemic.
The electrocardiogram was normal for all but one (4), who
had first degree heart block (1°H.B.). The chest x-ray
was also normal in all patients. The overall lung function
measurement values are given as mean + SEM.
1. Results of the overall lung function measurements
These measurements showed that the mean total lung
capacity (TLC) was 5.70 + 0.2 litres (111.9 + 3.3% of
predicted normal values), vital capacity (VC) was 3.48 + 0.2
litres (113.6 + 6.1% predicted), residual volume (RV) was
2.22 + 0.2 litres (125.9 + 12.5% predicted) (Tables 1,12).
The finding that the residual volume was consistently higher
than that predicted resulted from these measurements being
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made by the body plethysmograph, whereas the predicted
values were made by the Helium dilution method. Thus
in a separate study of 26 subjects (12 normal and 14
patients with chronic obstructive lung disease) studied
twice by both the Helium dilution method and by the body
plethysmograph, the plethysmographic values for RV were
higher than those using the He-dilution method (Figure 35).
The mean RV/TLC% ratio was 39+4 (111.3 + 10.0% predicted).
The mean FEVi.o w&s 2.72 + 0.2 litres (119.0 + 7.3% predicted),
FVC was 3.21 +0.3 litres (110.8 + 8.5% predicted) and
FEVi/FVC% was 85 + 2.1 (107.4 + 2.3% predicted) (Tables 1,12),
which were all within the normal limits.
• •
Vmax 50 (maximum flow at 50% VC) and Vmax 30 (maximum
flow at 30% VC) were not measured in 2 patients (1,2), but
were normal for the rest, with a mean Vmax 50 of 3.57 + 0.4
litres/sec and a mean Vmax 30 of 1.83 + 0.25 litres/sec
(Tables 1,12). The mean transfer factor for carbon monoxide
(Tco) was 6.60 + 0.4 mmol/min/kPa (76.7 + 4.8% predicted),
some of these patients (2,4,7) being below the predicted
normal values in the "control" study, even before
radiotherapy (Tables 1,12). The mean specific conductance
(sGaw) was 1.240 + 0.10 sec.-1kPa-''" in 8 patients.
Following radiotherapy these studies of overall lung
function were repeated at 1 month, 3 months, 6 months, 9
months and 12 months for each patient (Tables 2-11). A
summary of the results of these measurements, with the mean
and standard error, is shown in Table 12 and also in





The residual volume (RV) values in litres as measured with
the Helium dilution (y-axis) and the body plethysmograph (x-axis)
in normal subjects (o) and in patients with chronic obstructive
lung disease (•).





The mean VC at 1 month was 3.56 + 0.2 litres
(116.9 + 5.2% predicted), at 3 months was 3.47 + 0.2 litres
(111.0 + 5.3% predicted), at 6 months was 3.34 + 0.2 litres
(105.5 + 5.4% predicted), at 9 months was 3.34 + 0.2 litres
(105.5 + 6.3% predicted) and at 12 months was 3.33 + 0.2'
litres (106.6 + 6.2% predicted), all of which showed no
significant change from the control values (Table 12).
The RV/TLC% also showed no significant changes from their
control values before radiotherapy. FVC did not change
following radiotherapy, as compared to the control values
(Table 12, Figure 36) and the mean Vmax 50 was 3.55 + 0.5
L/sec at 1 month, 3.53 + 0.48 L/sec at 3 months, 3.51 + 0.45
L/sec at 6 months, 3.52 + 0.52 L/sec at 9 months and
3.59 + 0.54 L/sec at 12 months, again showing no significant
difference as compared to their control value. The mean
values of Vmax 30 at different intervals following radiotherapy
showed no significant differences, as compared to their
control value (Table 12).
The mean Tqq at 1 month was 6.52 +0.3 mmol/min/kPa
(75.9 + 3.1% predicted), at 3 months was 6.72 + 0.2 mmol/min/kPa
(77.6 +2.4% predicted), at 6 months was 6.95 + 0.2 mmol/min/kPa
(80.7 + 2.9% predicted), at 9 months was 6.61 + 0.2 mmol/min/kPa
(77.2 + 4.3% predicted) and at 12 months was 6.76 + 0.25
mmol/min/kPa (78.9 + 4.4% predicted), which showed no
significant change as compared to their control values
(Table 12, Figure 36). The mean sGaw at 1 month was 1.41 + 0.14
sec. "'"kPa \ at 3 months was 1.27 + 0.12 sec. "'"kPa \ at









The means and standard error of the forced vital capacity
(litres), transfer factor for carbon monoxide (mmol/min/kPa).
maximum flow rate at 50% vital capacity (L/sec) and specific
airways conductance (kPa~l.sec-l) of 10 patients studied
before radiotherapy, but after mastectomy, and at 1,3,6,9
and 12 months after radiotherapy. There was no significant
difference after radiotherapy, as compared to control values
for all these variables.
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1.48 + 0.15 sec.^kPa and at 12 months was 1.33 + 0.14
sec. "*"kPa These values were also not significantly
different from the control values (Table 12, Figure 36).
However, the mean TLC was 5.48 + 0.2 litres
(107.7 + 3.9% predicted) at 1 month, 5.40 + 0.2 litres
(104.0 + 3.5% predicted) at 3 months, 5.17 +0.1 litres
(99.6 + 1.7% predicted) at 6 months, 5.05 +0.1 litres
(97.6 + 2.5% predicted) at 9 months and 5.19 + 0.1 litres
(100.1 + 1.2% predicted) at 12 months (Table 12, Figure 37).
The results suggest that the radiotherapy caused a
reduction in mean TLC value which was significant (P<0.05)
at 1 month and more significant (P<0.01) at 6, 9 and 12
months after radiotherapy,, using paired t-test.
The mean RV was 1.97 + 0.15 litres (110.4 + 10.2%
predicted) at 1 month, 1.94 + 0.25 litres (109.6 + 12.0%
predicted) at 3 months, 1.83 + 0.2 litres (104.9 + 9.2%
predicted) at 6 months, 1.75 + 0.2 litres (94.2 + 10.4%
predicted) at 9 months and 1.86 + 0.2 litres (98.5 + 10.0%
predicted) at 12 months (Table 12, Figure 37). These values
at 1 and 3 months were not significantly lower than the
control values, but at 6, 9 and 12 months the mean RV were
significantly lower (P<0.05) than the control valuer,
implying that radiotherapy also reduced the mean RV.
The mean FEV^ was 2.73 + 0.2 litres (119.7 + 7.6%
predicted) at 1 month, 2.67 +0.2 litres (115.0 + 8.5%
predicted) at 3 months, 2.71 + 0.25 litres (116.4 + 9.4%
predicted) at 6 months, 2.65 +0.3 litres (113.8 + 10.5%
predicted) at 9 months and 2.61 +0.3 litres (112.2 + 10.5%
predicted)at 12 months (Table 12, Figure 37). Although the
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Figure 37
The means and standard errors of total lung capacity (litres),
residual volume (litres) and forced expiratory volume at
1.0 sec (litres) of 10 patients studied before radiotherapy,
but after mastectomy, and at 1,3,6,9 and 12 months after
radiotherapy. There was significant reduction at the 5% and
1% levels after mastectomy, as compared to the control values
in these patients.
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mean FEV^ values at 1 and 6 months were not significantly
different from the control values, those at 3, 9 and 12
months were significantly lower (P<0.05) than the control
values. Although this reduction in mean FEV^ after radiotherapy
was statistically significant, it was only 0.12 litres.
The mean values of the ratio of FEVi/FVC% at 1, 3 and 6
months were also significantly lower (P<0.05) than the
control value (Table 12); yet the mean FEVi/FVC% at 9
and 12 months was not significantly lower than the control
value. The overall lung function results for individual
patients will be mentioned later.
2. Results of regional lung function measurements
The regional distribution of perfusion/unit alveolus%
(Q/E%), ventilation distribution/unit alveolus% (V/E%) at
two flow rates (0.2 L/sec and 1.5 L/sec), lung volume% (V%)
were measured in 8 horizontal segments of each lung in each
individual patient. These results are shown in separate
tables, for each variable, in each individual patient and
will be mentioned later.
The results were also calculated as the average
values for the upper 3 segments of the. irradiated lung and
the same values of the non-irradiated (control) lung, and
also the differences between these average values in the
two lungs for each variable, i.e. for Q/E% (Tables 1,13),
for V% (Tables 1,14), for V/E% at 0.2 L/sec (Tables 1,15)
and for V/E% at 1.5 L/sec (Tables 1,16). These measurements
were made in 10 patients in the control study before
radiotherapy but after simple mastectomy and at 1 month,
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3 months, 6 months, 9 months and 12 months after
radiotherapy. However, the mean values calculated for
each variable included only 7 patients (1,3,4,6,8,9,10)
because it is believed (as will be mentioned later) that in
two patients (5,7) there were serious technical errors in
these values from malpositioning; therefore these two
patients were excluded from the study in calculation of the
mean values. Furthermore, patient (2) was not included
as she declined further study after one month.
The results are expressed as differences between the
averages (irradiated - non-irradiated), not ratios
(irradiated/non-irradiated) since these ratios were not
normally distributed. Thus, differences of the average
values for each of these variables were plotted against
time after radiotherapy, the trend of changes being observed
at each period after radiotherapy and also the values at
1, 3, 6, 9 and 12 months being each compared to those values
at the control study using the paired 't' test as well as
Wilcoxon's statistical tests of significance for paired
difference.
The mean perfusion per alveolus (Q/E%) of the difference
between irradiated and non-irradiated averages of the upper
3 segments at the control study was -0.6 + 2.9%, so that
the irradiated lung apex was not significantly less perfused
than the non-irradiated lung apex, as shown in Tables 1,13
and Figure 38. Following radiotherapy, each patient behaved
differently, but the trend of the mean values of Q/E% showed
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Figure 38
The perfusion/alveolus % calculated as the difference between
the average value of the upper 3 segments of the irradiated
lung and those of the non-irradiated lung for 7 patients,
plotted against time in months - studied before radiotherapy,
but after mastectomy, and at 1,3,6,9 and 12 months after
radiotherapy. The dotted line shows zero difference between
the two lungs. The dark line is the mean values for these
patients. There was no significant difference between the upper
zones of the 2 lungs before radiotherapy. However, there was
significant reduction (P <0.05) of perfusion/alveolus in the
irradiated upper zone at 1 month and at 6 months after radiotherap;
as compared to the control, but was not significant at 3,9 and
12 months after radiotherapy, as compared to the control,
(x) patient 1; (o) patient 3; (A) patient 4; (A) patient 6;
(o) patient 8; (■) patient 9; (□) patient 10; (•) the Mean.
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mean difference being -11.3 + 5.9% (Table 13, Figure 38)
at one month study. This reduction (mean difference) was
statistically significant (P<0.05) from the mean level
of difference between the two sides in the control study.
However, at 3 months the mean difference of Q/E% was
-7.1 + 4.8%. This was lower than the control value, but
not significantly different from it (Table 13, Figure 38);
whereas at 6 months the mean Q/E% difference was -12.9 + 5.5%,
which was significantly lower (P<0.05) than that in the
control study. However, at 9 months the mean Q/E% (-3.0 + 7.4%)
was again not statistically different from the mean
difference in the control study (Table 13, Figure 38).
Moreover, at 12 months the mean Q/E% difference was -8.3 + 4.1%,
again not statistically different from that in the control
study.
The mean difference of regional lung volume (V%)
(Tables 1,14 and Figure 39) was -0.19 + 0.2% at the
control study, -0.3 + 0.5% at 1 month, -0.29 + 0.4% at
3 months, 0.07 + 0.2% at 6 months, -0.28 + 0.2% at 9 months
and -0.37 + 0.2% at 12 months. All these values were not
significantly different from that in the control study.
The mean difference of ventilation per alveolus (V/E%) at
0.2 L/sec showed also non-significant change following
radiotherapy, as compared to the control values (Tables 1,15
and Figure 40). The mean difference of the averages
(irradiated upper 3 segments - non-irradiated upper 3
segments) at the control study was 0.06 + 4.5%, at 1 month
was -5.4 + 6.2%, at 3 months was -6.5+5.9%, at 6 months




The lung volume % calculated as the difference between the
average value of the upper 3 segments of the irradiated lung
and those of the non-irradiated lung for 7 patients, plotted
against time in months - studied before radiotherapy, but
after mastectomy, and at 1,3,6,9 and 12 months after
radiotherapy. The dotted line shows zero difference between
the two lungs. The dark line is the mean values for these
patients. There was no significant difference between the
upper zones of the two lungs either before radiotherapy or
after radiotherapy.
(x) patient 1; patient 3; (A) patient 4; (A) patient 6;
(o) patient 8; (■) patient 9; (□) patient 10; (•) the Mean.
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Figure 40
The ventilation/alveolus % at inspiratory flow rate of
0.2 L/sec, calculated as the difference between the average
value of the upper 3 segments of the irradiated lung and those
of the non-irradiated lung for 7 patients, plotted against
time in months - studied before radiotherapy, but after
mastectomy, and at 1,3,6,9 and 12 months after radiotherapy.
The dotted line shows zero difference between the two lungs.
The dark line is the mean values for these patients. There
was no significant difference between the upper zones of the
2 lungs either before radiotherapy or after radiotherapy,
(x) patient 1; (^7) patient 3; (A) patient 4; (4) patient 6;




it was 6.7 + 9.6%.
The mean difference of the averages of ventilation
per alveolus (V/E%) at 1.5 L/sec at the 6 months study was
significantly greater (P<0.05) than the mean difference
of the averages of the control study (Figure 41); where
the mean difference at the control study was -7.0 + 3.8%,
at 1 month was 1.9 + 2.5%, at 3 months was 5.4 + 3.6%,
these not being significantly different from the control
value. At 6 months the mean difference was 10.4 + 3.5%,
which is significantly greater than the control value (P<0.05).
This ventilation change gradually returned to normal at 9
and 12 months, where the mean difference at 9 months was
-0.78 + 3.3% and at 12 months was 6.07 + 3.0% (Tables 1,16
and Figure 41).
3. Overall and regional lung function results
for individual patients
Patient 1
This 46 year old woman had a poorly differentiated
stage II carcinoma of the right breast treated with simple
mastectomy and radiotherapy. The minimum radiation dose
to the right lung apex was 4035 rads. She was a non-smoker;
her height, weight, haemoglobin and WBC count are shown in
Table 1, together with her overall and regional lung function
measurements, the ECG and chest x-ray findings during the
control study. Following radiotherapy (Tables 12,2A), this
patient was studied at 1, 3, 6, 9 and 12 months. Her TLC






The ventilation/alveolus % at inspiratory flow rate of
1.5 L/sec, calculated as the difference between the average
value of the upper 3 segments of the irradiated lung and those
of the non-irradiated lung for 7 patients, plotted against
time in months - studied before radiotherapy, but after
mastectomy, and at 1,3,6,9 and 12 months after radiotherapy.
The dotted line shows zero difference between the two lungs.
The dark line is the mean values for these patients. There
was no significant difference between the upper zones of the
2 lungs before radiotherapy and at 1,3,9 and 12 months after
radiotherapy. There was significant increase (P<0.05) of
ventilation/alveolus in the irradiated upper zone at 6 months
after radiotherapy, as compared to the control value,
(x) patient 1; (c7) patient 3; (A) patient 4; (A) patient 6;
(o) patient 8; (■) patient 9; (□) patient 10; (•) the Mean.
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but these values were still within the normal range (i.e.
predicted value + 2 x S.D.) for a women of her age and
height. Her RV fell by 0.95 litres at 6 months and 0.87
litres at 12 months, but was also still within her normal
ranges. Her FEVi and the other overall lung function
measurements were within the normal range. No change
was found in her ECG or the chest x-ray following
radiotherapy (Table 2A, Figure 42). The regional lung
function, as calculated for each variable, (Q/E%, V%,
V/E% at 0.2 L/sec and V/E% at 1.5 L/sec) in 8 horizontal
segments of each lung, and the differences between the
irradiated segments and the non-irradiated segments were
calculated (Tables 2B,2C,2D,2E) and plotted against the
corresponding segments (Figures 43,44,45,46) and sequentially
with time after radiotherapy.
The regional lung function was also calculated as
the difference between the average of the upper 3 segments
of the irradiated lung and that of the upper 3 segments of
the non-irradiated lung (Tables 1,13,14,15,16). These
differences were also plotted against time following
radiotherapy (Figures 36,37,38,39). The difference between
the average Q/E% for the upper 3 segments of the irradiated
lung and those of the non-irradiated lung was 0.6% in the
control measurements. At one month this difference became
-28.5% (i.e. the Q/E% of the irradiated lung in the upper
3 segments decreased), at 3 months this difference was
-25.7%, at 6 months it became -33.9%, at 9 months it
was -34.7% and at 12 months this difference became less




The chest x-ray of patient 1 at the "control"
study (A) and at 6 months after radiotherapy (B).




The difference in the regional distribution of perfusion
in 8 horizontal segments of the irradiated lung and those
of the non-irradiated lung in patient 1.
(•) pre-radiotherapy "control"; (o) 1 month study;
(□) 3 months study; (■) 6 months study; (A) 9 months study;
(A) 12 months study.
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Figure 44
The difference in the regional lung volume distribution
in 8 horizontal segments of the irradiated lung and those
of the non-irradiated lung in patient 1.
(•) pre-radiotherapy "control"; (o) 1 month study;
(□) 3 months study; (■) 6 months study; (A) 9 months study;
(A) 12 months study.
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upper segment of the irradiated lung fell, as compared
to those of the non-irradiated lung and this reduction
was worse at 6 months and 9 months, but it tended to
improve at 12 months in this patient (Table 13, Figure 38).
The difference between the average values of the
regional lung volume (V%) in the upper 3 segments of the
irradiated and those of the non-irradiated lung was 0.47%
in the control measurments, 1.6% at 1 month, 0.84% at
3 months, 0.9% at 6 months, 0.63% at 9 months and -0.14%
at 12 months (Table 14, Figure 39). These values were
within the normal ranges for such measurements.
The difference between the average of the upper 3
segments of the irradiated lung and that of the non-irradiated
lung for V/E% at 0.2 L/sec was -10.8% at the control
measurements, -37.9% at 1 month, -4.8% at 3 months, 17.3%
at 6 months, 9.7% at 9 months and 26.9% at 12 months
(Table 15, Figure 40). These values showed reduction in
ventilation at 1 month, which was increased thereafter.
The difference for V/E% at 1.5 L/sec was 9.7% at the
control measurements, 10.1% at 1 month, -6.0% at 3 months,
1.3% at 6 months, -7.9% at 9 months and 9.3% at 12 months
(Table 16, Figure 41). These changes showed reduction in
V/E% at 3 months which almost returned to normal at 12
months.
Patient 2
This 61 year old woman had a highly sclerosing stage
I carcinoma of the right breast treated with simple
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Figure 45
The difference in the regional distribution of ventilation
(0.2 L/sec) in 8 horizontal segments of the irradiated
lung and those of the non-irradiated lung in patient 1.
(•) pre-radiotherapy "control"; (o) 1 month study;
(□) 3 months study; (■) 6 months study; (A) 9 months study;
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Figure 46
The difference in the regional distribution of ventilation
(1.5 L/sec) in 8 horizontal segments of the irradiated
lung and those of the non-irradiated lung in patient 1.
(•) pre-radiotherapy "control"; (o) 1 month study;
(□) 3 months study; (■) 6 months study; (A) 9 months study;
(A) 12 months study.
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mastectomy and radiotherapy. The minimum radiation dose
to the right lung apex was 4070 rads. She was a smoker;
her height, weight, haemoglobin, WBC count, overall and
regional lung function measurements are shown in Table 1,
together with the ECG and chest x-ray findings at the control
period. Following radiotherapy (Tables 12,3A) this
patient was studied at 1 month and she declined further
study. Thereafter another study was carried out on her
at 24 months. Her TLC was not changed at 1 month or at
24 months, nor were her RV values. Her ECG was normal at
1 month and at 24 months. Moreover, the chest x-ray showed
%
no changes at 1 month and at 24 months (Table 3A). Her
regional lung function, as calculated for each variable
(Q/E%, V%, V/E% at 0.2 L/sec and V/E% at 1.5 L/sec) in the
8 horizontal segments for each lung, together with the
differences between the irradiated segments and the non-
irradiated segments at the control study and at 1 month
and 24 months after radiotherapy are shown in Tables 3B,3C,
3D and 3E.
The averages of the upper 3 segments of the irradiated
lung and those of the non-irradiated lung for each variable
was calculated, together with the differences between these
averages for each variable (Tables 13,14,15,16). The
results of this patient were not included in the calculation
of the mean of the group in the sequential study as she
declined further study after one month.
Patient 3
This 54 year old woman had an anaplastic stage II
carcinoma of the left breast treated with simple mastectomy
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and radiotherapy. The minimum radiation dose to the left
lung apex was 4114 rads. She was a non-smoker; height,
weight, haemoglobin and WBC count, overall and regional lung
function measurements at the control period are shown in
Table 1, together with her ECG and chest x-ray findings,
which were normal. Following radiotherapy (Tables 12,4A)
this patient was studied at 1, 3, 6, 9 and 12 months.
Her TLC fell by 0.61 litres at 6 months, by 0.84 litres
at 9 months and by 0.55 litres at 12 months, although these
values for TLC were within her predicted normal range
(i.e. predicted + 2 x S.D.). Her RV reduced by 0.77 litres
at 6 months, by 1.19 litres at 9 months and by 0.81 litres
at 12 months. These values for RV were also within the
predicted normal range for this patient. FEV^ reduced
by 0.60 litres at 12 months after radiotherapy, as compared
to her control value. Moreover, Vmax 50 was reduced by
0.89 L/sec at 6 months and by 1.21 L/sec at 12 months; also
Vmax 30 was reduced by 0.42 L/sec at 6 months and by 1.21 L/sec
at 12 months (Table 4A). Tco, on the other hand, did not
change and neither did sGaw. The chest x-ray was normal
throughout the study (Tables 1,4A); whereas the ECG showed
T wave changes starting at 3 months after radiotherapy with
a T inverted (+) in III and flat T in avf which persisted
through all the study and, in addition, at 6 months showed
flat T in all the leads, at 9 months showed biphasic T
wave in V4_5 and at 12 months showed ST depression in leads
II, avf and V5_q.
The regional lung function was again calculated for
each variable (Q/E%, V%, V/E% at 0.2 L/sec and V/E% at 1.5
L/sec) in the 8 horizontal segments, together with the differences
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between the irradiated and the non-irradiated lung
segments (Tables 4B,4C,4D,4E).
The averages of the upper 3 segments for each lung
and the difference between the irradiated and the non-irradiated
average are shown in Tables 1,13,14,15,16, at the control
study and at the different periods after radiotherapy.
The difference of the averages was plotted sequentially
against time for each variable and as shown in Figures
38,39,40,41. The irradiated side showed reduction in the
Q/E% at 1 month, down to a difference of -15.2%, as
compared to a difference of -0.2% in the control measurement.
However, at 3 months the difference was -6.2%, at 6
months was -3.8% and at 12 months the difference between
the average of Q/E% of the upper 3 irradiated segments and
those of the non-irradiated segments was zero (Figure 38).
The lung volume (V%) average of the upper 3 segments and
the difference between the irradiated and the non-irradiated
average are shown in Table 14, Figure 39 and were not changed
significantly throughout the study in this patient. The
averages of the upper 3 segments for V/E% at 0.2 L/sec and
at 1.5 L/sec are shown in Tables 15,16 respectively,
together with the difference between the irradiated and
the non-irradiated average at each study and the differences
for these two variables were plotted against time following
radiotherapy (Figures 40,41). These differences for V/E%
at 1.5 L/sec were unchanged through time; whereas those
for V/E% at 0.2 L/sec showed -5.9% at the control, 9.3%
at 1 month, -5.6% at 3 months, 15.9% at 6 months,
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-10.1% at 9 months and 38.1% at 12 months.
Patient 4
This 43 year old woman had an anaplastic stage I
carcinoma of the left breast treated with simple mastectomy
and radiotherapy. The minimum radiation dose to the left
lung apex was 4115 rads. She was a non-smoker; her height,
weight, haemoglobin and WBC count are shown in Table 1,
together with her overall and regional lung function
measurements, ECG and chest x-ray findings at the control
study, which were normal. Following radiotherapy (Tables 12,5A)
this patient was studied at 1, 3, 6, 9 and 12 months. The
TLC was reduced by 0.42 litres at 6 months and by 0.54 litres
at 12 months, but these values were within her predicted
normal range (i.e. predicted + 2 x S.D.). The RV and FEVi,
Vmax 50, Vmax 30, T^o &nd sGaw were unchanged throughout
the study, as compared to their control values (Table 5A).
The chest x-rays were normal at 1 month and 3 months, but
at 6 months showed a faint shadow in the left upper lobe (+)
which was still there at 9 months and returned back to normal
at 12 months (Table 5A, Figure 47). The ECG showed first
degree heart block (1°H.B.) in the control study, which
persisted through all the study and, in addition, at 1 month
T wave was inverted in V^, at 3, 6 and at 9 months T inverted
also in avL and in Vi_5, but at 12 months slight improvement
occurred in that the T wave was flat in aVL and T inverted
in Vi_g. The regional lung function for Q/E% (Table 5B),




The chest x-rays of patient 4: was normal at "control"
study (A); had a faint shadow in the left upper lobe
at 6 months (B) and at 9 months (C); and returned back
to normal at 12 months (D).
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at 1.5 L/sec (Table 5E) were calculated, together with
the differences between the irradiated and the non-irradiated
8 horizontal lung segments.
The average of the upper 3 segments for Q/E% of each
lung was calculated, together with the difference between
the average of the irradiated lung and that of the non-
irradiated lung (Table 13) and these differences plotted
against time following radiotherapy (Figure 38). The Q/E%
reduced in the irradiated lung at 1 month, 6 months and
12 months, as compared to the control Q/E%.
The V% average of the upper 3 segments for each lung
and the differences are shown in Table 14 and again these
differences were plotted against time (Figure 39), which
showed no significant change in V% of the irradiated lung,
as compared to the non-irradiated lung.
The V/E% at 0.2 L/sec and at 1.5 L/sec average of
the upper 3 segments for each lung and the differences
between the irradiated and the non-irradiated lung (Tables 15,16)
showed reduction in the irradiated V/E% at the 3 months
study, which returned back to normal thereafter (Figures 40,41).
Patient 5
This 59 year old woman had stage II adenocarcinoma
of the left breast treated with simple mastectomy and
radiotherapy. The minimum radiation dose to the left lung
apex was 4150 rads. She was a non-smoker; her height, weight,
haemoglobin and WBC count are shown in Table 1, together
with her overall and regional lung function measurements,
141.
ECG and chest x-ray findings, which were normal.
Following radiotherapy (Tables 12,6A) this patient was
studied at 1, 3, 6, 9 and 12 months. Her TLC did not
change through all the study, neither did her RV, FEVi
and all the other parameters of the overall lung function
(Table 6A). The chest x-ray was normal at 1 month. However,
at 3 months and 6 months it showed slight streaky opacity
in the left upper lobe (+), which returned to normal at
9 months and 12 months (Table 6A). The ECG was normal at
1 month and 3 months. However, at 6 months and 9 months
it showed T wave inversion (1) in V1-V5, which returned to
normal at the 12 months study (Table 6A). The regional
lung function for each variable (Q/E%, V%, V/E% at 0.2 L/sec
and V/E% at 1.5 L/sec) in 8 horizontal lung^ segments are shown
in Tables 6B,6C,6D,6E. Data for the 9 months study were
not available due to a technical fault in the videotape
recording system. The averages of the upper 3 segments of
the irradiated lung and those of the non-irradiated lung, and
the differences between them, for each variable are shown
in Tables 13,14,15,16.
In each patient analysis of variance was performed
to compare the data of the upper 3 segments of each lung
with the lower 5 segments of that lung in each parameter.
In this patient it was found that the perfusion in the
upper part of each lung was greater than that of the
lower part of that lung through all the study, with the
exception of the data at 12 months. At the 12 months
study,, for example, the Q/E% in the upper 3 segments of
the irradiated lung was (-68.66%), i.e. less than those of
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the lower 5 segments of that lung and the Q/E% of the upper
3 segments of the non-irradiated lung was (-67.12%), less
than the lower 5 segments of that lung. However, the data
at the control study showed that the Q/E% of the irradiated
lung was 23.6% greater than those of the lower 5 segments
of that lung and the Q/E% of the upper 3 segments of the
non-irradiated lung was 40.87% greater than those of the
lower 5 segments of that lung. These results would imply
that the normal gravitational apex to base gradient of
perfusion down the lung was inverted, and are thus open
to grave suspicion. Therefore malpositioning of the patient
before the gamma camera was suspected. On checking the
polaroid film of the count image during the 12 months
study and comparing it with those taken at control (Figure 48),
1 month, 3 months and 6 month studies, it was apparent that
the apices of both lungs were excluded in these studies.
Therefore all the regional data of this patient were
excluded in the calculation of the mean values in both
tables and figures.
Patient 6
This 47 year old woman had stage I mucoid carcinoma
of the left breast treated with simple mastectomy. After
one year's observation she developed metastases in the
mastectomy scar and was then treated with a course of
radiotherapy (Duncan, Forrest, Gray, Hamilton, Langlands,
Prescott, Shivas and Stewart, 1975). The minimum
radiation dose to the left lung apex was 4190 rads. She
was a non-smoker; height, weight, haemoglobin and WBC
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PERFUSION SCAN IN PATIENT 5 ON 2 OCCASIONS
12 m after Radiotherapy
APEX CUT OFF CORRECT POSITION
Control
Figure 48
Two polaroid films showing perfusion scan taken at the
control study (left) and at 12 months study (right)
in patient 5. The apices of both lungs are excluded
from the field of the gamma camera in the control study,
whereas they were included in the field at the 12 months
study.
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count are shown in Table 1, together with her overall
and regional lung function measurements, ECG and chest
x-ray at the control study, which were all normal.
Following radiotherapy (Tables 12,7A) this patient was
studied at 1, 3, 6, 9 and 12 months. Her TLC was reduced
by 1.02 litres at 6 months and by 1.38 litres at 12 months;
yet these values were still within her predicted normal
ranges (predicted + 2 x S.D.). Her RV was reduced by 0.67
litres at 6 months and by 1.23 litres at 12 months; these
values were also within her predicted normal ranges. Her
Tco (Table 7A) was reduced by 1.36 mmol/min/kPa at 12 months,
still within her predicted normal range. All the other
measurements of the overall lung function were unchanged.
Her chest x-ray was normal at 1 month, 3 months and
6 months, but there was a slight hazy opacity in the upper
lobe at 9 months, which was still present at 12 months (+)
(Table 7A). The ECG showed T wave inversion in V]__2-3 as
early as 1 month after radiotherapy and this persisted
through all the study. In addition, at 6 months, 9 months
and 12 months T wave was inverted also in V4_5 (Figure 49).
The regional lung function for the variables Q/E% (Table 7B),
V% (Table 7C), V/E% at 0.2 L/sec (Table 7D) and V/E% at
1.5 L/sec (Table 7E) were calculated together with the
differences between the irradiated and the non-irradiated
8 horizontal lung segments.
The averages of the upper 3 segments in the irradiated
and the non-irradiated lungs, together with their
differences, are shown in Table 13 for Q/E%, Table 14
for V%, Table 15 for V/E% at 0.2 L/sec and in Table 16 for V/E%
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The ECGs (standard 12 leads) of patient 6, at the
"control" study and subsequently at 1, 3, 6, 9 and
12 months after radiotherapy. T wave inversion in
the anterior chest leads after radiotherapy.
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at 1.5 L/sec. The irradiated lung showed reduction in
Q/E% at 1 month, which returned back to normal thereafter
(Figure 38). The difference in the averages of V% did not
change throughout the study (Figure 39). The V/E% at
0.2 L/sec in the irradiated lung decreased at 1 and 3
months, returned to normal at 6 months and decreased again
thereafter (Figure40), whereas V/E% at 1.5 L/sec increased
in the irradiated lung, as compared to the non-irradiated
lung at 6 months and returned back to normal thereafter
(Figure 41).
Patient 7
This 57 year old woman had stage II invasive carcinoma
of the right breast treated with simple mastectomy and
radiotherapy. The minimum radiation dose to the right
lung apex was 3910 rads. She was an ex-smoker; height,
weight, haemoglobin and WBC count are shown in Table 1,
together with her overall and regional lung function
measurements, ECG and chest x-ray at the control study.
Her RV in the control study was greater than her predicted
normal range (i.e. predicted + 2 x S.D.), whereas her
FVC and Tgo were below the predicted normal ranges for a
woman of her age and height. Following radiotherapy
(Tables 12,8A) this patient was studied at 1, 3, 6, 9
and 12 months. Her TLC reduced by 0.64 litres at 6 months
and by 0.5 litres at 12 months; yet these values were
within her predicted normal range (predicted + 2 x S.D.).
The RV values also reduced by 0.48 litres at 6 months and
by 0.32 litres at 12 months. Moreover, her FEVi was
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reduced by 0.45 litres at 6 months and the same reduction
persisted throughout at 9 months and 12 months. This
reduction meant that her FEV]_ fell to below the predicated normal
range in this patient. All the other values of the
overall lung function were unchanged through all the
study (Table 8A). The chest x-ray was normal at 1 month
and 3 months. However, at 6 months, 9 months and 12 months
there was a slight opacity (+) in the right upper lobe
(Table 8A). The ECGs were normal throughout the study.
The regional lung function for each variable (Q/E%, V%,
V/E% at 0.2 L/sec and V/E% at 1.5 L/sec) in 8 horizontal
lung segments are shown in Tables 8B,8C,8D,8E. The
averages of the upper 3 segments of the irradiated lung
and those of the non-irradiated lung, and the differences
between them for each variable are shown in Tables 13,14,
15,16. In this patient also, analysis of variance showed
that perfusion in the upper part of the lung was greater
than that in the lower part of the lung and for the
reasons discussed earlier, it was concluded that malpositioning
of the patient was present in both the control study and the
3, 6, and 9 month studies. Malpositioning was confirmed
on checking the polaroid films taken at the time of the
study. Thus the regional data of this patient was also
excluded in the calculation of the means and values in both
tables and figures.
Patient 8
This 50 year old woman had stage II scirrhous carcinoma
of the right breast treated with simple mastectomy and
148.
radiotherapy. The minimum radiation dose to the right
lung apex was 4115 rads. She was a non-smoker; height,
weight, haemoglobin and WBC count are shown in Table 1,
together with her overall and regional lung function
measurements, ECG and chest x-ray at the control study,
which were all normal. Following radiotherapy (Tables 12,9A)
this patient was studied at 1, 3 and 6 months only as the
patient developed metastases in her liver after this period.
Her TLC was reduced by 0.42 litres at 6 months, although
still within her predicted normal ranges (predicted + 2 x S.D.).
Her RV was reduced by 0.2 litres at 6 months. All the
other variables of overall lung function were unchanged,
except TcO which was reduced by 1.43 mmol/min/kPa at
3 months and by 1.86 mmol/min/kPa at 6 months; yet it
was still within her predicted normal range (Table 9A).
The ECGs were normal throughout the study. Chest x-ray,
on the other hand, was normal at 1 month, but showed a
slight opacity (+) in the right upper lobe at both the 3
month and at the 6 month studies (Table 9A). The regional
lung function of the variables Q/E% (Table 9B), V% (Table 9C),
V/E% at 0.2 L/sec (Table 9D) and V/E% at 1.5 L/sec
(Table 9E) were calculated, together with the differences
between the irradiated and the non-irradiated 8 horizontal
lung segments.
The averages of the upper 3 segments in the irradiated
and the non-irradiated lungs, together with their differences
are shown in Table 13 for Q/E%, Table 14 for V%, Table 15
• •
for V/E% at 0.2 L/sec and in Table 16 for V/E% at 1.5 L/sec.
The average Q/E% of the upper 3 segments of the irradiated
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lung showed progressive reduction at 1 month, 3 months
and 6 months, as compared to the average of the upper 3
segments of the non-irradiated lung (Figure 38). The
V% was almost unchanged through all the study (Figure 39).
The V/E% at 0.2 L/sec showed reduction in the irradiated
upper lung at 3 months and 6 months (Figure 40). However,
the V/E% at 1.5 L/sec was greater in the irradiated lung
apex at 3 months and 6 months, as compared to those
of the non-irradiated side (Figure 41).
Patient 9
This 42 year old woman had stage I scirrhous
carcinoma of the left breast treated with simple mastectomy
and radiotherapy. The minimum radiation dose to the left
lung apex was 4000 rads. She was a non-smoker; height,
weight, haemoglobin and WBC count are shown in Table 1,
together with her overall and regional lung function
measurements, ECG and chest x-ray at the control study,
which were all normal. Following radiotherapy (Tables
12,10A) this patient was studied at 1, 3, 6, 9 and 12
months. Her TLC was reduced by 0.77 litres, 0.69 litres,
0.37 litres, 0.71 litres and 0.05 litres at 1 month, 3
months, 6 months, 9 months and 12 months respectively.
These values were within the predicted normal ranges for
this patient (predicted + 2 x S.D.). Her RV fell by 0.58
litres at 9 months, which was below her predicted normal
range and returned back to normal at 12 months (Table 10A).
All the other variables of the overall lung function were
unchanged through all the study. The chest x-rays were
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normal and unchanged throughout the study (Table 10A).
The ECGs showed T wave inversion (+) in V2-Vg,3 months
after radiotherapy, which persisted throughout the study
(Table 10A). The regional lung function for the
variables Q/E% (Table 10B), V% (Table 10C), V/E% at 0.2
•L/sec (Table 10D) and V/E% at 1.5 L/sec (Table 10E) were
calculated together with the differences between the
irradiated and the non-irradiated 8 horizontal lung
segments.
The averages of the upper 3 segments in the
irradiated and the non-irradiated lungs, together with
their differences are shown in Table 13 for Q/E%, Table 14
for V%, Table 15 for V/E% at 0.2 L/sec and in Table 16 for
V/E% at 1.5 L/sec. The average Q/E% of the upper 3 segments
of the irradiated lung was greater than that of the
non-irradiated lung at the control study. However, at
6 months the average in the irradiated upper lung fell and
returned back at 9 months; whereas at 12 months this
average in the irradiated lung fell and showed less
perfusion than the non-irradiated lung (Table 13, Figure 38).
The average V% did not change throughout the study
(Figure 39). The V/E% at 0.2 L/sec increased at 3 months,
returned to the control level at 6 months, but showed
reduction in the irradiated upper lung at 12 months
(Figure 40). The V/E% at 1.5 L/sec increased in the




This 35 year old woman had a stage I intraduct
carcinoma of the left breast treated with simple
mastectomy. After one year's observation she developed
lymph node metastases and was therefore treated with
a course of radiotherapy at that time (Duncan et al,
1975). The minimum radiation dose to the left lung apex
was 4135 rads. She was a non-smoker; height, weight,
haemoglobin and WBC count are shown in Table 1, together
with her overall and regional lung function measurements,
ECG and chest x-ray at the control study, which were all
normal. Following radiotherapy (Tables 12,11A) this
patient was studied at 1, 3, 6, 9 and 12 months. Her TLC
was reduced by 0.41 litres at 6 months and at 9 months;
whereas at 12 months it was reduced by 0.34 litres. These
values were around the lower limit of her predicted normal
ranges (predicted + 2 x S.D.). The RV was not changed
throughout the study and all other lung volumes were
likewise unchanged (Table 11A). The Tco, on the other
hand, was reduced by 1.33 mmol/min/kPa at 3 months, but
returned to around the control value thereafter (Table 11A).
The chest x-ray was normal at 1 month, 3 months and 6
months. However, at 9 and 12 months the chest x-rays
showed slight opacity (+) in the left upper lobe (Table 11A).
The ECGs showed a biphasic T wave in V2 at 1 month and at
3 months the T wave was also flat in Vi_5, which then
persisted throughout the study (Table 11A).
The regional lung function for the variables Q/E%
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(Table 11B), V% (Table 11C), V/E% at 0.2 L/sec (Table 11D)
and V/E% at 1.5 L/sec (Table HE) were calculated together
with the differences between the irradiated and the
non-irradiated 8 horizontal lung segments.
The averages of the upper 3 segments in the irradiated
and the non-irradiated lungs, together with their differences
are shown in Table 13 for Q/E%, Table 14 for V%, Table 15 for
V/E% at 0.2 L/sec and in Table 16 for V/E% at 1.5 L/sec. The
average Q/E% of the upper 3 segments of the irradiated lung
was reduced progressively at 3 months and at 6 months; it
returned to normal at 9 months (Figure 38).
The average V% did not change through all these studies
(Figure 39). The V/E% at 0.2 L/sec was reduced at 1 month
and 3 months, but returned to around normal thereafter
(Figure 40). The V/E% at 1.5 L/sec increased at 6 months
and returned to normal thereafter (Figure 41).
4. Summary
In these 10 women the radiotherapy affects the total
and regional lung function (Figures 36-41), in the following
manner:
i. It caused significant reduction in the total
lung capacity (TLC) without changing the vital capacity (VC).
This TLC reduction was mainly due to the significant reduction
in residual volume (RV). Thus, radiotherapy caused a
restrictive defect (Figure 37).
ii. No effect was detected on the airways of the
lung since the sGaw (a test for large airway function) and
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vmax anc* Vmax 30 (tests for small airway function)
showed no change after radiotherapy (Figure 36).
iii. Tco (& test for ventilation-diffusion and
perfusion function) was unchanged after radiotherapy
(Figure 36).
iv. Comparison of regional ventilation at slow
flow rate, between the irradiated lung and the non-irradiated
"control" lung, in the upper 3 segments, showed no changes,
either before radiotherapy or sequentially at 1, 3, 6, 9
and 12 months after radiotherapy (Figure 40). However,
regional ventilation at higher flow rate showed less
ventilation in the treated side before radiotherapy, but
showed significantly higher ventilation at 6 months, as
compared to the pre-radiotherapy value, and was still higher
at the 12 months study (Figure 41).
v. There was a signficant reduction in perfusion
of the upper zone of the irradiated lung corresponding to
the region receiving the radiotherapy. These perfusion
changes were significant as early as 1 month after radio¬
therapy (Figure 38), and returned back to normal at 9 months
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in some patients, as detected by radio-active Xe studies.
These perfusion reductions were confirmed by lung scan at
90m12 months for each patient using Tc macroaggregated albumin.
vi. There were no consistent radiological changes
in most of these patients..
vii. ECGs showed T wave changes in those patients who
had their radiotherapy to the left side.
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ii) Cross-sectional Study
The measurements in this study were made on one
occasion only in each patient. The 48 women studied had had
simple mastectomy and radiotherapy for their breast
cancer between 1 and 14 years previously (Figure 50).
These women were divided into two groups; those without
changes in the chest x-ray (Table 17) and those with
radiological changes attributed to the radiotherapy (Table 18).
1. Results of the overall and regional lung function
in the first group (i.e. with no radiological
changes
The number of women studied in this group was 23
and they were studied once between 1 and 14 years after
radiotherapy (Table 17, Figure 50). The age range of
the patients in this group was between 42-73 years
(Figure 51). Ten patients were non-smokers, 2 were
ex-smokers and the rest were smokers. The height, weight,
haemoglobin, WBC count, histopathological diagnosis and the
stages for each individual patient in this group are shown
in Table 17. The minimum radiation dose to the irradiated
lung apex ranged between 3760 and 4340 rads (Table 17).
The irradiated side was on the left in 9 women and on the
right in the rest of this group (Table 17). The ECGs
showed T wave changes in 7 out of the 9 patients in whom
the radiotherapy was to the left breast. None of the
patients who received radiotherapy to the right breast
showed any T wave changes in the ECG (Table 17). As
mentioned before, this group showed no radiological changes














Forty-eight women studied once between 1-14 years after
radiotherapy for breast cancer.
those with no radiological changes




The age distribution of 48 women studied once between
1-14 years after radiotherapy for breast cancer.
those with no radiological changes
^ those with radiological changes
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The overall lung function measurements, together
with the regional lung function measurements for each
individual patient, with the means and standard errors,
are shown in Table 17. The static and dynamic lung
volumes and Tco were also expressed as a percentage of
the predicted normal values (Table 17). The TLC% predicted
in these patients were distributed around 100% predicted,
with a mean value of 100 + 3.9% and thus were normal for
these patients (Figure 52). Moreover, the RV% predicted
for these patients are shown in Figure 53, all except
6 patients, had RV values of less than 100%. Furthermore,
the FEVi% predicted showed that these patients had a normal
FEVi with a mean value of 111 + 3.5% (Table 17, Figure 54).
However, the Tco, expressed as a percentage of the predicted
normal values for these women, was below 100% in all but
2 patients with a mean value of 76 + 3.7% (Table 17, Figure
55). In 6 of these women, the Tco% was below 2 S.D. of the
predicted normal value for such women.
On* the other hand, the regional lung function
measurements [perfusion/unit alveolus% (Q/E%), ventilation/unit
alveolus at 0.5 L/sec (V/E%) and lung volume (V%)]showed that
the average value of perfusion per alveolus (Q/E%) of the
upper 3 segments of the irradiated lung was less than the
average of the upper 3 segments of the non-irradiated lung,
the differences between these averages being shown in Table 17,
Figure 56. The mean reduction in perfusion/alveolus of the
irradiated upper lung was -13.1 + 3.2%. This reduction of Q/E%
in the irradiated lung was highly significant (P <0.005),
using Wilcoxon's rank test for paired difference.
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However, the average regional volume (V%) of the
upper 3 segments in the irradiated lung was not significantly
different from that of the same 3 segments in the non-irradiated
lung, the differences between these averages for each
patient being shown in Table 17, Figure 57, with a mean
difference of 0.12 + 0.15%.
Furthermore, the V/E% average of the upper 3 segments
in the irradiated lung was also not significantly different
from those of the non-irradiated lung, and the difference
between these averages for each patient are shown in Table 17,
Figure 58, with a mean difference of 1.9 + 2.6%.
2. Results of the overall and regional lung function
in the second group (i.e. with radiological
changes
The number of women studied in this group was 25.
They were also studied once between 1 and 14 years after
radiotherapy (Table 18, Figure 50). The age range of
the patients in this group was between 36-75 years
(Table 18, Figure 51). The age, smoking history, height,
weight, haemoglobin, WBC count, histopathological diagnosis
and the clinical staging of the breast cancer in each
patient are shown in Table 18. The minimum radiation dose
to the irradiated lung apex ranged between 3480 and 4260 rads
(Table 18). The irradiated side was on the right in 15
patients and on the left in the rest (Table 18).
The ECGs were normal in most of the patients and only
4 out of 10 patients who had their radiotherapy to the left
side showed some T wave inversion in the chest leads (Table 18).
The chest x-ray changes, on the other hand, were
graded without knowledge of physiological findings, according
to the severity of the radiological changes alone and
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Figure 5 2
The total lung capacity as % predicted in 48 patients studied
once between 1-14 years after radiotherapy.
those with no radiological changes







The residual volume as % predicted in 48 patients
studied once between 1-14 years after radiotherapy.
^those with no radiological changes
dthose with radiological changes
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were scored between (+) for slight opacification in
the irradiated upper lung, (++) for medium changes in
the irradiated lung and (++ + ) for severe changes in the
irradiated lung (Table 18).
The overall and regional lung function measurements
for the individual patients in this group, together with
the means and standard errors, are shown in Table 18.
The TLC, VC, RV, RV/TLC%, FEVj^, FVC, EEV1/FYC and Tco were
expressed also as a percentage of the predicted normal
values (Table 18). The TLC, as a percentage of the predicted
normal value in these patients, was normally distributed
around 100%, with a mean value of 99 + 2.2% and was thus
normal for these patients (Figure 52). Furthermore, the
RV% predicted for these patients are shown in Figure 53, all
but 6 patients showed values below 100% predicted. The
FEVi% predicted was below the normal range in 2 patients;
otherwise it was higher than 100% of the predicted normal
value in 19/25 of the patients in this group, with a mean
value of 110 + 4.29% (Table 18, Figure 54).
On the other hand, the T^q, as a percentage of
the predicted normal value (Table 18, Figure 55), was below
100% in all but 2 patients, with a mean value of 75 + 2.61%,
and in 5 patients it was below the normal ranges for these
patients (i.e. predicted + 2 x S.D.).
However, the regional lung function measurements of
Q/E%, V/E% and V% showed almost the same results as in
the first group of patients, who did not show radiological




The forced expiratory volume at 1.0 sec as % predicted
in 48 patients studied once between 1-14 years after
radiotherapy.
^those with no radiological changes
^those with radiological changes
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Figure 5 5
The transfer factor for carbon monoxide (Tco) as % predicted
in 48 patients studied once between 1-14 years after
radiotherapy.
^ those with no radiological changes
m those with radiological changes
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Figure 56
The perfusion/alveolus % calculated as the difference
between the average value of the upper 3 segments of the
irradiated lung and that of the non-irradiated lung in 48
patients studied once between 1-14 years after radiotherapy
for breast cancer.
^ those with no radiological changes
m those with radiological changes
There was highly significant reduction (P <0.005) in the
upper zones of the irradiated lung, as compared to those of
the non-irradiated lung in both groups.
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segments in the irradiated lung was less than that of
the non-irradiated lung and the differences between these
averages, with a mean reduction of -11.8 + 4.2% (Table 18,
Figure 56) was highly significant (P <0.005), using
Wilcoxon's rank test for paired differences. Furthermore,
the V% average of the upper 3 segments in the irradiated
lung was not significantly different from the average of
the upper 3 segments in the non-irradiated lung. The
differences between these averages was normally distributed
around zero% difference, with a mean difference of
0.04 + 0.15% (Table 18, Figure 57).
Moreover, the V/E% average of the upper 3 segments
in the irradiated lung was not significantly different from
that of the non-irradiated lung. The differences between
these averages are shown in Table 18 and Figure 58, which
shows that the V/E% differences of averages are distributed
normally around zero%, with a mean difference of 1.25 + 2.3%.
3. Summary
Both these groups of patients in the cross-sectional
study (with or without radiological changes attributable
to radiotherapy) showed normal overall lung function (i.e.
within the predicted normal values for women with similar
age and height to these patients). However, only Tco was
on the lower side. On the other hand, regional lung function
measurements in both groups showed significant (P <0,005)
reduction in the regional distribution of perfusion in the
upper region of the irradiated lung, as compared to that
of the non-irradiated lung. However, there was no
166.
TOP 3 VORRAD-NON IRRAD)
Figure 57
The lung volume % calculated as the difference between the
average value of the upper 3 segments of the irradiated
lung and that of the non-irradiated lung in 48 patients
studied once between 1-14 years after radiotherapy for
breast cancer.
£3 those with no radiological changes
| those with radiological changes
There was no signficant difference between the upper zones
of the 2 lungs in both groups.
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Figure 58
The ventilation/alveolus % calculated as the difference
between the average value of the upper 3 segments of the
irradiated lung and that of the non-irradiated lung in
48 patients studied once between 1-14 years after
radiotherapy for breast cancer.
^ those with no radiological changes
those with radiological changes
There was no significant difference between the upper
zones of the 2 lungs in both groups.
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significant difference in the regional distribution of
ventilation and in lung volume between the upper region





The present study has demonstrated a variable response
to radiotherapy of the lungs in each patient. These
responses bore no relation to age, height, weight, smoking
history, the total lung capacity (TLC), the forced
expiratory volume at 1.0 sec (FEV^ or the FEV^/FVC ratio
of the patient. They were also not related to the histo-
pathological type, the stage or the side of the carcinoma
of the breast. We thus presume that they reflect the
degree of damage caused by radiation, and the individual
patient's response of lung tissue to that damage. Technical
factors, including the quality of radiation, the total dose
and the rate at which the total dose was delivered (i.e.
the dose, the number of fractions and the time over which
the doses were delivered), as well as the volume of the
lung tissue irradiated, were kept almost the same in all
these patients, so that these potential variables, which
were suggested by Gross (1977) as important, cannot account
for the variability in response.
1. Overall lung function
The overall lung function measurements showed
reduction of the total lung capacity (TLC) after
radiotherapy in 8 out of the 10 patients. This reduction
was significant (P<0.05) at one month after radiotherapy
and was also significant (P<0.01) at 6, 9 and 12 months
after radiotherapy, as compared to the control values
(Figure 37). This reduction in TLC was mainly due to the
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reduction in residual volume (RV) in these patients
(Figure 37), as the vital capacity (VC) was not changed
by radiotherapy, as compared to control values. The
reduction in TLC and RV following radiotherapy is in
keeping with the findings of Emirgil and Heinemann (1961)
and Prato et al (1977).
The FEV-p "although showing a statistically significant
reduction in the mean value at 3, 9 and 12 months, as
compared to the mean control value (Figure 37), was only
reduced by a very small amount in absolute terms, the
maximal reduction in the mean FEV-^, as compared to the control
value, being only 0.11 litres, which lies within the
standard deviation of the measurements. This minimal
change in FEV-^ following radiotherapy is similar to the
findings of Prato et al (1977) following radiotherapy
60
with Co for breast cancer in 25 patients, for they also
found no changes in FEV-^. However, in this present study
there was no change (statistically or absolute) in VC
or FVC following radiotherapy, as compared to the control
values in each patient (Figure 36), unlike the findings
of Emirgil and Heinemann (1961) and Prato et al (1977).
The Vmax 50 and Vmax 30 showed no change following
radiotherapy, as compared to the control values (Figure 36),
in keeping with the findings of Prato et al (1977). It
has been said (Mead, Turner, Macklem and Little, 1967)
that in the lower three-quarters of the vital capacity,
maximum expiratory flow rates reflect the dimensions of
those airways which lie between the alveoli and the equal
pressure points in the intrathoracic airways. This would
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imply that the small airways of the lungs were unchanged
following radiotherapy.
No change could be detected in the specific airway
conductance (sGaw) following radiotherapy, as compared
to the control value (Figure 36), which suggests that
there was no change in the large airways of the lungs
(trachea and major bronchi) which constitute the major
part of resistance to air flow in the lungs (Macklem and
Mead, 1967).
Transfer factor (Tqo)
The Tcq values showed no significant change
following radiotherapy, in a paired comparison with the
control value in each patient (Figure 36). However,
patient 6 showed a fall in T^q at 9 and 12 months after
radiotherapy, as compared with the control value, and in
this patient there were also radiological changes (slight
hazy opacity), coinciding with the reduction in TcO.
Patient 8 also showed reduction in TcO at 3 and 6 months
after treatment, which also coincided with changes in the
chest x-rays (Table 9A, Figure 59); patient 10 showed
reduction in TcO after 3 months, without any radiological
changes and the T^q returned to normal in the subsequent
studies in this patient. This reduction in Tco in these
3 patients is in keeping with the findings of Emirgil and
Heinemann (1961) in their 4 breast cancer patients, who were
treated with approximately the same radiation dose over
the same period. Similar results were obtained by
Voutilainen et al (1962); Brady et al (1965); Germon
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Figure 59
The chest x-ray of patient 8 was normal at the
"control" study (A), and had a faint shadow in the
right upper lobe at 6 months after radiotherapy (B).
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et al (1968); Boushy et al (1970) following radiotherapy
in patients with bronchogenic carcinoma. The reduction
in Tco in these 3 patients is also in keeping with the
results of thoracic irradiation in animals (Sweany et al,
1959; Teates, 1965).
The pathological changes in radiation-induced
lung damage in animal studies (Gross, 1977) consisted of
thickening and folding of the basement membrane, increase
in size and number of type 2 pneumocytes, swelling of
capillaries with widespread capillary obstruction due to
platelets, fibrin and collagen (Phillips, 1966; Adamson
et al, 1970; Phillips et al, 1972), with resultant
encroachment on the alveolar spaces (Phillips, Benak and
Ross, 1972). These changes will cause a reduction in
the diffusing capacity as the alveolar-capillary membrane
component (Dm) of the barrier to diffusion, separating the
alveolar gas from the haemoglobin molecules in the red
cells, will increase in the irradiated region; as:
Ad
Dm = "Y" (Bates and Christie, 1965)
2
Where A = the total area of the lung membrane (in cm )
d = the diffusion coefficient for^unit area and
unit thickness (in mlCO.mm Hg.Cm-2,Cm-1)
and y = the average thickness of the membrane (in cm)
Probably of greater importance, the capillary obstruction
in the irradiated region will cause some reduction in blood
flow (Q) and thus contribute to the reduction in CO uptake
(Vco), which is considered as a process limited both by
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diffusion and flow, as expressed by the following
equation:
Vco = Q- PACO (1-exp [—]) (Piiper and Sikand, 1966)
QB
Where Q = blood flow in ml/min
6 = the slope of the CO dissociation curve of
the blood in mlCO.ml blood-! mm Hg-1
PA^q = the alveolar CO pressure in mm Hg
D = the diffusing capacity
In summary, therefore, the reduction in Tqq in patients 6,
8 and 10 was presumed to result from the reduction in Dm,
which in turn appears to arise from the radiation damage.
However, the other patients showed no change in Tqq
following radiotherapy (Figure 36). Moreover, the transfer
coefficient (Kco) was calculated for all the 10 patients
before radiotherapy and at the different intervals
after radiotherapy by dividing the T^q by TLC, giving Kco in
mmol min "*"kPa "'"L \ This transfer coefficient increased
following radiotherapy, as compared to the control values.
This resulted as the Tcq did not change in 7/10 of these
patients; whereas in all 10 patients the TLC was reduced
significantly following radiotherapy. However, the increased
Kco was not significant at 6 months after therapy, as
compared to the control value, although it was significantly
higher (P<0.05) at 9 months and 12 months. This might
arise if the T^q in the control study was lower as a
result of anaemia following the mastectomy (as anaemia causes
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reduction in 9 and thus reduction in Tgg [Rankin,
McNeill and Forster, 1961]), as for example the Hb in
#
patient 9 was 10.8 g/dl at the time of the control study
and was 11.8 at the time of the 9 months and 12 months
studies; or the Tgo after radiotherapy increased due
to a training effect. The increased Kgo after radiotherapy,
as compared to the control value, may be due to increase
in the volume of the blood in the other pulmonary
capillaries, possibly due to redistribution of blood
from the irradiated region to the other areas of the lung.
2. Radiological changes
The chest x-rays in these patients showed either
no changes following radiotherapy (patients 1, 2, 3 and
9) or only a very slight hazy opacity in the upper zone
of the irradiated lung at 3 and 6 months or at 6 and 9
months after therapy, which thereafter returned to normal
in patients 4 and 5. However, in patients 6 and 10 slight
chest x-ray changes persisted in the upper zone of the left
irradiated lung at 9 and 12 months after radiotherapy.
Patient 7 showed slight chest x-ray changes at 6, 9 and
12 months and patient 8 also showed similar changes at
3 and 6 months after radiotherapy in the upper zone of the
right irradiated lung. These findings were in keeping
with other reports (Hagen et al, 1971; Gross, 1977).
The chest x-ray changes occurred in the region which
received the irradiation. The radiological changes could
be either pulmonary or pleuro-pulmonary. Furthermore,
these changes were very slight and started in some patients
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at 3 months, and at 6 or 9 months after radiotherapy in
others. These radiological changes either cleared and
returned to normal, or persisted at the 12 months study.
In general, these radiological changes bore no relationship
to the changes in lung volumes or Tco changes in 8/10 patients.
For example, patients 1, 2, 3 and 9, who had a reduced
TLC and RV after radiotherapy, showed no radiological
changes, and in patient 10 TCQ was reduced at 3 months,
but returned back to normal thereafter, whereas her
chest x-ray only showed changes at 9 and 12 months after
radiotherapy. Moreover, patients 4, 5 and 7 showed chest
x-ray changes after radiotherapy without any changes in
Tcq. Thus it was only two patients (6 and 8) who showed
a reduction in T^q which coincided with the changes in
their chest x-rays after radiotherapy.
3. Electrocardiographic changes
The electrocardiogram (ECG) was normal and unchanged
in the four patients who had radiotherapy on the right
side. However, all those six patients who had their
radiation to the left side showed ECG changes after radiotherapy,
as compared to the control ECG. These ECG changes
consisted of flattening or inversion in the T waves in
the anterior chest leads after radiotherapy (Figure 49
in patient 6), as noted by Catteral and Ogilvie (1959),
Catteral (1960) and Takaoka et al (1968). These T wave
changes in the anterior chest leads developed as early as
one month after therapy in some patients (4 and 6) or
as late as 6 months in others (patient 5 ). These ECG
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changes returned back to normal in one patient (5) at
the time of the 12 months study, but the changes
persisted in the others.
4. Regional lung function : Lung volume and perfusion
The regional lung function studies showed no
significant difference in the regional lung volume
E
(expressed as a % of the total lung capacity, ^ X 100 = V%
^Tot
where E = equilibration regional count rate) between the
upper 3 segments of the irradiated lung, as compared to
the same 3 segments of the non-irradiated lung, either
before radiotherapy or at the different intervals after
radiotherapy. These findings are in contradiction to those
of Prato et al (1977) who found that the regional lung
capacity (TLCr) of the irradiated lung apex was reduced
6 0
at 60 or more days following radiotherapy with Co in
I
their breast cancer patients. However, their values
were calculated as the ratios of the values in the irradiated
side to that of the non-irradiated lung apex, and also as
the ratio of the average of the measurements at 60 days
or more after radiotherapy, as compared to the pre-
irradiation values. We suggest that it is intrinsically
unlikely that these ratio values were distributed in a
Gaussian fashion, but as they do not give individual
values, we cannot prove this point. Furthermore, in
their technique for measuring the regional lung function,
their patients lay supine, unlike the present studies,
where the patients were seated, with the lungs vertical.
However, these authors reported that the reduction in TLCr
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was only minor, and they felt that the reduction in
blood flow was responsible for limiting the capacity
for function in the irradiated region. In this present
study there was a slight reduction at 1 month after
radiotherapy in the regional lung volume in the irradiated
lung apex, as compared to the non-irradiated apex in
5/7 patients, but in the other two patients there was
slight increase in regional volume of the irradiated apex.
These changes were slight, and lay within the error
expected from simple repetition and could be due to the
relative reproducibility of the measurements. The
perfusion/alveolus (Q/E%), calculated as the average of
the upper 3 segments of the irradiated lung, was not
significantly different from the average of the upper
3 segments of the non-irradiated lung in the control study.
This implies that simple mastectomy had no effect on
regional blood flow to these areas. However, at 1 and
6 months the Q/E% was reduced in the irradiated upper
lung, as compared to that in the same upper zone of the
non-irradiated lung, and this reduction was significant
(P <0.05 value) when compared to the control values.
However, at 3, 9 and 12 months the reduction in the average
Q/E% of the irradiated lung did not reach significance
level (P<0.20) when compared to the control values.
Although the sequential Q/E% measurements in each patient
behaved differently, in general almost all the 7 patients
included in calculating the mean values, (as mentioned
in the tables and shown in the figures) showed a reduction
in Q/E% in the irradiated upper region of the lung
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as compared to a similar region in the non-irradiated
lung, at different times after radiotherapy, and as
compared to the control values. These findings were
in keeping with the results of Abe (1974) who reported
reduction in pulmonary blood flow after post-operative
irradiation for breast cancer patients, as assessed by
131
I MAA scanning. Furthermore, the results in this
present study are in agreement with the findings of Prato
et al (1977) who studied their patients before and
0 Q
after five field Co radiotherapy for breast cancer.
These authors found that the ratio of the amount of
blood flow to ventilated alveoli [(Q)r] of the
irradiated/non-irradiated lung apex after radiotherapy,
after being "normalized" to the pre-irradiation value,
by dividing the values by the [(Q)r] ratio of the upper zones in the same
lungs in the pre-irradiation measurements, was more markedly
reduced at about 60 days after therapy than later on.
Our results are also in keeping with those of Bake et
al (1969) who did not have pre-irradiation "control"
measurements, but nonetheless reported reduction in
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perfusion/unit lung volume (as measured by Xe ) in
the lower half of the irradiated lung, as compared with
that of the non-irradiated lung, at 2-4 months after
radiotherapy, but this reduction was not significant
1-4 months later. Their irradiation technique for breast
cancer differs from that used in the present study, since
they used conventional radiation therapy with 165-190 KeV,
and the treatment was given directly to 3 fields [supra¬
clavicular, internal mammary (this accounting for the
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effects on the lower region) and operative area] with
a surface dose of 3000 rads. In addition a fourth field
was given tangentially to the lower part of the operative
area with a surface dose of 2700 rads. Furthermore, the
reduction in perfusion that we have found in this study
is in agreement with those reported by Johnson et al
(1968) and Goldman et al (1969) who reported the
development of ischaemic changes in the irradiated region
131
as detected by lung scans using I MAA, following
irradiation of the lung for intra-thoracic neoplasms.
These findings were in agreement with those of Teates (1968),
Johnson et al (1970), Korswower et al (1971) and Freedman
et al (1974) who showed that thoracic irradiation caused
reduction in perfusion of the pulmonary artery of the
irradiated lung, as compared to the non-irradiated control
lung, in dogs, mice and rabbits respectively, again when
131
studied by lung scans using I MAA. The histopathological
changes in these animal studies following thoracic
irradiation showed variable thickening of the alveolar
wall with prominence of bizarre enlarged alveolar lining
cells, and also marked thickening of media and intimal
lining of vessel walls. Pleural thickening was also
reported (Teates, 1968).
The reduction in perfusion which we have found
could be due to these histopathological changes in the
capillaries after irradiation (Gross, 1977). The reduced
perfusion/alveolus in the irradiated side at 1, 3 and 6
months, which occurred in all of these 7 patients, could
be due to changes in the endothelial cells, leading to
swollen and obstructed capillaries in the irradiated area
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(Phillips, 1966; Phillips et al, 1972). Later at
9 and 12 months the slowly dividing capillary endothelial
cells may have responded to a feedback stimulus to divide
rapidly (Ellis, 1967) so that regenerated new capillaries
are found which improved the perfusion in the irradiated
area. Furthermore, some of this improvement may be
due to a physiological reduction in the local vascular
resistance by opening up new channels (recruitment) and
by distension of those already open (Hughes, 1976).
This improvement in perfusion occurred as early as 3
months in some patients (3 and 6), and as late as 12
months in others (patient 1). The reason for the
perfusion/alveolus not returning back to the pre-irradiation
value in the irradiated lung in most of these patients
is presumed to result from a loss of capillaries caused
by irradiation (Gross, 1977).
The reduction in perfusion/alveolus in the irradiated
region is most probably a genuine reaction to the
radiation dosage, since it happened only in the irradiated
lung, and only in the region corresponding to that
irradiated, and did not develop in the corresponding
regions of the non-irradiated lung. Moreover, these
changes occur sequentially following radiotherapy and
coincide with the pathological changes observed in
experimental animals after irradiation (Gross, 1977).
Furthermore, they could not have arisen from an increase
in lung volume in the irradiated area (as the Q values
of each segment are divided by E values for that segment
to give the Q/E values), as there was no significant change
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in the regional lung volume (V%) after radiotherapy,
E
as compared to control, where V% = r= X 100, as mentionedETot
earlier. Moreover, values for the reciprocal (1/E) in
the upper 3 segments of the irradiated lung and those
of the non-irradiated lung were calculated before and
at the different intervals after radiotherapy, and again
found to be not changed. As the relation between E and
1/E is a rectangular hyperbola, a small undetected change
in E might cause larger change in 1/E, and thus will
affect the values of Q/E, in turn. However, this was
not the case, as calculated values of 1/E were unchanged.
Regional ventilation
The average value of ventilation/alveolus (V/E%)
at an inspiratory flow rate of 0.2 L/sec in the upper 3
segments of the irradiated lung was not significantly
different from the average of the non-irradiated lung in
the control study. The results in this measurement showed
wide scatter, with a different response in each patient,
which probably resulted from the difficulty in voluntarily
controlling this low constant inspiratory flow rate up to
total lung capacity. In general, no significant change
could be detected in the mean values for the 7 patients at
different intervals after radiotherapy, as compared to
the control value. Six out of 7 of these patients showed
some reduction in ventilation at 1 month and/or 3 months,
which increased thereafter, in keeping with the findings
of Prato et al (1977) [although the inspiratory flow rate
was not mentioned in their study]. This reduction could be
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due to the formation of some fibrin, haemorrhages and
debris in the alveolar space, in addition to the oedema,
debris, infiltrated inflammatory cells and increased
connective tissue in the interstitial spaces, as a result
of irradiation (Gross, 1977). The reduction in
ventilation/alveolus in the irradiated lung after
radiotherapy is neither due to an increase in regional
lung volume (V%) nor due to a decrease in 1/E, as mentioned
earlier. Therefore, this reduction in ventilation/alveolus
of the irradiated upper lung could be due to a reduction
in the compliance of the upper zone of the irradiated lung,
as the distribution of ventilation at such a low inspiratory
flow rate is determined mainly by the regional compliance
(Dollfuss et al, 1966; Bake et al, 1974). To confirm this
suggestion, the ratio of V/E% at 0.2 L/sec V/E (0.2) of
the upper 3 segments to that of V/E (0.2) of the lower
3 segments of the same lung was calculated for each side,
in each patient before and at different intervals after
radiotherapy. The ratio of this compliance of the upper
to that of the lower zones of the same lung (Cjj/Cl) can be
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assessed by the distribution of ventilation of a Xe bolus
inspired at this low flow rate (0.2 L/sec) (Bake et al,
1974). This concept depends on the theoretical response
of two-compartment lung model having different regional
time constants (Pedley, Sudlow and Milic-Emili, 1972).
Figure 60 shows the two-compartment model of the lung as
applied in this study, where Cu, Ru and Vy are the
compliance, resistance and the flow of the upper zone







A schematic diagram of the two-compartment model
of the lung (After Pedley et al, 1972).
C'U'C'L = compliances of the upper and lower 3
segments respectively
= the resistances of the upper and lower 3
segments respectively
Vy,VL = the flows of the upper and lower 3 segments
respectively
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resistance and the flow of the lower zone respectively.
The dead space is the volume of the apparatus and of the
airways down to the bifurcation and including the main
bronchi. At very small flow rates, when the mechanics
of the lung are dominated by elastic effects, equation (30)
of Pedely et al (1972) is applicable, i.e.:
APEU = APEL + APg ^1
Where APEu is the elastic pressure drop between the
point of bifurcation and the upper zone
APel is the elastic pressure drop between the
point of bifurcation and the lower zone
APq is the difference in pleural pressure
between the centres of mass of the upper and
lower zones as a result of the vertical
gradient in pleural pressure (Dollfuss et
al, 1967; Hughes et al, 1970)
In the linear P-V relationship model of Pedely et al,
this equation is written as:
Xn = JL + APG (2)CU CL
Since PEU = Vy/Cy
and PEL =
Where CE and CL are constant compliances of the two zones
and Vy and VL are the volume of the two zones
Upon differentiating this equation (2) with respect
to time, these authors obtained the following equation:
VCU = VCL
i.e. vu = cu
VL
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Therefore, the ventilation ratio (0.2 L/sec) of the upper 3
segments to the lower 3 segments (Vu/Vl) of irradiated and
non-irradiated lung was calculated in each patient, so as
to measure the compliance ratio (Cu/Cl) of each lung before
and after radiotherapy. For example, in patient 1, the
values of Vu/Vl and thus of Cu/Cl for each lung in the pre-
radiotherapy "control" study and at different times after
radiotherapy are:
Patient 1 Values of compliance (upper zone )/compliance
(lower zone) = Cu/Cl = Vu/Vl
Control 1 month 3 months 6 months 9 months 12 months
Irr Non-Irr Irr Non-Irr Irr Non-Irr Irr Non-Irr Irr Non-Irr Irr Non-Irr
0.98 0.93 0.73 1.26 0.46 0.79 0.68 0.85 0.47 0.69 0.73 0.72
These ratios of Vu/Vl and thus Cu/Cl were not different
between the two sides in the control study. However, at
1, 3, 6 and 9 months after radiotherapy the Cu/Cl of the
irradiated side was markedly reduced (possibly due to
reduction in the compliance of the upper zone), when
compared to the values of the non-irradiated side. On
the other hand, the Cu/Cl ratio at 12 months study was almost
the same in both sides, but the values of the ratio were less
than those before irradiation.. Moreover, the dead space
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volume, which determines the time taken for the Xe bolus
to be vertically distributed was unchanged throughout the
study (i.e. the volume of the apparatus and of the airways
187.
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between the point where the Xe bolus given at the
mouth down to the bifurcation and including the main bronchi
as=shown in Figure 60. Thus these findings support the
suggestion that the compliance of the irradiated lung was
reduced. This is in agreement with the findings of
Sweany et al (1959) and Teates (1965) after thoracic irra¬
diation in experimental animals (dogs). The pathology of
the irradiated lungs in these animals confirmed the radiation
damage in these lungs. Such a reduction in compliance of
the irradiated lungs was also observed in rats following
experimental irradiation (Naimark et al, 1970; Shrivastava
et al, 1974).
The ventilation/alveolus (V/E%) at the higher
inspiratory flow rate of 1.5 L/sec, again expressed as the
average value of the upper 3 segments of each lung, was
slightly lower in the irradiated lung than the non-irradiated
lung in the pre-irradiation "control" study, but this
difference was not significant. At 1 and 3 months after
therapy the ventilation/alveolus increased in the upper
zone of the irradiated lung, but was still not different
from that in the non-irradiated lung, nor from the values
in the control study. However, at 6 months all the patients
showed greater ventilation/alveolus at 1.5 L/sec in the upper
zone of the irradiated lung, as compared to those of the
non-irradiated lung and this difference was significantly
greater (P<0.05) than the difference between the two sides
in the control study. Later, at 9 and 12 months, the
ventilation/alveolus was reduced, so that there were then
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no significant differences, either between the two
lungs, or when compared to the control values. The
increase in ventilation/alveolus in the irradiated lung
at 6 months after radiotherapy could not be attributed to
a decrease in regional lung volume (V%), nor to an increase
in 1/E (as mentioned earlier). It seems unlikely that
this increase in ventilation in the irradiated lung at 6
months was caused by practice in the respiratory manoeuvre,
because it was not shown in the 9 and 12 month studies.
Another possibility to account for this increase in
ventilation could be a reduction in the regional airway
resistance in the irradiated lung zones, because at this
high inspiratory flow rate the distribution of regional
ventilation is mainly determined by the regional resistance
(Robertson et al, 1969; Bake et al, 1974). This reduction
in regional airway resistance may arise from dynamic
distension of the intra pulmonary airways, caused by
reduction in the applied regional pleural pressure (Bake
et al, 1974; Pedely et al, 1972), which in turn could be
due to the reduction in the compliance of the irradiated
region and a local increase in the elastic recoil pressure,
the pathophysiological basis for this compliance change
being discussed previously.
5. Summary
In summary, the results of this sequential study showed
that this dose and technique of radiotherapy caused:
A. Reduction in TLC and RV (i.e. restrictive type of
ventilation defect), which could be due to:
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1. Diminution in regional volume of the irradiated
zone caused by the encroachment of the interstitial tissue
into the alveolar spaces, some of which become replaced
later by fibrous tissue.
2. Local distortion of the intrapleural pressure
over the irradiated region, due to the local reduction
in compliance, as shown by the distribution of the regional
ventilation during slow inspiration.
3. Thickening of the pleura, locally in the irradiated
zone, may contribute to this reduction in local distension
of the lung in this zone.
B. Defective gas transfer in 3 out of 10 patients which
was presumably due to reduction in local area or increase
in local thickness of the diffusing membrane (Dm).
C. Marked reduction in regional perfusion to each
alveolus in the irradiated upper zones of the lung, which may
be caused by destruction and obstruction of the regional
capillary bed.
D. Slight reduction in the regional ventilation/alveolus
at a low inspiratory flow rate in 6 out of 7 patients,
as a result of the transient diminution in the regional
compliance in the irradiated area, which may be due to diffuse
pulmonary reaction in the irradiated lung parenchyma.
E. Increased regional ventilation/alveolus at a high
inspiratory flow rate, due to reduction in regional airway
resistance, caused by dynamic distension of intrapulmonary
airways in the irradiated region.
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F. No regional lung volume reduction could be
detected in these patients which may be due to redistribution
in lung volume from zones with high lung volume to other zones
with low lung volume, as the upper 3 segments are studied by
the gamma camera field throughout, and if this region of the
lung became smaller and fibrosed, the lower segment
(i.e. segment 4) might be pulled and thus occupy part of
the upper 3 segment field originally studied.
ii) Cross-sectional Study
This study identified two groups of patients, both
of whom had simple mastectomy followed by radiotherapy for
their breast cancer, one group showing radiological changes
attributed to the radiotherapy, whereas the other group did
not show such radiological changes. However, there was
no significant difference between these two groups with respect
to their mean values of age, height, weight, nor in their
smoking history, or mean values of overall lung function (TLC,
VC, RV, RV/TLC%, FEVx, FVC, FEVi/FVC%, Vmax 50, Vmax 30, TC0
and sGaw) or the mean values of regional lung function
measurements (V%, Q/E% and V/E%).
Both groups showed normal TLC values for all these
patients, when expressed as the mean value, and also as a
percentage of the prediced normal value, when studied between
1-14 years after radiotherapy. The TLC values in these
patients were either unchanged after radiotherapy, or
alternatively the unknown control values before treatment
were higher than 100% of the predicted value, and subsequently
fell. However, this cross-sectional study provides no
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evidence that the TLC changed systematically alter
radiotherapy in these patients, as pre-irradiation "control"
values in each individual are not available. The findings
of the sequential studies and those of previous work
(Emirgil and Heinemann, 1961) nonetheless make it possible
that their TLC had fallen after radiotherapy. Furthermore,
36/48 of patients in this study had RV values below 100%
of the predicted normal value, which supports the possibility
that RV was reduced following radiotherapy. However, 12/48
of these patients from both groups had an RV value of
over 100% predicted, but as all of these 12 patients were
smokers, this might explain this finding (Woolf and
Suero, 1971).
Moreover, the FEV-^ in the 37/48 of these patients showed
values over 100% predicted, which may also be due to the
effect of radiotherapy in causing a regional increase in
the elastic recoil of the lung, and thus increased the
calibre of the airway relative to the size of the lung
(as discussed before). However, in those 11/48 patients in
whom the FEV-^ was reduced, again all were smokers which might
explain this finding (Woolf and Suero, 1971).
Furthermore, T^q values in all but 4 patients (both
smokers and non-smokers) were low, being on average about
76% of the predicted normal values in both groups, which was
probably due to the effect of radiotherapy in causing a
reduction in area, or increase in thickness of the diffusing
membrane (Dm), in addition to the effect of smoking
(Woolf and Suero, 1971). However, this cross-sectional study
does not provide firm evidence to attribute the low values
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of T^o to the effect of radiotherapy, as again the pre-
radiotherapy "control" measurements are not available.
The results of this cross-sectional study do
indicate that the radiological findings attributed to the
radiotherapy bore no relation to the low values of Tcq
or to the high values of FEV^ in these patients, which
supports the findings in the smaller number of patients
followed in the sequential longitudinal study. The ECG
changes attributed to radiotherapy were present in 11/19
of these patients who had their radiotherapy on the left
side, and these ECG changes bore no relationship to the
time following radiotherapy. Again, we cannot be certain that
these changes were due to a radiation effect, but the
changes were similar to those found in the sequential study,
and in previous work (Catteral et al, 1959; Takaoka et al,
1968) and it seems probable that they arose as a result
of the radiotherapy.
The regional lung function measurements in this study
showed similar results to those found in the sequential
study, in that the regional perfusion/alveolus (Q/E%), which
09m
was assessed by Tc MAA, was reduced in the upper region
of the irradiated lung, as compared to that of the non-irradiated
lung, whereas there was no difference in either in the
regional lung volume (V%) or in the regional distribution
of ventilation/alveolus (V/E% at 0.5 L/sec) between the
upper regions of the irradiated lung and those of the non-irradia¬
ted lung.
The reduction in perfusion/alveolus (Q/E%) in the
irradiated side was present in 40/48 of these patients and
193.
was presumably due to destruction and obstruction of the
pulmonary capillary bed in the irradiated region (Gross, 1977).
The magnitude of the reduction in perfusion/alveolus was
not related to the side of radiotherapy, the time in
years after radiotherapy or to the severity of the
radiological changes attributed to the radiotherapy.
The regional ventilation/alveolus in this study was
measured at an inspiratory flow rate of 0.5 L/sec. The
ventilation/alveolus in the upper region of both lungs was
not different, which is in contradiction to the findings of
Prato et al (1977). This could again be because they
calculated their statistical significance from the ratios
between the irradiated and the non-irradiated lung regions;
whereas in this present study the results were calculated
as differences, as differences tend to be distributed in
a Gaussian manner, whereas ratios are not. Furthermore,
Prato et al (1977) reported reduction in the volume of the
irradiated region, as compared to the non-irradiated region,
and this reduction in regional volume could account for the
reduction in ventilation in their data. The truth of this
assumption is supported by the fact that the reductions in
both the regional volume and in the regional ventilation/alveolus
are the same, 0.78 and 0.79 respectively.
In the present study we could not detect any changes
in regional lung volume in the irradiated lung of these
patients, as compared to the non-irradiated lung, again in
contrast to the findings of Prato et al (1977). However,
this could be due to the redistribution of lung volume, some
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normal alveoli possibly displacing the damaged fibrosed
alveoli in this long term study. Prato et al (1977)
calculated their results on the ratios between the two
sides, which might be thought to magnify the picture more
than expressing the results as differences; for example,
the difference between 0.8 and 1.0 is only 0.2, whereas
a ratio of 0.8/1.0 is 80%.
iii) Summary
The primary aim was to study the effects of the
Edinburgh routine radiotherapy given for breast cancer
on the total and regional lung function in women with
normal lungs. This study has succeeded in identifying that
this treatment caused a slight restrictive defect in overall
pulmonary function, but mainly a reduction in the regional
perfusion/alveolus in the irradiated lung zones. Thus the
earliest and main effect of radiotherapy is upon the
pulmonary vascular bed in the irradiated region. This effect
seems likely to have happened in most of these patients, and
was found to be present from as little as 1 month after
radiotherapy (sequential study) to as long as 14 years after
radiotherapy (cross-sectional study).
We did not have the opportunity in this study to
include sufficient patients in the sequential study to
predict those who would subsequently develop symptomatic
radiation pneumonitis in its severe form and which ones would
not. A firm answer to this question will require the
sequential study of a larger series of patients, but it
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does seem that the methods utilised in the present study,
particularly the measurements of regional performance and
estimates of regional compliance, will prove to be
sufficiently sensitive for this purpose.
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CONCLUSIONS
It was concluded from this study that:
1. A radiation dose of 4250 rads "to max", delivered in
10 fractions over 4 weeks to the axilla and
supraclavicular region in the treatment of breast
cancer, had little effect on overall lung function
in these 10 women who had normal chest x-rays
and pulmonary function before radiotherapy.
2. However, perfusion to the alveoli in the irradiated
region was reduced, without clinical or radiological
changes, from as little as one month, to as long
as 14 years after radiotherapy, in 27 patients.
3. The earliest effect of radiotherapy appears to be
upon the pulmonary vascular bed of the irradiated
region.
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%Predictedvalu sinb ack t
TABLE7 Patient6
Perfusion/UnitAlveolus%i8V rticalSlices(ToptB ttom)ftheL ngtPre-r dio herapy (Control)a dtDifferentInt va sAfterRadiotherapy
Control1month3months6months9months12months
Q/E%
IrrNon-IrrDiffIrNon-IrrDi fINon-IrrDi fINon-Irri fNon-IrrDi fNon-Irri f
Top144.056.-12.038.116 9-78.022 047.-25.02836.-8.063 .2.7-2.7 261.065.0-4.056.8 -12.036.047.-11.038.715686.08-0.8 385.085.083.090 -7.075.68..661.01.0701 .9.85 34 5 4108.017.96.0105.0-9.0123.93497.08512.01.086.1514.0123.5-9.5 5117.0126.-9.020155123.04.12 .011.0116.04.21 .66 15 6114.027.-13.02 .17141.024.1 5.04.0-9.02298 4.0 7115.0127.-12.02 .071455.0133.0149.064.0-15.024.1 .1 .875 71 Bottom8114.023.-9.0079611.64.0115.033.04.-11.04.123.18 17 41 7
TABLE7C Patient6






















































































Ventilation/UnitAlve lus%(0.2L/s)i8V rticalSlices(TopB ttom)fheL ngatPr - radiotherapy(Control)dtDiffer ntIntervalsAf rRadio herapy AIMUlllJlJUUHtnaII1UUU1I33-III IILIIk̂L1 I LH5
V/E%
(0.2L/s)
IrrNon-IrrDiffINon-I riffIrNon-I rDi fNon-Irri fIon-I rDi fINon-I ri f
Top196.0732367.05615.77 0-1210 .05 .49854.797 5-12.8 2112.086.6718-78 .090.-83.0759 8.-120 .13 33 3121.0947796.0-17108.02122.09035.0411.909 4116.0912521 0.0-184.26.0932.7.0-124.91168 5105.096111.05-40.24 0-141 .9 35.02-722.27 66 6101.0965123.07.0-4123.-6114.099560 .-9.9 72 7109.08.115.030-158614.093.212-178 359. Bottom893.0105.0-126992-135 .46 080.77 .082-17 349 94
TABLE7E Patient6





Top172.098.0-26116.0131.0-1558.058.01.01.039 .087.0392.795.1-2.4285.0100.0-15138.0132.0679.073.06102.0748108.02.6108.46.91.53106.0100.0138.0148.0-10115.072825.089.36112.06.119.211.4.84123.0103.0131.060.0-2923.0958125.069111.00.12 .617.63.05124.0111.0I397.018.0-211 7.01 2.051 3.0949109.01 4.05106.6109.4-2.86109.09144.055.0-11117.0107.07.01.069 .0.0-49 .797.3-6.6 789.095.0-626.027.0-1114.0110.0111.097495.086.078.269.75 Bottom863.067.0-422.02 .0-211 .0111.081.077.043.0'77.0-456.69.2- .6
TABLE8A Patient7












































































































%Predictedvalu sinb ack t
TABLE8 Patient7
Perfusion/UnitAlve lus%in8VerticalSlice(T ptBo tom)fhL gat- radiotherapy(Con rol)dtDifferentIntervalsA t rRadiothe ap
Control1month3ths692n
Q/E%4 IrrNon-IrrDiffINon-I
Top1102.060-5897.912134633315 95 7-41.4 289.0126.-37.91 273612 70415-1164.1 4-47.2 3102.011-995.82357287-51 48 .06 99- 4 4108.07.994.526121038.73 0110 587.922 6 5113.0067954817817.217.49 719. 683.098-15102.7.0-77 11216.2612 .06 22 .9 766.077-11106.98-803.351 71 .7 Bottom853.08 .-30102.02671-1576913805 914 0-8
TABLE8C Patient7




IrrNon-IrrDiffIon-I riffrNon-I rDi fIon-I ri fNon-Irri fIon-I rDi f
Top14.23 70 5.12 48.30 51 02 2-1.2.7-0.43 430 9 26.95 81 1.0 55.234.8-0.5.10.4 765 -0.49 37.910 8.61 07.4-0.36.78- .119 5-3.48 172-0.04 49.07.41 68 9.0210.87 8209.6-1.6590 7 59.17 51.678 2.9 00 3.1819.6-0.5240 8 68.76 62 19.071 3.8429.18 30 8.0- .26 24608 76.14.41 75 9.0 564.91 87 20.056 695.363-0.47 Bottom83.62.21.43 390 8.174.69-0.33 8.30 52 761.20
TABLE8D Patient7
Ventilation/UnitAlveolus%(0.2L/s)8V rticalSlices(TopB ttom)ftheL ngat Pre-radiotherapy(Control)dtDiffer ntInt rvalsAf rRadio he apy
^^Control1month3m nths6months9months12months
(0.2L/s)jrrNon-IrrDiffIrNon-I ri fINon-I rDiffINon-I ri fINon-I rDi fNon-Irri f Top166.099-3395.0144.0-49610 .0-435.0121772-156.07 .-4.4 289.0130.0-4103.0147.-44111.028-171 6.04 -1069 -268..3-13.3 3113.05.-2103.029- 618.05.-3121.05.-14.01 -101 .3- .3 4114.097.716.0.-131.005.2613.04.-11 9.05429.78 54 2 5131.09381 5.0014131.09 302.07-5125.07.85.918 8 6110.087234.7 094.08 .81.092.-11118.094.419.492 526 9 785.068.1772.06562.03-16 .075- 58 .07-71 4.387.6.6 Bottom853.08.-547.09 -26.049-351.063-12.0769.96 81
TABLE8E Patient7
Ventilation/UnitAlveolus%(1.5L/s)i8V rticalSlices(TopB ttom)fheLungat Pre-radiotherapy(Con rol)dtDifferentInt rvalsAf rRadio herapy
(1.5L/s)
IrrNon-IrrDiffn-I ri fIrNon-IrrDi fINon-IrriffINon-IrrDi fINon-Irriff
Top1168.070-2156.092-36165.056.13 .056.0-40115.47- .3 2143.0157.0-14361-24168.053.51 8.03 -20821.391 9.54 .6-11.1 3135.0996120.013 -161 5.02 .51 .013 .-109625.-291 8.587 4136.08947124.031 1.01348123.08578.0-212 .997 71 2 5109.0713898.035110.095.516.09276.01 -118.2822 4 671.052.1970.061.9508.0-89 .785.09.61 939 750.0341642.04-235.07-1279.01868.- 05.36 09 Bottom832.04.-231.03-231.0-106 .6-459.1041 65 .-9.
TABLE9A Patient8

















































































































%Predictedvalu sinb ack t
TABLE9 Patient8








IrrNon-IrrDiff-Irri fIrNon-I ri fon-I rDiIN -I rfon-I ri f






5115.00411 2.002.5.03 -15.010.7-7. 6118.07..31.0113 .941 .024-5.0 7120.03.-3.01407.7.11922-3.01 54.
Bottom8129.030.-1.016971 04-4.0980 -2
TABLE9C Patient8








IrrNon-IrrDiffon-I riffIN n-I ri frNon-IrrDi fIon-I riNon-I ri f


















3 4 5 6 7
>m8
TABLE9D Patient8
Ventilation/UnitAlve lus%(0.2L/s)i8VerticalS ice(TopBo t m)fhLu gP e- radiotherapy(Con rol)dtDifferentInt rvalsAftRadiot r py
Control1month3nths69t2
IrrNon-IrrDiff 58.061-37427-159 8 80.04-43.5 271-1269 1 98.07.1615859-140- 9 95.0112.0-172.884040671.4PatientDevelopedLi rM tastases 109.08.19 .1067-1 101.011 .-107.06249435 104.08-412.2513996333 107.013 _624.136 0-127765993
TABLE9E Patient8




IrrNon-IrrDiffIrNon-IrrDi fINon-IrrDi fINon-IrrDi fNon-IrrDi fNon-IrrDi f






























































































































































































IrrNon-IrrDiffIrNon-Irri fINon-IrrDi fINon-IrrDi fNon-IrrDi fNon-IrrDi f
Top105.01 -1 .0109.84.28295.0-13.064.382-18.066 2.6 289.054106.08521103.08 .296.079 61 .475.701 3103.082211 1.097144.093211 1.069 404.977 72 2

















75.66 9-1.3113.688 425 2
30.36 9-6.6
TABLEIOC Patient9









IrrNon-IrrDiff-IrriffNon-I rDi fIro -IiINon-I ri fon-I rDi f
Top11.20 574.12 90.0 23.79-0.24 55 -1.0.36 -1.2 36.07.3-1.36.75-0.87.9-1.4 8.38-0.5.16-0.57 29. 7.89 7-1.9 7.310.2- .98.4 7.7 7.18 -1.06.25-0.3
5.5
-2.0
2.671.960 71 5.4066-0.26 6.967 27-0.31 7.088 85-1.77
4.03 30 7.8.9-0.1 5.2105.86.2-0.4 7.38 2-0.96.57 7-1.2 5.67.3-1.75.67 3-1.7
9.6-1.27 0.-2.69411.883 940.5279 - .7 9.6-1.96 78.9-2.26.129 66-3.54.872.9
7.3
9.5-2.2
6.0-0.54.767 08-2.325 91.35.6 7-1.4






















75.00. 101.097 123.016. 114.009 107.011. 107.090 87.079 68.05.
17
80.074. 132.00428 142.0113. 135.0111.
-4122.0108. 89.06 63.09. 41.07
29 24 14
85.869.-16.0 84.290.7-6.5 99.57 91 6
69.92.27 758.19 3-2 .2 83.574 7.874.3101.3-27.0 96.381 814.582.1112.6- 0.5
102.713 9-11.2104.696.15 58914.5-24.9 103.611 1-7.500.9492 40.2-27.8 100.118 2-18.1106.914 4-7.592 5-31.1 98.4105.4-7.0123 413106 6-17.4
-6
81.45 9- .5111.25 9-4.7
83.22 6-1.4
TABLE10E Patient9









IrrNon-IrrDiffIon-Irri fINon-I rDiffIon-Irri fINon-I rDi fNon-I ri f









113.42 50.9875 02.11 .11 .9-0.8
139.0152410 .56 0- .52.81 2.811.53 105.88 6-2.87.9 512 311 .306 59 103.98.0-4.12 798 34.108.2.39 90.11 5.7-15.612.11 0 72.985 4-12.5114.22 7-8 64.272 1-7.993.7103.1-9.4
97.32 44.9 86.173.512 6 59.57 02.
TABLE11A Patient10
























































































































IrrNon-IrrDiffI n-I ri fIrNon-I rDi fIon-I ri fNon-I rDi fIon-Irri f
Top153.06-3.064.073.-9.0274-7.0 260.0591..76 0-17.033.49.-16.0
58.972 4-13.5 55.367-12.0



























IrrNon-IrrDiff-Irri fIrNon-I ri fon-I rDiIN -I ri fon-I ri
Top13.39-0.6. 25.96 4-0.5.7 37.8 48.1 57.5 6.97.30 5 7.90 2 7.5
7.2 7.5



















1.16 67-0.17 68 24- .58.3-1.0 2.343 90.462 831 17..1-0.4
3.1 5.6 6.6 6.6 7.6
3.3-0.2 5.8-0.2




Ventilation/UnitAlve lus%(0.2L/s)i8VerticalSl ce(TopB ttom)ftheLu gaPr - radiotherapy(Control)dtDifferentInt rvalsAft rR iotherapy
V/E%Control1month3s6months9months12months
(0.2L/s)
IrrNon-IrrDiffon-I riffIrNon-I rDi fNon-Irri fI -I riINon-I rDi f
Top104.095.8791-458.089-313.8 2-5.15.760-4.466.877 3- 0.5 2111.002905.-25773.0-3666 27 75.56884 4-15.78 .09 1-6.1 3107.013.-607.01 5 89612.0-1689 95 778- .69 .19 .3-0.2 4106.019-1308.01 412 .-2308.893 15 707 60.51 .0-6.5 584.0114.0-309109.159820.0-221708 38 7112.34 87 1 .4.23 670.0112.0-428 .1 7.-26816.0343.28.11 3g3.49.0- 5.6 762.0113.0-519118.0-2671 .0-32408.42 11 .66 5i.s1 .1- 9.6 Bottom858.0100.04279101.0-22831 8.0-255.94 3.41 7 .19 3-1 .2
TABLE11E Patient10
Ventilation/UnitAlve lus%(1.5L/s)i8VerticalS iceTopBo tom)fhu gP e- radiotherapy(Control)dtDifferentIntervalsA tRa rapy
^Control1month3m ths6on s9m t2onths
(1.5L/s)""~ Irr'Non-IrrDiffNon-I r-I riffIron Ir- ri fNon-I rD Top181.00l1 2.07.57647.41 1 2616 13 .7-19.69 22-2 0 291.0088.102-14288 61 9.09 9.2 82-9.8-4.1 382.099-17117.05.224198 1058 2- 3.143.7 498.0102.0-410.28137 625.26-23.874.5 5106.07-134 Q2121 39 725 686 21 .5-31.3051 83.7 6109.016-79813-151 9.05.242 735 263 606 8-43.24 14. 7113.0061.0796212 57 947 6589 7-3 .15 8-3. Bottom8101.099.287615 943 81 138-8.165 77 3- 1.6
TABLE12
SUMMARYOFTHESEQUENTIALL NGITUDINALST Y MEANS5S.E.OF10PATIENT












































































































5.17+0.1(99.61 7) 3.34+0.2(105.55 4) 1.83+0.2(104.99 ) 35+.(10 .09 3) 2.71+0 25(116.49 4) 3.33+0.3(112.50.0) 81+2.2(10 .94) 3.51+0 45 1.91+0 24 6.95+0.2(80.72 ) 1.42+0.15
5.05+0.1(97.62 ) 3.34+0.2(105.56 ) 1.75+0.2(94.20 4) 34+4.3(98.910 7) 2.65+0.3(113.80. ) 3.30+0 25(111.58 4) 79+3.65(98.34 2) 3.52+0 1.74+0 26 6.61+0.2(77.24 3) 1.48+0 15
5.19+0(100.12) 3.33+0 2(106.66. ) 1.86+0.2(98.50 0) 36+4.1(104.21 .1) 2.61+0.3(112.210.5) 3.24+0 3(109.71 .0) 81+2.9(99.43 5) 3.59+0. 4 1.79+0 32 6.76+0 25(78.94 4) 1.33+0.14
TABLE13






































































































































































































































Patii No 1 2 3 4 *5 6 *7 8 9 10 Mean S.E.
TABLE14
LungVolume(V%)[averagvaluf rtheupper3seg ents]firradi t dandnon-irradiatedlu s10wo beforeradiotherapy(control)a ddifferentintervalsfterra i t
Control1month3m t s6months9nths12m nths
IrrNon-IrrDiffn-I riffINo -Irrron-I rDi fN Ii fINon-I ri f 6.025 550 4770.11 6.34 3846 15.20 904 7.638- .14 6.325.191 34 90-0.37PatientDecl nedFurth rS u y 5.27.40-0.136 137 0-0.904 8 675.6370- .350 5.37230.144 79-0.205 56-0.06408. 676 6.004-0.405.3310 68232- .57TechnicalError501 1 5.476 20-0.734 8. 3-1.6390.105 504.7- 29360 87 6.335 50.8064 .197604 60- .603 31 275 45-0.15 4.605.37-0.7749-1.504 26336. 6PatientDevelopedLiv rM tastas s 3.6390-0.274 28-0.57.5 7- 8. 160 503. 337-0.56 5.6773-0.0694.81.15 48-0.046 21 1048 4 5.15.34-0.195.275-0.3014029.360 71- .28- 7 +0.3.2+0.43.52+0.3 Thedataofthesepa ientswereexcludedin calculationsoftheme nbe ausel- positioningftheati nt.
TABLE15
















































































































































































































































incalculationsofthemeansbecausef malpositioningofthepati n .
TABLE16






























































































































































































































incalculationsoftheme nsbecause malpositioningofthep ti nt.
TABLE17
CLINICALA DFU CTIONALMEASUREMENTS23WOM N,WI HNRADI L GICAL CHANGES,1-14YEARSAFTERRADIATIONTHERAPYFOT IBR STC C R

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Effect of radiotherapy on total and regional lung function.
A.I. Kanbour, P.K. Wraith, M.F. Sudlow, A.O. Langlands,
A.L. Muir and D.C. Flenley
Clinical Science and Molecular Medicine, 1978, 54, IIP.
When modern high voltage radiotherapy is used in
combination with simple mastectomy for treatment of
carcinoma of the breast, the lung apex on the treated side
receives up to 4250 rads. Minor changes in overall lung
function following such therapy have been reported
(Emirgil and Heinemann, 1961, Journal of Applied Physiology,
16, 331), but these are more pronounced when symptomatic
radiation pneumonitis develops, which occurs in about 10%
of such patients (Gross, 1977, Annals of Internal Medicine,
86, 81). We have measured FEVi, FVC, lung volumes, transfer
factor, flow volume curves and airways resistance in ten
women aged 35-61 years, after simple mastectomy, but before
radiotherapy, and at 1, 3, 6, 9 and 12 months following
4250 rads to the axilla and supraclavicular region and
4500 to the chest wall by tangential fields given in 10
fractions over 4 weeks, as part of their treatment of
carcinoma of the breast. Regional ventilation and perfusion
133
was measured with radioactive Xe, using a gamma camera
linked on-line to a computer. Before radiotherapy, but
after simple mastectomy, the mean FEVi was 118 (SE 7.4)%
of predicted normal, FVC 111 (SE 8.5)%, TLC 112 (SE 3.3)%,
RV 120 (SE 12.4)% and Tco 77 (SE 4.8)% of predicted normal
values. Three months after radiotherapy there was a 10%
reduction in TLC, and 28% reduction in RV, but transfer
factor and the other measurements were unchanged, as were the
chest x-rays. Comparison of regional ventilation
between the irradiated lung and non-irradiated "control"
lung, at the same vertical height, showed no changes
either before radiotherapy or sequentially at 1, 3, 6, 9
and 12 months thereafter. However, there was a consistent
and significant reduction in perfusion of the upper zones
of the irradiated lung, corresponding to the region
receiving the radiotherapy. These perfusion changes were
detected in some patients as early as 1 month after
radiotherapy, and returned towards normal at 9 months, but
there were no radiological changes. We conclude that
these doses of radiation affect the pulmonary vascular bed,
in irradiated areas, even where this is not clinically
or radiologically apparent. We could detect no effects
of the radiation on the airways or parenchyma of the irradiated
zones.
APPENDIX II
The relative distribution of airflow resistance in normal
subjects and patients with airway obstruction.
A.I. Kanbour, N.J. Douglas, M.F. Sudlow and D.C. Flenley.
Clinical Science and Molecular Medicine, 1977, 52, 27P.
The site of airway obstruction in patients with chronic
airways obstruction is probably in airways less than 2-3
mm in diameter. Some patients with asthma may show a
similar pattern, but in others narrowed larger airways'
may be responsible for the increased resistance.
Despas, Leroux and Macklem (1972, Journal of Clinical
Investiation, 51^, 3235) measured changes in maximum
expiratory flow (MEFV) breathing air and when breathing a
80% helium, 20% oxygen mixture (He/02). Maximum flow at
50% VC (Vmax 50) breathing He/02 was variably increased in
patients with asthma, but unchanged in patients with chronic
bronchitis.
We have studied normal subjects (age range 18-37
years, mean FEVi 3.91 litres, mean FVC 4.66 litres), patients
with asthma (age range 14-38 years, mean FEVi 2.25 litres,
mean FVC 3.69 litres) and patients with chronic irreversible
airways obstruction (age range 55-72 years, mean FEVi 1.65
litres, mean FVC 2.43 litres).
We have measured MEFV and specific conductance (sGaw)
in a body plethysmograph breathing air and breathing He/02 •
The response to breathing He/02 did not distinguish the three
groups using the fractional increase in Vmax 50 compared
to the Vmax 50 breathing air. However, we found that the
lower the initial Vmax 50, the smaller the fractional increase.
At Vmax 25 some subjects showed a reduction in maximum
flow rate breathing He/02-
In all subjects sGaw increased on breathing He/02,
but this increase was not related to the initial value of
airway resistance (AWR). It appeared that some patients
with chronic airways obstruction had a lesser response than
normal subjects. Patients with asthma could not be distinguished
from normal subjects.
The change in sGaw breathing He/02 should be more
influenced by the site of airways obstruction than the Vmax 50
as sGaw is measured at the same flow rate in all subjects.
During the measurement of AWR the mean velocity of flow
in the large airways is similar in all subjects and any changes
in AWR with He/02 must arise from differences in the
distribution of resistance to airflow. However, for Vmax 50
the initial value varied, hence the mechanics of air flow in
the airways in different individuals was not comparable.
The poor response of sGaw to He/02 in patients with
chronic airways obstruction suggests that the resistance
of the peripheral airways is relatively greater than normal.
The distribution of resistance in our patients with asthma
is normal.
